https://semaglutides.org/news/2026/#rule-702-general-causation-hearing-opens-mdl-3094-20262026-09-15T01:35:26Zweekly https://semaglutides.org/news/2026/#status-check-two-unreconciled-medicare-semaglutide-prices-2027-20262026-09-15T03:04:33Zweekly https://semaglutides.org/news/2026/#status-check-no-glp-1-injury-settlement-no-20262026-09-15T03:04:58Zweekly https://semaglutides.org/news/2026/#tga-counterfeit-retatrutide-eightfold-semaglutide-dose-20262026-09-15T03:32:11Zweekly https://semaglutides.org/news/2026/#mdl-3094-daubert-hearing-20262026-09-15T03:32:22Zweekly https://semaglutides.org/news/2026/#easd-2026-milan-sets-up-competitor-data-20262026-09-15T03:32:27Zweekly https://semaglutides.org/news/2026/#generic-liraglutide-cash-prices-run-three-eleven-times-20262026-09-15T03:32:49Zweekly https://semaglutides.org/news/2026/#label-check-what-current-zepbound-prescribing-information-actually-20262026-09-15T03:32:37Zweekly https://semaglutides.org/news/2026/#novo-38-percent-us-obesity-share-cmd-week-20262026-09-15T03:32:38Zweekly https://semaglutides.org/news/2026/#novo-nordisk-rebrands-novo-introduces-novo-way-20262026-09-15T03:32:36Zweekly https://semaglutides.org/news/2026/#roche-pharma-day-three-obesity-mechanisms-20262026-09-15T03:33:00Zweekly https://semaglutides.org/news/2026/#semaglutide-cash-prices-settle-149-499-band-while-20262026-09-15T03:32:57Zweekly https://semaglutides.org/news/2026/#sixteen-challenger-programs-phase-3-none-before-2027-20262026-09-15T03:33:17Zweekly https://semaglutides.org/news/2026/#status-check-balance-window-closes-january-one-committed-state-20262026-09-15T03:33:23Zweekly https://semaglutides.org/news/2026/#status-check-bridge-copays-excluded-from-part-d-affordability-mechanisms-20262026-09-15T03:33:13Zweekly https://semaglutides.org/news/2026/#status-check-no-balance-state-no-post-2027-medicare-answer-20262026-09-15T03:33:18Zweekly https://semaglutides.org/news/2026/#status-check-novo-675-list-price-above-every-negotiated-price-20262026-09-15T03:33:33Zweekly https://semaglutides.org/news/2026/#status-check-zepbound-caremark-class-action-live-as-restoration-nears-20262026-09-15T03:33:32Zweekly https://semaglutides.org/news/2026/#lean-mass-race-dozen-programs-one-approved-drug-20262026-09-15T03:33:50Zweekly https://semaglutides.org/news/2026/#tirzepatide-evidence-base-what-has-what-has-not-20262026-09-15T03:33:58Zweekly https://semaglutides.org/news/2026/#state-of-play-september-20262026-09-15T03:33:59Zweekly https://semaglutides.org/news/2026/#aetna-posts-zepbound-formulary-addition-effective-october-20262026-09-15T04:24:18Zweekly https://semaglutides.org/news/2026/#amgen-maritide-readouts-outside-2026-window-20262026-09-15T04:24:31Zweekly https://semaglutides.org/news/2026/#astrazeneca-obesity-case-two-fall-readouts-20262026-09-15T04:24:52Zweekly https://semaglutides.org/news/2026/#baseline-keyword-serp-landscape-captured-semaglutides-org-20262026-09-15T04:24:34Zweekly https://semaglutides.org/news/2026/#branded-tirzepatide-self-pay-prices-sit-far-below-20262026-09-15T04:24:41Zweekly https://semaglutides.org/news/2026/#china-semaglutide-generics-stuck-data-exclusivity-20262026-09-15T04:25:00Zweekly https://semaglutides.org/news/2026/#chinese-licensing-sets-price-of-entry-obesity-20262026-09-15T04:25:17Zweekly https://semaglutides.org/news/2026/#cms-2027-medicare-landscape-still-pending-before-open-enrollment-20262026-09-15T04:25:06Zweekly https://semaglutides.org/news/2026/#corbus-canyon-1-topline-crb-913-20262026-09-15T04:24:53Zweekly https://semaglutides.org/news/2026/#india-generic-semaglutide-price-war-six-months-on-20262026-09-15T04:25:22Zweekly https://semaglutides.org/news/2026/#mazdutide-us-path-theoretical-lilly-phase-2-published-20262026-09-15T04:25:06Zweekly https://semaglutides.org/news/2026/#pfizer-obesity-case-rests-on-monthly-injectable-20262026-09-15T04:25:31Zweekly https://semaglutides.org/news/2026/#status-check-globe-guard-drug-pricing-model-rules-unfinalized-20262026-09-15T04:25:39Zweekly https://semaglutides.org/news/2026/#status-check-marketplace-weakest-glp-1-coverage-channel-2027-20262026-09-15T04:25:33Zweekly https://semaglutides.org/news/2026/#status-check-pbm-delinking-does-not-bite-until-2028-20262026-09-15T04:25:25Zweekly https://semaglutides.org/news/2026/#survodutide-heads-to-easd-without-filing-date-20262026-09-15T04:25:47Zweekly https://semaglutides.org/news/2026/#compounding-fight-state-of-play-september-20262026-09-15T04:26:13Zweekly https://semaglutides.org/news/2026/#viking-vk2735-maintenance-data-outstanding-readout-20262026-09-15T04:26:15Zweekly https://semaglutides.org/news/2026/#science-times-ai-reddit-analysis-overlooked-side-effects-20262026-09-15T05:14:45Zweekly https://semaglutides.org/news/2026/#retatrutide-30-billion-forecast-q1-2027-filing-20262026-09-15T05:15:02Zweekly https://semaglutides.org/news/2026/#citi-raises-lilly-price-target-1600-20262026-09-15T05:15:03Zweekly https://semaglutides.org/news/2026/#doustdar-not-winner-takes-all-obesity-20262026-09-15T05:15:05Zweekly https://semaglutides.org/news/2026/#eloralintide-phase-3-tirzepatide-combination-20262026-09-15T05:15:08Zweekly https://semaglutides.org/news/2026/#kailera-trades-below-ipo-price-data-slips-20262026-09-15T05:15:26Zweekly https://semaglutides.org/news/2026/#obesityweek-2026-late-breakers-surface-20262026-09-15T05:15:41Zweekly https://semaglutides.org/news/2026/#r-zepbound-passes-233-000-members-r-mounjaro-20262026-09-15T05:15:33Zweekly https://semaglutides.org/news/2026/#telehealth-platforms-compounded-pathway-narrows-september-20262026-09-15T05:15:55Zweekly https://semaglutides.org/news/2026/#lilly-morgan-stanley-healthcare-conference-20262026-09-15T05:34:49Zweekly https://semaglutides.org/news/2026/#canadian-grocers-generic-semaglutide-pharmacy-volumes-20262026-09-15T04:25:49Zweekly https://semaglutides.org/news/2026/#glp1-bipolar-hospitalization-20262026-09-15T04:25:53Zweekly https://semaglutides.org/news/2026/#novo-aligns-ozempic-price-with-canadian-generics-20262026-09-15T04:25:57Zweekly https://semaglutides.org/news/2026/#wegovy-pill-four-to-one-lead-over-foundayo-20262026-09-15T04:26:29Zweekly https://semaglutides.org/news/2026/#ukraine-charges-27-falsified-tirzepatide-ring-20262026-09-15T04:26:08Zweekly https://semaglutides.org/news/2026/#largest-musculoskeletal-synthesis-date-no-bone-joint-effect-20262026-09-15T03:33:52Zweekly https://semaglutides.org/news/2026/#musculoskeletal-meta-analysis-1-25-million-people-finds-20262026-09-15T03:34:01Zweekly https://semaglutides.org/news/2026/#meta-analysis-links-glp-1-drugs-lean-mass-20262026-09-15T04:26:09Zweekly https://semaglutides.org/news/2026/#penn-researchers-publish-ai-study-400-000-glp-20262026-09-15T04:26:15Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-tally-32-glp-1-peptides-20262026-09-15T04:26:31Zweekly https://semaglutides.org/news/2026/#hims-margin-reset-one-year-2027-test-20262026-09-15T05:15:33Zweekly https://semaglutides.org/news/2026/#review-consolidates-case-glp-1-drugs-psoriasis-20262026-09-15T05:15:41Zweekly https://semaglutides.org/news/2026/#fda-approves-scholar-rock-apitegromab-isembyld-20262026-09-15T03:34:00Zweekly https://semaglutides.org/news/2026/#lillys-tirzepatide-reaches-57-glp-1-market-20262026-09-15T03:34:17Zweekly https://semaglutides.org/news/2026/#wernicke-encephalopathy-signal-semaglutide-tirzepatide-20262026-09-15T03:34:23Zweekly https://semaglutides.org/news/2026/#review-finds-mfn-drugmakers-hold-section-232-tariff-relief-until-2029-20262026-09-15T03:34:33Zweekly https://semaglutides.org/news/2026/#aarp-briefs-members-bridge-savings-ahead-of-open-enrollment-20262026-09-15T04:26:46Zweekly https://semaglutides.org/news/2026/#semaglutide-patent-cliff-analysis-20262026-09-15T04:26:40Zweekly https://semaglutides.org/news/2026/#fda-approves-isembyld-apitegromab-first-myostatin-inhibitor-20262026-09-15T04:26:54Zweekly https://semaglutides.org/news/2026/#jp-morgan-resumes-hims-coverage-neutral-20262026-09-15T04:26:35Zweekly https://semaglutides.org/news/2026/#lilly-shares-close-1-115-70-market-value-20262026-09-15T04:26:55Zweekly https://semaglutides.org/news/2026/#mfn-deal-state-pushback-medwatch-20262026-09-15T04:26:53Zweekly https://semaglutides.org/news/2026/#oral-glp1-tracker-september-20262026-09-15T04:26:51Zweekly https://semaglutides.org/news/2026/#wegovy-pill-foundayo-both-hit-record-weekly-prescriptions-20262026-09-15T04:26:58Zweekly https://semaglutides.org/news/2026/#danone-yogurt-sales-surge-among-us-glp-1-users-20262026-09-15T05:18:21Zweekly https://semaglutides.org/news/2026/#health-canada-counterfeit-glp1-advisory-20262026-09-15T05:15:51Zweekly https://semaglutides.org/news/2026/#lilly-begins-selling-foundayo-israel-20262026-09-15T05:15:55Zweekly https://semaglutides.org/news/2026/#lilly-completes-ataibeckley-20262026-09-15T05:16:06Zweekly https://semaglutides.org/news/2026/#lilly-tirzepatide-ckd-phase-2-completes-20262026-09-15T05:16:08Zweekly https://semaglutides.org/news/2026/#novo-town-hall-september-20262026-09-15T05:16:07Zweekly https://semaglutides.org/news/2026/#virginia-approves-power-project-lilly-goochland-20262026-09-15T05:16:45Zweekly https://semaglutides.org/news/2026/#china-approves-wegovy-mash-20262026-09-15T03:34:33Zweekly https://semaglutides.org/news/2026/#seventh-circuit-retatrutide-argument-preview-september-20262026-09-15T03:34:30Zweekly https://semaglutides.org/news/2026/#weight-regain-model-20262026-09-15T04:28:19Zweekly https://semaglutides.org/news/2026/#lilly-glp1-windfall-womens-health-push-20262026-09-15T04:27:17Zweekly https://semaglutides.org/news/2026/#cell-reports-asprosin-obesity-memory-explains-regain-20262026-09-15T04:27:08Zweekly https://semaglutides.org/news/2026/#current-obesity-names-engagement-unsolved-problem-digital-obesity-20262026-09-15T04:27:19Zweekly https://semaglutides.org/news/2026/#foundayo-prescriber-base-8000-to-36000-20262026-09-15T04:27:26Zweekly https://semaglutides.org/news/2026/#lilly-china-93-percent-growth-international-share-20262026-09-15T04:27:16Zweekly https://semaglutides.org/news/2026/#lilly-refers-200-entities-regulators-law-enforcement-20262026-09-15T04:27:23Zweekly https://semaglutides.org/news/2026/#frontiers-review-divergent-ocular-safety-across-glp-1-drugs-20262026-09-15T04:27:26Zweekly https://semaglutides.org/news/2026/#umbrella-review-quantifies-glp-1-drugs-insulin-adjuncts-20262026-09-15T04:27:49Zweekly https://semaglutides.org/news/2026/#ql-biopharm-registers-semaglutide-zovaglutide-switch-trial-20262026-09-15T05:16:39Zweekly https://semaglutides.org/news/2026/#huntsville-tif-district-lilly-alabama-plant-20262026-09-15T05:16:33Zweekly https://semaglutides.org/news/2026/#novo-research-head-20262026-09-15T05:16:42Zweekly https://semaglutides.org/news/2026/#cagrisema-diabetic-neuropathy-trial-20262026-09-15T05:16:35Zweekly https://semaglutides.org/news/2026/#review-raises-untested-question-tirzepatide-oral-progestogens-20262026-09-15T05:16:54Zweekly https://semaglutides.org/news/2026/#weekly-basal-insulin-plus-semaglutide-combination-t2d-20262026-09-15T05:16:58Zweekly https://semaglutides.org/news/2026/#nmpa-accepts-hengrui-ribupatide-filing-t2d-20262026-09-15T03:34:37Zweekly https://semaglutides.org/news/2026/#endocrine-society-obesity-scientific-statement-center-on-obesity-20262026-09-15T03:34:45Zweekly https://semaglutides.org/news/2026/#analysis-puts-tirzepatide-nearly-two-thirds-lillys-quarterly-20262026-09-15T04:27:39Zweekly https://semaglutides.org/news/2026/#medscape-tirzepatide-beats-semaglutide-weight-not-safety-20262026-09-15T04:27:50Zweekly https://semaglutides.org/news/2026/#forbes-says-administration-left-pbms-largely-untouched-20262026-09-15T04:27:42Zweekly https://semaglutides.org/news/2026/#clark-hill-guidance-fifth-circuit-tirzepatide-compounding-20262026-09-15T04:27:48Zweekly https://semaglutides.org/news/2026/#morgan-stanley-downgrade-20262026-09-15T04:29:57Zweekly https://semaglutides.org/news/2026/#novo-q3-ziltivekimab-impairment-view-20262026-09-15T04:28:05Zweekly https://semaglutides.org/news/2026/#mounjaro-cv-nod-physician-views-20262026-09-15T04:28:01Zweekly https://semaglutides.org/news/2026/#foodnavigator-glp-1-messaging-consumers-more-selective-20262026-09-15T04:28:07Zweekly https://semaglutides.org/news/2026/#zealand-zupreme-2-marked-completed-20262026-09-15T04:28:30Zweekly https://semaglutides.org/news/2026/#tiktok-fake-glp-1-market-targets-women-20262026-09-15T05:16:56Zweekly https://semaglutides.org/news/2026/#counsel-guidance-patient-specific-justification-after-fifth-circuit-20262026-09-15T05:17:01Zweekly https://semaglutides.org/news/2026/#mannkind-licenses-inhaled-glp1-rose-pharma-20262026-09-15T05:17:03Zweekly https://semaglutides.org/news/2026/#novo-opens-pediatric-cagrisema-t2d-trial-20262026-09-15T05:17:14Zweekly https://semaglutides.org/news/2026/#weightwatchers-appoints-stephen-bye-ceo-20262026-09-15T05:17:38Zweekly https://semaglutides.org/news/2026/#weightwatchers-dear-media-glp-1-podcast-20262026-09-15T05:34:28Zweekly https://semaglutides.org/news/2026/#truveta-19-percent-jump-glp-1-prescribing-seniors-after-bridge-20262026-09-15T01:36:17Zweekly https://semaglutides.org/news/2026/#aleniglipron-open-label-extension-16-2-weight-loss-20262026-09-15T03:34:56Zweekly https://semaglutides.org/news/2026/#cms-bridge-prior-authorization-under-12-hours-no-formal-appeal-20262026-09-15T03:34:59Zweekly https://semaglutides.org/news/2026/#ers-2026-semaglutide-tied-40-percent-fewer-asthma2026-09-15T03:35:01Zweekly https://semaglutides.org/news/2026/#lilly-mochi-conspiracy-claims-trimmed-september-20262026-09-15T03:35:05Zweekly https://semaglutides.org/news/2026/#novo-shuts-two-more-ziltivekimab-heart-trials-20262026-09-15T03:35:06Zweekly https://semaglutides.org/news/2026/#amycretin-late-stage-20262026-09-15T03:35:18Zweekly https://semaglutides.org/news/2026/#sandoz-canada-generic-semaglutide-launch-excludes-glp1-targets-20262026-09-15T03:35:25Zweekly https://semaglutides.org/news/2026/#novo-capital-markets-day-preview-analysts-20262026-09-15T04:28:34Zweekly https://semaglutides.org/news/2026/#obesity-market-forecast-20262026-09-15T04:28:29Zweekly https://semaglutides.org/news/2026/#cms-limited-bridge-outreach-manufacturers-advertise-program-20262026-09-15T04:28:57Zweekly https://semaglutides.org/news/2026/#eight-generic-semaglutide-files-health-canada-20262026-09-15T04:29:08Zweekly https://semaglutides.org/news/2026/#gallup-revises-2026-glp-1-obesity-estimates2026-09-15T04:28:51Zweekly https://semaglutides.org/news/2026/#emarketer-glp-1-use-reshapes-whole-household-habits-20262026-09-15T04:28:56Zweekly https://semaglutides.org/news/2026/#moonwalk-raises-70m-adipose-rnai-obesity-20262026-09-15T04:28:48Zweekly https://semaglutides.org/news/2026/#novo-shares-ziltivekimab-halt-outweighs-step-young-20262026-09-15T04:28:54Zweekly https://semaglutides.org/news/2026/#novo-share-performance-sept-20262026-09-15T04:29:04Zweekly https://semaglutides.org/news/2026/#zepbound-cost-offset-published-numbers-dom-20262026-09-15T04:29:27Zweekly https://semaglutides.org/news/2026/#peerj-meta-analysis-confirms-regain-withdrawal-improvement-side-20262026-09-15T04:29:13Zweekly https://semaglutides.org/news/2026/#structure-therapeutics-clinical-data-oral-small-molecule-amylin-20262026-09-15T04:29:19Zweekly https://semaglutides.org/news/2026/#three-guided-q3-obesity-milestones-still-open-20262026-09-15T04:29:30Zweekly https://semaglutides.org/news/2026/#amgen-shares-slide-after-rival-lp-a-failure-20262026-09-15T05:17:22Zweekly https://semaglutides.org/news/2026/#step-young-obesityweek-20262026-09-15T01:36:03Zweekly https://semaglutides.org/news/2026/#lilly-us-manufacturing-passes-50-billion-20262026-09-15T04:29:26Zweekly https://semaglutides.org/news/2026/#mounjaro-india-top-selling-drug-tirzepatide-share-20262026-09-15T04:29:38Zweekly https://semaglutides.org/news/2026/#semaglutide-tirzepatide-equivalent-weight-loss-type-2-diabetes-20262026-09-15T04:29:35Zweekly https://semaglutides.org/news/2026/#no-final-503b-bulks-determination-september-20262026-09-15T04:29:35Zweekly https://semaglutides.org/news/2026/#north-carolina-confirms-no-restoration-state-employee-glp-20262026-09-15T04:29:45Zweekly https://semaglutides.org/news/2026/#case-report-four-semaglutide-doses-at-once-pen-error-20262026-09-15T05:17:14Zweekly https://semaglutides.org/news/2026/#glp-1-drugs-fewer-nerve-complications-than-dpp-4-inhibitors-20262026-09-15T05:17:27Zweekly https://semaglutides.org/news/2026/#head-head-asthma-analysis-finds-no-advantage-tirzepatide-20262026-09-15T05:17:34Zweekly https://semaglutides.org/news/2026/#lilly-international-growth-canada-generic-constraints-20262026-09-15T05:17:56Zweekly https://semaglutides.org/news/2026/#novo-buyback-9-billion-dkk-september-20262026-09-15T05:17:42Zweekly https://semaglutides.org/news/2026/#novo-stock-step-young-20262026-09-15T05:17:41Zweekly https://semaglutides.org/news/2026/#medicare-second-negotiation-round-savings-20262026-09-15T04:29:45Zweekly https://semaglutides.org/news/2026/#lilly-employee-pbm-rightway-caremark-context-20262026-09-15T05:17:50Zweekly https://semaglutides.org/news/2026/#lilly-moves-against-imports-counterfeit-mounjaro-20262026-09-15T05:34:17Zweekly https://semaglutides.org/news/2026/#medicaid-obesity-coverage-count-twelve-states-falling-october-20262026-09-15T03:35:38Zweekly https://semaglutides.org/news/2026/#hims-waitlist-149-wegovy-ozempic-novo-partnership-20262026-09-15T04:30:07Zweekly https://semaglutides.org/news/2026/#lillydirect-self-pay-ladder-refill-condition-confirmed-20262026-09-15T04:29:53Zweekly https://semaglutides.org/news/2026/#weightwatchers-lillydirect-med-plus-nationwide-20262026-09-15T04:30:11Zweekly https://semaglutides.org/news/2026/#zepbound-savings-card-2026-terms-tighter-caps-confirmed-20262026-09-15T04:30:05Zweekly https://semaglutides.org/news/2026/#weightwatchers-chequp-uk-partnership-expanded-20262026-09-15T05:18:22Zweekly https://semaglutides.org/news/2026/#novo-halts-hermes-athena-ziltivekimab-trials-20262026-09-15T03:05:01Zweekly https://semaglutides.org/news/2026/#foundayo-reaches-44-000-weekly-scripts-oral-glp-20262026-09-15T03:35:38Zweekly https://semaglutides.org/news/2026/#patient-injury-suits-mochi-supplier-network-pharmacies-20262026-09-15T03:35:33Zweekly https://semaglutides.org/news/2026/#pediatric-glp1-prescribing-study-20262026-09-15T03:35:41Zweekly https://semaglutides.org/news/2026/#retatrutide-30-3-average-weight-loss-triumph-1-20262026-09-15T03:35:45Zweekly https://semaglutides.org/news/2026/#washington-shuts-aequita-pharmacy-mochi-supply-chain-20262026-09-15T03:36:01Zweekly https://semaglutides.org/news/2026/#lilly-retatrutide-enforcement-scale-detail-20262026-09-15T05:39:37Zweekly https://semaglutides.org/news/2026/#novo-begins-phase-3-two-cagrilintide-presentations-20262026-09-15T04:30:18Zweekly https://semaglutides.org/news/2026/#lilly-registers-phase-1-gastric-emptying-study-tirzepatide-20262026-09-15T05:18:01Zweekly https://semaglutides.org/news/2026/#medscape-not-an-easy-way-out-rethinking-glp-1-stigma-20262026-09-15T05:18:02Zweekly https://semaglutides.org/news/2026/#novo-new-injectable-obesity-phase-3-september-20262026-09-15T05:18:17Zweekly https://semaglutides.org/news/2026/#state-boards-retatrutide-20262026-09-15T05:18:06Zweekly https://semaglutides.org/news/2026/#strive-pharmacy-presources-peptide-ingredients-503a-rule-20262026-09-15T05:18:26Zweekly https://semaglutides.org/news/2026/#veru-enobosarm-glp1-muscle-study-closes-enrollment-20262026-09-15T05:19:08Zweekly https://semaglutides.org/news/2026/#california-sb-1089-sent-governor-20262026-09-15T03:36:10Zweekly https://semaglutides.org/news/2026/#novo-united-labs-ubt251-phase-2-19-7-percent-20262026-09-15T03:36:11Zweekly https://semaglutides.org/news/2026/#nyu-genetic-study-links-glp1r-activity-male-pattern-hair-loss-20262026-09-15T03:36:10Zweekly https://semaglutides.org/news/2026/#easo-position-statement-incretin-therapies-comprehensive-obesity-care-20262026-09-15T04:30:13Zweekly https://semaglutides.org/news/2026/#fda-shortage-record-still-lists-liraglutide-shortage-while-20262026-09-15T04:30:15Zweekly https://semaglutides.org/news/2026/#menarini-licenses-gan-lee-bofanglutide-europe-20262026-09-15T04:30:47Zweekly https://semaglutides.org/news/2026/#novo-wins-copycat-pharmacy-false-ad-suit-20262026-09-15T04:30:33Zweekly https://semaglutides.org/news/2026/#state-licensing-boards-warning-notices-ruo-peptides-20262026-09-15T04:30:38Zweekly https://semaglutides.org/news/2026/#ildong-sets-september-29-topline-oral-glp1-20262026-09-15T05:18:26Zweekly https://semaglutides.org/news/2026/#aspen-africa-mounjaro-forecast-20262026-09-15T05:18:42Zweekly https://semaglutides.org/news/2026/#structural-blueprint-of-glp-1-signaling-brain-disease-20262026-09-15T05:18:45Zweekly https://semaglutides.org/news/2026/#superluminal-raises-60m-mc4r-obesity-drug-20262026-09-15T05:18:40Zweekly https://semaglutides.org/news/2026/#tirzepatide-help-post-bariatric-hypoglycemia-three-cases-20262026-09-15T05:18:42Zweekly https://semaglutides.org/news/2026/#only-indiana-commits-balance-medicaid-model-29-states-decline-20262026-09-15T03:05:06Zweekly https://semaglutides.org/news/2026/#modern-healthcare-documents-employer-glp-1-retreat-cigna-pwc-starbucks-20262026-09-15T03:36:15Zweekly https://semaglutides.org/news/2026/#nature-late-life-semaglutide-extends-lifespan-female-mice-20262026-09-15T03:36:20Zweekly https://semaglutides.org/news/2026/#starbucks-ends-glp-1-weight-loss-coverage-october-20262026-09-15T03:36:27Zweekly https://semaglutides.org/news/2026/#medicare-bridge-blockbuster-revenue-lilly-analyst-20262026-09-15T04:30:39Zweekly https://semaglutides.org/news/2026/#fda-screens-glp-1-ingredients-at-border-fake-pharmacy-labels-20262026-09-15T04:30:32Zweekly https://semaglutides.org/news/2026/#oac-presses-pepsico-starbucks-to-keep-glp-1-coverage-20262026-09-15T04:30:41Zweekly https://semaglutides.org/news/2026/#poison-control-surge-unapproved-glp-1-products-20262026-09-15T04:30:53Zweekly https://semaglutides.org/news/2026/#september-pricing-snapshot-lillydirect-pens-vials-20262026-09-15T04:31:07Zweekly https://semaglutides.org/news/2026/#upper-macungie-final-approval-lilly-fogelsville-20262026-09-15T04:31:10Zweekly https://semaglutides.org/news/2026/#edo-finds-pharma-nfl-ads-twice-effective-prime-20262026-09-15T05:18:45Zweekly https://semaglutides.org/news/2026/#updated-zepbound-mounjaro-labels-posted-20262026-09-15T05:18:59Zweekly https://semaglutides.org/news/2026/#fda-updates-unapproved-glp-1-guidance-compounded-tirzepatide-20262026-09-15T03:04:54Zweekly https://semaglutides.org/news/2026/#glp-1-injury-dockets-reach-4-022-216-20262026-09-15T03:05:03Zweekly https://semaglutides.org/news/2026/#fda-green-list-import-alert-fraudulent-compounded-labels-20262026-09-15T03:36:35Zweekly https://semaglutides.org/news/2026/#fda-posts-batch-warning-letters-online-peptide-sellers-20262026-09-15T03:36:44Zweekly https://semaglutides.org/news/2026/#fifth-circuit-semaglutide-delisting-opinion-september-20262026-09-15T03:36:51Zweekly https://semaglutides.org/news/2026/#glp1-litigation-september-20262026-09-15T03:36:49Zweekly https://semaglutides.org/news/2026/#jpml-count-4-022-pending-mdl-3094-216-20262026-09-15T03:36:51Zweekly https://semaglutides.org/news/2026/#kff-poll-one-third-aware-trumprx-most-doubt-price-policies-20262026-09-15T03:37:03Zweekly https://semaglutides.org/news/2026/#lilly-cuts-foundayo-self-pay-prices-two-doses-20262026-09-15T03:37:05Zweekly https://semaglutides.org/news/2026/#20-drugmakers-have-drug-pricing-agreements-20262026-09-15T03:37:17Zweekly https://semaglutides.org/news/2026/#wegovy-pill-germany-launch-20262026-09-15T03:37:22Zweekly https://semaglutides.org/news/2026/#hims-securities-class-action-velanki-filed-20262026-09-15T03:37:20Zweekly https://semaglutides.org/news/2026/#unitedhealthcares-updated-weight-loss-prior-authorization-program-takes-20262026-09-15T03:37:22Zweekly https://semaglutides.org/news/2026/#mounjaro-heart-label-payer-leverage-analysis-20262026-09-15T04:30:57Zweekly https://semaglutides.org/news/2026/#bmj-canada-250-dollar-patent-fee-lapse-20262026-09-15T04:31:00Zweekly https://semaglutides.org/news/2026/#esc-2026-tirzepatide-maintenance-20262026-09-15T04:31:10Zweekly https://semaglutides.org/news/2026/#npj-higher-semaglutide-dose-fewer-neuropsychiatric-events-20262026-09-15T04:31:11Zweekly https://semaglutides.org/news/2026/#mash-outcomes-master-protocol-including-tirzepatide-recruiting-20262026-09-15T04:31:20Zweekly https://semaglutides.org/news/2026/#novo-haegebarth-global-research-petersen-external-innovation-20262026-09-15T04:31:22Zweekly https://semaglutides.org/news/2026/#pfizer-starts-september-berobenatide-phase-3-trials-20262026-09-15T04:31:55Zweekly https://semaglutides.org/news/2026/#reuters-company-by-company-reference-glp-1-pricing-deal-terms-20262026-09-15T04:31:30Zweekly https://semaglutides.org/news/2026/#time-reports-mfn-medicaid-prices-not-lowest-for-consumers-20262026-09-15T04:31:28Zweekly https://semaglutides.org/news/2026/#virtual-glp-1-program-strength-coaching-improves-both-20262026-09-15T04:31:32Zweekly https://semaglutides.org/news/2026/#brazil-paraguay-anvisa-dinavisa-counterfeit-agreement-20262026-09-15T05:19:00Zweekly https://semaglutides.org/news/2026/#cspc-registers-phase-2-syh2069-type-2-diabetes-20262026-09-15T05:19:30Zweekly https://semaglutides.org/news/2026/#hims-shares-fall-fda-unapproved-glp-1-warning-20262026-09-15T05:19:07Zweekly https://semaglutides.org/news/2026/#lancet-diabetes-endocrinology-editorial-soaring-glp-1-use-20262026-09-15T05:19:08Zweekly https://semaglutides.org/news/2026/#regeneron-trevogrumab-readout-date-moves-20262026-09-15T05:19:22Zweekly https://semaglutides.org/news/2026/#solera-adds-noom-weight-management-network-20262026-09-15T05:19:24Zweekly https://semaglutides.org/news/2026/#nyt-doustdar-profile-second-act-20262026-09-15T05:19:28Zweekly https://semaglutides.org/news/2026/#treasure-ckd-reaches-estimated-primary-completion-no-results-20262026-09-15T05:19:27Zweekly https://semaglutides.org/news/2026/#rule-702-expert-hearing-tests-whether-glp-1-20262026-09-15T03:05:11Zweekly https://semaglutides.org/news/2026/#five-semaglutide-presentations-now-market-once-20262026-09-15T03:37:34Zweekly https://semaglutides.org/news/2026/#generic-liraglutide-undercuts-every-branded-glp-1-acquisition-20262026-09-15T03:37:39Zweekly https://semaglutides.org/news/2026/#semaglutide-indication-map-20262026-09-15T03:37:45Zweekly https://semaglutides.org/news/2026/#wegovy-self-pay-prices-20262026-09-15T03:37:47Zweekly https://semaglutides.org/news/2026/#lilly-fda-retatrutide-appeal-20262026-09-15T04:31:44Zweekly https://semaglutides.org/news/2026/#compounded-price-gap-20262026-09-15T04:31:33Zweekly https://semaglutides.org/news/2026/#mdl-3094-4000-cases-20262026-09-15T04:31:49Zweekly https://semaglutides.org/news/2026/#jama-pediatrics-biliary-events-youth-glp-1-20262026-09-15T04:31:53Zweekly https://semaglutides.org/news/2026/#glp1-liability-estimates-20262026-09-15T04:31:55Zweekly https://semaglutides.org/news/2026/#mash-semaglutide-only-20262026-09-15T04:32:07Zweekly https://semaglutides.org/news/2026/#ajmc-glp-1-linked-lower-obesity-related-cancer-risk-20262026-09-15T04:32:17Zweekly https://semaglutides.org/news/2026/#wegovy-hfpef-review-20262026-09-15T04:32:06Zweekly https://semaglutides.org/news/2026/#zenagamtide-naming-20262026-09-15T04:32:25Zweekly https://semaglutides.org/news/2026/#corbus-expects-topline-phase-1b-results-peripheral-cb1-20262026-09-15T05:19:44Zweekly https://semaglutides.org/news/2026/#glp1-environmental-debate-20262026-09-15T05:19:57Zweekly https://semaglutides.org/news/2026/#medicaid-cohort-glp-1-use-and-new-depression-diagnoses-20262026-09-15T05:19:41Zweekly https://semaglutides.org/news/2026/#nice-orforglipron-appraisal-20262026-09-15T05:19:49Zweekly https://semaglutides.org/news/2026/#optometry-guidance-glp-1-naion-what-to-tell-patients-20262026-09-15T05:21:54Zweekly https://semaglutides.org/news/2026/#oral-glp1-market-size-20262026-09-15T05:19:49Zweekly https://semaglutides.org/news/2026/#obesity-pillars-orforglipron-older-adults-post-hoc-20262026-09-15T05:20:02Zweekly https://semaglutides.org/news/2026/#medicare-glp-1-bridge-enrollment-passes-half-million-20262026-09-15T03:05:28Zweekly https://semaglutides.org/news/2026/#brazil-clears-two-more-semaglutide-pens-interchangeable-20262026-09-15T03:37:57Zweekly https://semaglutides.org/news/2026/#guardian-gray-market-retatrutide-patients-20262026-09-15T03:37:57Zweekly https://semaglutides.org/news/2026/#mfn-agreements-reach-26-manufacturers-89-percent-branded-market-20262026-09-15T03:38:01Zweekly https://semaglutides.org/news/2026/#house-bill-10185-part-d-premium-credit-2027-20262026-09-15T04:32:13Zweekly https://semaglutides.org/news/2026/#adjust-t1d-extension-shows-glycemic-gains-fade-stopping-20262026-09-15T04:32:12Zweekly https://semaglutides.org/news/2026/#brazil-glp-1-smuggling-seizures-triple-20262026-09-15T04:32:25Zweekly https://semaglutides.org/news/2026/#hims-hers-launches-branded-glp-1s-australia-20262026-09-15T04:32:23Zweekly https://semaglutides.org/news/2026/#lilly-buys-merida-20262026-09-15T04:32:32Zweekly https://semaglutides.org/news/2026/#lilly-foundayos-big-consumer-ad-campaign-fronted-martha-20262026-09-15T04:32:52Zweekly https://semaglutides.org/news/2026/#lilly-registers-2001-patient-orforglipron-overweight-trial-20262026-09-15T04:32:35Zweekly https://semaglutides.org/news/2026/#taltz-zepbound-one-year-20262026-09-15T04:32:38Zweekly https://semaglutides.org/news/2026/#penn-glp1-male-pattern-hair-loss-study-20262026-09-15T04:32:56Zweekly https://semaglutides.org/news/2026/#brazil-glp1-black-market-reuters-20262026-09-15T04:32:45Zweekly https://semaglutides.org/news/2026/#glp1-low-starter-doses-effective-reuters-20262026-09-15T04:32:58Zweekly https://semaglutides.org/news/2026/#sciwind-ecnoglutide-phase-3-knee-osteoarthritis-20262026-09-15T04:33:08Zweekly https://semaglutides.org/news/2026/#sun-pharma-secures-section-232-tariff-relief-pricing-agreement-20262026-09-15T04:33:15Zweekly https://semaglutides.org/news/2026/#zepbound-label-revision-keeps-dual-weight-sleep-apnea-20262026-09-15T04:33:02Zweekly https://semaglutides.org/news/2026/#altimmune-performa-registers-1800-patient-phase-3-20262026-09-15T05:20:48Zweekly https://semaglutides.org/news/2026/#boston-globe-ozempic-hypocrisy-shamed-either-way-20262026-09-15T05:20:07Zweekly https://semaglutides.org/news/2026/#fda-telehealth-advertising-compliance-warning-20262026-09-15T05:20:07Zweekly https://semaglutides.org/news/2026/#innovent-mazdutide-9mg-phase-3-record-unknown-20262026-09-15T05:20:28Zweekly https://semaglutides.org/news/2026/#meta-analysis-newer-glp-1-agents-nondiabetic-adults-weight-loss-20262026-09-15T05:20:33Zweekly https://semaglutides.org/news/2026/#penn-hair-loss-findings-reach-mainstream-coverage-20262026-09-15T05:20:24Zweekly https://semaglutides.org/news/2026/#semaglutide-analysis-6239-adults-beyond-weight-20262026-09-15T05:20:24Zweekly https://semaglutides.org/news/2026/#wegovy-pill-4-mg-introductory-price-expires-20262026-09-15T05:20:50Zweekly https://semaglutides.org/news/2026/#white-house-favored-nation-deals-nine-manufacturers-20262026-09-15T05:20:51Zweekly https://semaglutides.org/news/2026/#ascletis-doses-first-patient-global-phase-3-asc30-20262026-09-15T03:38:08Zweekly https://semaglutides.org/news/2026/#weight-drugs-trigger-cultural-body-trauma-for-women-20262026-09-15T05:20:52Zweekly https://semaglutides.org/news/2026/#esc-2026-heart-failure-guideline-backs-semaglutide-tirzepatide-hfpef-20262026-09-15T03:38:12Zweekly https://semaglutides.org/news/2026/#large-cohort-compares-glp-1-drugs-spironolactone-resistant-20262026-09-15T04:33:14Zweekly https://semaglutides.org/news/2026/#novo-esc-2026-oral-semaglutide-organ-protection2026-09-15T04:33:21Zweekly https://semaglutides.org/news/2026/#lilly-cardiovascular-indication-dual-gip-glp-1-agonist-20262026-09-15T03:05:27Zweekly https://semaglutides.org/news/2026/#lilly-mounjaro-heart-indication-built-head-head-trial-20262026-09-15T03:05:44Zweekly https://semaglutides.org/news/2026/#mounjaro-cv-filing-20262026-09-15T03:05:34Zweekly https://semaglutides.org/news/2026/#foundayo-passes-40-000-weekly-prescriptions-20262026-09-15T04:33:15Zweekly https://semaglutides.org/news/2026/#google-updates-site-reputation-abuse-guidance-editorially-overseen-20262026-09-15T04:33:28Zweekly https://semaglutides.org/news/2026/#india-generics-struggle-20262026-09-15T04:33:35Zweekly https://semaglutides.org/news/2026/#pcpa-tiered-generic-semaglutide-pricing-20262026-09-15T05:20:57Zweekly https://semaglutides.org/news/2026/#hadassah-what-happens-to-jewish-food-culture-age-of-ozempic-20262026-09-15T05:20:52Zweekly https://semaglutides.org/news/2026/#fda-approves-mounjaro-cardiovascular-indication-20262026-09-15T03:05:40Zweekly https://semaglutides.org/news/2026/#fifth-circuit-upholds-fdas-glp-1-shortage-delistings-20262026-09-15T03:05:39Zweekly https://semaglutides.org/news/2026/#novo-confirms-2027-us-list-price-cut-20262026-09-15T03:38:14Zweekly https://semaglutides.org/news/2026/#researchers-propose-adaptive-maintenance-framework-beyond-continue-stop-20262026-09-15T03:38:30Zweekly https://semaglutides.org/news/2026/#william-blair-maps-rest-of-2026-obesity-catalysts-20262026-09-15T03:38:28Zweekly https://semaglutides.org/news/2026/#china-nmpa-accepts-wegovy-pill-filing-20262026-09-15T04:33:38Zweekly https://semaglutides.org/news/2026/#eudravigilance-analysis-compares-suicide-self-injury-glp-1-20262026-09-15T04:33:36Zweekly https://semaglutides.org/news/2026/#fifth-circuit-record-lilly-23-billion-capacity-20262026-09-15T04:33:32Zweekly https://semaglutides.org/news/2026/#arla-foods-ingredients-revenue-up-19-percent-glp-1-whey-20262026-09-15T05:21:05Zweekly https://semaglutides.org/news/2026/#deutsche-bank-downgrades-novo-20262026-09-15T05:21:33Zweekly https://semaglutides.org/news/2026/#lilly-registers-china-phase-3-orforglipron-20262026-09-15T05:21:45Zweekly https://semaglutides.org/news/2026/#cagrisema-korea-phase-3-start-20262026-09-15T05:21:20Zweekly https://semaglutides.org/news/2026/#both-tirzepatide-labels-updated-basis-surpass-cvot-20262026-09-15T03:38:35Zweekly https://semaglutides.org/news/2026/#court-lets-zepbound-formulary-lawsuit-against-cvs-caremark-20262026-09-15T03:38:39Zweekly https://semaglutides.org/news/2026/#cvs-walgreens-each-fill-100000-medicare-bridge-prescriptions-20262026-09-15T03:38:41Zweekly https://semaglutides.org/news/2026/#kff-estimates-medicare-bridge-cost-1-3-to-10-billion-20262026-09-15T03:38:48Zweekly https://semaglutides.org/news/2026/#real-world-analysis-finds-gray-market-retatrutide-underperforms-20262026-09-15T03:39:02Zweekly https://semaglutides.org/news/2026/#abbvie-phase-2-amylin-analog-abbv-295-20262026-09-15T04:33:40Zweekly https://semaglutides.org/news/2026/#glp-1-medicines-force-rethink-obesity-eating-disorder-care-20262026-09-15T04:33:46Zweekly https://semaglutides.org/news/2026/#glp1-construction-wave-lilly-site-detail-20262026-09-15T04:33:53Zweekly https://semaglutides.org/news/2026/#digital-engagement-linked-persistence-persistence-results-20262026-09-15T04:33:57Zweekly https://semaglutides.org/news/2026/#ftc-complaint-names-fifteen-ad-platforms-hims-tracking-20262026-09-15T04:34:05Zweekly https://semaglutides.org/news/2026/#jama-psychiatry-glp-1-mortality-serious-mental-illness-20262026-09-15T04:34:01Zweekly https://semaglutides.org/news/2026/#zepbound-healthcare-costs-study-20262026-09-15T04:33:57Zweekly https://semaglutides.org/news/2026/#meta-analysis-pools-real-world-incretin-results-bariatric-20262026-09-15T04:34:12Zweekly https://semaglutides.org/news/2026/#obesity-action-coalition-assesses-bridge-opening-weeks-troa-cosponsors-20262026-09-15T04:34:10Zweekly https://semaglutides.org/news/2026/#walgreens-says-half-of-bridge-patients-new-to-glp-1s-20262026-09-15T04:34:20Zweekly https://semaglutides.org/news/2026/#white-house-prepares-medicaid-mfn-deals-midsize-biotechs-20262026-09-15T04:34:18Zweekly https://semaglutides.org/news/2026/#pfizer-files-japan-phase-3-monthly-berobenatide-20262026-09-15T05:21:14Zweekly https://semaglutides.org/news/2026/#fda-records-novo-nordisk-notice-saxenda-will-discontinued-20262026-09-15T03:05:59Zweekly https://semaglutides.org/news/2026/#kff-documents-medicare-bridge-excludes-5-9-million-sicker-patients-20262026-09-15T03:05:51Zweekly https://semaglutides.org/news/2026/#business-group-health-14-percent-employers-dropping-glp-1-2027-20262026-09-15T03:38:55Zweekly https://semaglutides.org/news/2026/#chipotle-shake-shack-smoothie-king-run-glp-1-20262026-09-15T03:38:59Zweekly https://semaglutides.org/news/2026/#four-glp1-decisions-20262026-09-15T03:39:09Zweekly https://semaglutides.org/news/2026/#large-employer-glp-1-coverage-falls-60-72-20262026-09-15T03:39:12Zweekly https://semaglutides.org/news/2026/#pepsico-drops-employee-weight-loss-drug-coverage-october-20262026-09-15T03:39:12Zweekly https://semaglutides.org/news/2026/#va-dod-guideline-discourages-stopping-effective-obesity-medication-20262026-09-15T03:39:27Zweekly https://semaglutides.org/news/2026/#genentech-hanmi-deal-20262026-09-15T04:34:36Zweekly https://semaglutides.org/news/2026/#foundayo-type-2-diabetes-decision-q4-2026-window2026-09-15T04:34:22Zweekly https://semaglutides.org/news/2026/#veteran-analysis-glp-1-fewer-overdoses-drug-related-deaths-20262026-09-15T04:34:27Zweekly https://semaglutides.org/news/2026/#novo-failed-acquisitions-tally-20262026-09-15T05:21:26Zweekly https://semaglutides.org/news/2026/#surpass-peds-commentary-tirzepatide-youth-type-2-diabetes-20262026-09-15T05:21:21Zweekly https://semaglutides.org/news/2026/#nutraingredients-glp-1-companion-nutrition-race-heats-up-20262026-09-15T05:21:34Zweekly https://semaglutides.org/news/2026/#guardian-asks-how-to-talk-about-changing-bodies-ozempic-age-20262026-09-15T05:40:13Zweekly https://semaglutides.org/news/2026/#fda-issues-batch-peptide-warning-letters-naming-tirzepatide-20262026-09-15T03:39:29Zweekly https://semaglutides.org/news/2026/#fda-tallies-1-700-adverse-event-naming-compounded-20262026-09-15T03:39:29Zweekly https://semaglutides.org/news/2026/#lilly-novo-nad-challenges-glp-1-copycat-ads-20262026-09-15T03:39:33Zweekly https://semaglutides.org/news/2026/#novo-nordisk-opens-zenagamtide-phase-3-trial-20262026-09-15T03:39:44Zweekly https://semaglutides.org/news/2026/#amgen-maritime-2-extension-opens-enrollment-20262026-09-15T04:35:04Zweekly https://semaglutides.org/news/2026/#fda-warns-research-use-only-peptide-sellers-20262026-09-15T04:34:35Zweekly https://semaglutides.org/news/2026/#foundayo-uk-launch-20262026-09-15T04:34:39Zweekly https://semaglutides.org/news/2026/#lilly-novo-national-advertising-division-copycats-20262026-09-15T04:34:42Zweekly https://semaglutides.org/news/2026/#lilly-novo-lanham-act-503b-compliance-claims-20262026-09-15T04:35:02Zweekly https://semaglutides.org/news/2026/#nad-noom-willow-health-drop-compounded-glp-1-claims-20262026-09-15T04:35:03Zweekly https://semaglutides.org/news/2026/#nice-requests-more-information-foundayo-appraisal-20262026-09-15T04:35:02Zweekly https://semaglutides.org/news/2026/#zenagamtide-head-to-head-semaglutide-korea-20262026-09-15T04:35:24Zweekly https://semaglutides.org/news/2026/#china-obesity-drug-advertising-workarounds-20262026-09-15T04:35:02Zweekly https://semaglutides.org/news/2026/#english-high-court-dynamic-blocking-order-counterfeits-20262026-09-15T05:21:46Zweekly https://semaglutides.org/news/2026/#orforglipron-older-adults-post-hoc-attain-20262026-09-15T05:21:59Zweekly https://semaglutides.org/news/2026/#real-world-tirzepatide-one-year-mace-infections-20262026-09-15T05:22:05Zweekly https://semaglutides.org/news/2026/#pharma-weight-loss-advertising-china-feature-20262026-09-15T05:22:03Zweekly https://semaglutides.org/news/2026/#wdbj-parents-hiding-glp-1-use-from-children-20262026-09-15T05:34:24Zweekly https://semaglutides.org/news/2026/#ledisa-glp-1-patch-false-advertising-class-action-20262026-09-15T05:22:04Zweekly https://semaglutides.org/news/2026/#states-reject-medicaid-glp1-price-deal-20262026-09-15T03:39:39Zweekly https://semaglutides.org/news/2026/#bmj-fact-check-uk-glp-1-death-reports-yellow-card-20262026-09-15T04:35:20Zweekly https://semaglutides.org/news/2026/#tirzepatide-linked-lower-stroke-risk-glp-1-drugs-20262026-09-15T04:35:22Zweekly https://semaglutides.org/news/2026/#medicare-274-negotiated-semaglutide-price-explained-20262026-09-15T04:35:36Zweekly https://semaglutides.org/news/2026/#lilly-breaks-ground-houston-generation-park-20262026-09-15T04:35:25Zweekly https://semaglutides.org/news/2026/#regeneron-olatorepatide-phase-2-obesity-registry-20262026-09-15T04:35:32Zweekly https://semaglutides.org/news/2026/#scholar-rock-apitegromab-regulatory-update-august-20262026-09-15T04:36:19Zweekly https://semaglutides.org/news/2026/#scholar-rock-embraze-lean-mass-data-and-regulatory-update-20262026-09-15T04:35:49Zweekly https://semaglutides.org/news/2026/#structure-accomplish-phase-3-trials-recruiting-20262026-09-15T04:35:56Zweekly https://semaglutides.org/news/2026/#unitedhealthcare-publishes-updated-glp-1-quantity-limits-september-20262026-09-15T04:35:54Zweekly https://semaglutides.org/news/2026/#biopharma-dive-cost-and-perception-reshape-glp-1-market-20262026-09-15T05:22:03Zweekly https://semaglutides.org/news/2026/#delhi-high-court-sun-pharma-semaglutide-tablets-20262026-09-15T05:22:14Zweekly https://semaglutides.org/news/2026/#rexall-novo-canada-home-delivery-20262026-09-15T05:22:24Zweekly https://semaglutides.org/news/2026/#aon-projects-employer-healthcare-costs-rise-9-5-percent-2027-20262026-09-15T03:39:55Zweekly https://semaglutides.org/news/2026/#pbms-commit-display-trumprx-cash-prices-real-time-benefit-tools-20262026-09-15T03:39:56Zweekly https://semaglutides.org/news/2026/#guardian-documents-brands-scrapping-plus-sizes-glp-1-20262026-09-15T03:40:02Zweekly https://semaglutides.org/news/2026/#glp1-changing-us-healthcare-20262026-09-15T04:35:58Zweekly https://semaglutides.org/news/2026/#gubra-h1-2026-three-partnered-obesity-programs-20262026-09-15T04:36:00Zweekly https://semaglutides.org/news/2026/#meta-analysis-13-243-patients-links-glp-1-20262026-09-15T04:36:08Zweekly https://semaglutides.org/news/2026/#novo-phase-3-lowest-effective-wegovy-pill-dose-20262026-09-15T04:36:17Zweekly https://semaglutides.org/news/2026/#brazilian-web-survey-documents-glp-1-self-medication-20262026-09-15T05:22:22Zweekly https://semaglutides.org/news/2026/#lilly-kenosha-site-expansion-opening-20262026-09-15T05:22:27Zweekly https://semaglutides.org/news/2026/#upper-macungie-planners-endorse-lilly-campus-20262026-09-15T05:22:20Zweekly https://semaglutides.org/news/2026/#astrazeneca-three-selene-phase-3-trials-amylin-analog-20262026-09-15T03:40:07Zweekly https://semaglutides.org/news/2026/#mississippi-boards-jointly-bar-providers-research-grade-peptides-20262026-09-15T03:40:12Zweekly https://semaglutides.org/news/2026/#novo-presses-fda-semaglutide-ddc-list-20262026-09-15T03:40:15Zweekly https://semaglutides.org/news/2026/#oral-wegovy-outsells-foundayo-first-shared-quarter-20262026-09-15T03:40:28Zweekly https://semaglutides.org/news/2026/#pcos-does-not-blunt-tirzepatide-weight-loss-54-20262026-09-15T03:40:25Zweekly https://semaglutides.org/news/2026/#pharmacy-acquisition-cost-generic-liraglutide-falls-third-six-20262026-09-15T03:40:35Zweekly https://semaglutides.org/news/2026/#va-launches-622-veteran-semaglutide-alcohol-use-disorder-trial-20262026-09-15T03:40:33Zweekly https://semaglutides.org/news/2026/#achieve-5-orforglipron-basal-insulin-results-20262026-09-15T04:36:13Zweekly https://semaglutides.org/news/2026/#amylin-design-debate-lilly-eloralintide-readout-20262026-09-15T04:36:20Zweekly https://semaglutides.org/news/2026/#ftc-first-tracking-pixel-health-data-case-hims-20262026-09-15T04:36:23Zweekly https://semaglutides.org/news/2026/#foundayo-q2-2026-sales2026-09-15T04:36:26Zweekly https://semaglutides.org/news/2026/#nature-reviews-endocrinology-calls-gip-direction-question-seeming-20262026-09-15T04:36:35Zweekly https://semaglutides.org/news/2026/#foodnavigator-new-consumer-data-challenges-glp-1-food-forecasts-20262026-09-15T04:36:53Zweekly https://semaglutides.org/news/2026/#overton-nominated-fda-commissioner-compounding-dockets-20262026-09-15T04:36:49Zweekly https://semaglutides.org/news/2026/#northeastern-asks-whether-ozempic-is-reviving-eating-disorders-20262026-09-15T04:36:39Zweekly https://semaglutides.org/news/2026/#retatrutide-demand-physician-patient-tension-20262026-09-15T05:22:29Zweekly https://semaglutides.org/news/2026/#remodel-findings-suggest-kidney-protection-not-diabetes-specific-20262026-09-15T05:22:32Zweekly https://semaglutides.org/news/2026/#resilience-lilly-750-million-biomanufacturing-20262026-09-15T05:22:42Zweekly https://semaglutides.org/news/2026/#koreas-regulator-finds-no-confirmed-causal-link-mounjaro-pancreatitis-20262026-09-15T05:22:39Zweekly https://semaglutides.org/news/2026/#novo-takes-first-round-oral-obesity-duel-20262026-09-15T05:23:01Zweekly https://semaglutides.org/news/2026/#circulation-analysis-select-37-8-drop-inflammation-semaglutide-20262026-09-15T03:40:40Zweekly https://semaglutides.org/news/2026/#canada-warns-illegal-retatrutide-cbp-seizures-jump-20262026-09-15T04:37:06Zweekly https://semaglutides.org/news/2026/#enveda-completes-phase-1-env-308-20262026-09-15T04:37:07Zweekly https://semaglutides.org/news/2026/#fact-checkers-kff-question-drug-price-drop-attribution-20262026-09-15T04:36:55Zweekly https://semaglutides.org/news/2026/#no-lawful-503a-pathway-retatrutide-analysis-20262026-09-15T05:40:22Zweekly https://semaglutides.org/news/2026/#lilly-retatrutide-lawsuits-new-enforcement-playbook-20262026-09-15T04:37:02Zweekly https://semaglutides.org/news/2026/#orforglipron-maintenance-after-injectable-switch-20262026-09-15T04:37:25Zweekly https://semaglutides.org/news/2026/#glp-1-receptor-activation-suppresses-defensive-aggression-dmpag-20262026-09-15T05:22:44Zweekly https://semaglutides.org/news/2026/#hims-ceo-cnbc-ftc-headline-stock-recovers-20262026-09-15T05:22:57Zweekly https://semaglutides.org/news/2026/#white-house-claims-largest-drug-price-drop-trumprx-700-million-20262026-09-15T03:40:40Zweekly https://semaglutides.org/news/2026/#axios-analysis-glp-1-competition-behind-drug-price-decline-20262026-09-15T04:37:10Zweekly https://semaglutides.org/news/2026/#novo-132-knockoff-lawsuits-tally-20262026-09-15T04:37:27Zweekly https://semaglutides.org/news/2026/#researchers-name-glp-1-treatment-stigma-distinct-phenomenon-20262026-09-15T04:37:37Zweekly https://semaglutides.org/news/2026/#nestle-plans-products-for-ozempic-face-and-side-effects-20262026-09-15T04:37:24Zweekly https://semaglutides.org/news/2026/#lawsuit-claims-link-between-glp-1-drugs-and-blindness-20262026-09-15T04:37:25Zweekly https://semaglutides.org/news/2026/#novo-canada-ozempic-savings-card-20262026-09-15T04:37:37Zweekly https://semaglutides.org/news/2026/#mexico-approves-wegovy-oral-tablet-20262026-09-15T05:22:50Zweekly https://semaglutides.org/news/2026/#prolonged-glp-1-exposure-remodels-beta-cell-gene-expression-20262026-09-15T05:22:59Zweekly https://semaglutides.org/news/2026/#experiment-documents-weight-loss-drug-users-judged-harshly-20262026-09-15T03:40:46Zweekly https://semaglutides.org/news/2026/#one-year-after-semaglutide-shortage-compounding-compliance-review-20262026-09-15T05:23:09Zweekly https://semaglutides.org/news/2026/#states-regulate-compounded-glp-1s-above-federal-floor-20262026-09-15T05:40:39Zweekly https://semaglutides.org/news/2026/#foundayo-eighty-percent-glp1-naive-patients-20262026-09-15T04:37:41Zweekly https://semaglutides.org/news/2026/#novo-moves-preliminary-injunction-lilly-glp-1-ads-20262026-09-15T03:41:03Zweekly https://semaglutides.org/news/2026/#anti-obesity-fourth-class-20262026-09-15T04:37:43Zweekly https://semaglutides.org/news/2026/#lilly-sues-makers-generic-style-mounjaro-zepbound-copies-20262026-09-15T04:37:47Zweekly https://semaglutides.org/news/2026/#survey-1-226-patients-puts-numbers-skin-laxity-20262026-09-15T04:37:44Zweekly https://semaglutides.org/news/2026/#brain-switch-two-opposite-routes-weight-loss-20262026-09-15T05:23:06Zweekly https://semaglutides.org/news/2026/#foundayos-label-establishes-no-timing-rules-oral-glp-20262026-09-15T03:41:05Zweekly https://semaglutides.org/news/2026/#kff-prior-authorization-metrics-show-12-18-percent-20262026-09-15T03:40:58Zweekly https://semaglutides.org/news/2026/#retatrutide-black-market-crackdown-20262026-09-15T03:41:12Zweekly https://semaglutides.org/news/2026/#zealand-h1-2026-petrelintide-phase-3-timing-20262026-09-15T03:41:09Zweekly https://semaglutides.org/news/2026/#novo-ceo-claims-90-percent-oral-glp1-share-20262026-09-15T04:38:13Zweekly https://semaglutides.org/news/2026/#lilly-files-lawsuits-retatrutide-gray-market-20262026-09-15T03:06:02Zweekly https://semaglutides.org/news/2026/#anesthesiology-analysis-finds-no-increased-aspiration-risk-preoperative-20262026-09-15T03:41:16Zweekly https://semaglutides.org/news/2026/#prescription-drug-cpi-falls-3-1-percent-steepest-since-1963-20262026-09-15T03:41:27Zweekly https://semaglutides.org/news/2026/#u-s-news-2026-2027-glp-1-telehealth2026-09-15T03:41:34Zweekly https://semaglutides.org/news/2026/#kailera-q2-2026-oral-ribupatide-ind-active-20262026-09-15T04:38:27Zweekly https://semaglutides.org/news/2026/#novos-ceo-defends-lawsuit-concedes-lillys-lead-20262026-09-15T04:38:03Zweekly https://semaglutides.org/news/2026/#altimmune-q2-2026-cash-runway-pemvidutide-20262026-09-15T05:24:09Zweekly https://semaglutides.org/news/2026/#foundayo-europe-approval-20262026-09-15T04:38:10Zweekly https://semaglutides.org/news/2026/#lateral-septum-cravings-20262026-09-15T04:38:04Zweekly https://semaglutides.org/news/2026/#chrissy-metz-discloses-glp-1-use-joins-ro-20262026-09-15T03:41:44Zweekly https://semaglutides.org/news/2026/#hims-10q-discloses-60-million-ftc-legal-accrual-20262026-09-15T03:41:39Zweekly https://semaglutides.org/news/2026/#mhra-orforglipron-20262026-09-15T03:41:35Zweekly https://semaglutides.org/news/2026/#uk-becomes-country-europe-authorize-orforglipron-20262026-09-15T03:41:38Zweekly https://semaglutides.org/news/2026/#case-series-muscle-grip-strength-gains-tirzepatide-testosterone-20262026-09-15T04:38:25Zweekly https://semaglutides.org/news/2026/#hims-hers-q2-2026-revenue-753-million-gaap2026-09-15T04:38:20Zweekly https://semaglutides.org/news/2026/#systematic-review-finds-no-evidence-best-injection-20262026-09-15T04:38:21Zweekly https://semaglutides.org/news/2026/#novo-aws-ai-partnership-20262026-09-15T05:23:17Zweekly https://semaglutides.org/news/2026/#second-obesity-commentary-sets-safety-evidence-gaps-tirzepatide-20262026-09-15T04:39:10Zweekly https://semaglutides.org/news/2026/#wegovy-total-scripts-slip-obesity-share-399-20262026-09-15T04:38:29Zweekly https://semaglutides.org/news/2026/#uk-secures-lower-section-232-pharmaceutical-tariff-rate-20262026-09-15T04:38:54Zweekly https://semaglutides.org/news/2026/#doustdar-wegovy-pill-must-win-20262026-09-15T05:23:46Zweekly https://semaglutides.org/news/2026/#antitrust-suit-dismissed-20262026-09-15T03:06:04Zweekly https://semaglutides.org/news/2026/#cms-extends-medicare-glp-1-bridge-through-december-20262026-09-15T03:06:11Zweekly https://semaglutides.org/news/2026/#network-meta-analysis-ranks-liraglutide-last-three-obesity-20262026-09-15T04:38:50Zweekly https://semaglutides.org/news/2026/#reuters-glp-1-antitrust-dismissal-20262026-09-15T04:38:41Zweekly https://semaglutides.org/news/2026/#uk-yellow-card-figures-show-tirzepatide-largest-share-20262026-09-15T04:38:50Zweekly https://semaglutides.org/news/2026/#health-canada-generic-semaglutide-backlog-august-20262026-09-15T05:23:26Zweekly https://semaglutides.org/news/2026/#cms-bridge-plan-guidance-20262026-09-15T05:23:27Zweekly https://semaglutides.org/news/2026/#eli-lilly-48-revenue-growth-raises-2026-guidance2026-09-15T03:06:13Zweekly https://semaglutides.org/news/2026/#lilly-q2-revenue-jumps-48-23-billion-while-20262026-09-15T03:06:21Zweekly https://semaglutides.org/news/2026/#lilly-self-pay-now-zepbound-prescriptions-20262026-09-15T03:06:34Zweekly https://semaglutides.org/news/2026/#mounjaro-zepbound-top-14-8-billion-single-quarter-20262026-09-15T03:06:32Zweekly https://semaglutides.org/news/2026/#foundayo-posts-98-million-partial-quarter-below-expectations-20262026-09-15T03:42:01Zweekly https://semaglutides.org/news/2026/#q2-2026-earnings-comparison2026-09-15T03:42:05Zweekly https://semaglutides.org/news/2026/#retatrutide-filing-plan-20262026-09-15T03:42:04Zweekly https://semaglutides.org/news/2026/#lilly-tirzepatide-revenue-14-9-billion-one-quarter-20262026-09-15T03:42:12Zweekly https://semaglutides.org/news/2026/#amgen-q2-nine-maritide-phase-3-trials-20262026-09-15T04:39:10Zweekly https://semaglutides.org/news/2026/#lilly-fda-retatrutide-classification-20262026-09-15T04:38:59Zweekly https://semaglutides.org/news/2026/#network-meta-analysis-compares-glp-1-therapy-testosterone-20262026-09-15T04:39:06Zweekly https://semaglutides.org/news/2026/#lillys-public-pipeline-table-lists-brenipatide-macupatide-long-20262026-09-15T05:23:37Zweekly https://semaglutides.org/news/2026/#novo-injunction-dutch-semaglutide-nasal-spray-20262026-09-15T05:23:39Zweekly https://semaglutides.org/news/2026/#novo-q2-2026-raises-outlook2026-09-15T03:06:41Zweekly https://semaglutides.org/news/2026/#novo-q2-2026-brand-level-sales-split2026-09-15T03:42:10Zweekly https://semaglutides.org/news/2026/#reimagine-4-miss-20262026-09-15T03:42:15Zweekly https://semaglutides.org/news/2026/#novo-q2-2026-pipeline-impairments2026-09-15T04:39:07Zweekly https://semaglutides.org/news/2026/#novo-shares-fall-despite-q2-guidance-raise-20262026-09-15T04:39:18Zweekly https://semaglutides.org/news/2026/#pfizer-cuts-two-ex-metsera-obesity-programs-20262026-09-15T04:39:27Zweekly https://semaglutides.org/news/2026/#pnas-agrp-hunger-neurons-required-semaglutide-fat-loss-20262026-09-15T04:39:24Zweekly https://semaglutides.org/news/2026/#amgen-drops-amg513-20262026-09-15T05:23:52Zweekly https://semaglutides.org/news/2026/#altimmune-starts-performa-phase-3-pemvidutide-mash-20262026-09-15T04:39:30Zweekly https://semaglutides.org/news/2026/#danish-national-cohort-semaglutide-persistence-published-jama-network-20262026-09-15T04:39:39Zweekly https://semaglutides.org/news/2026/#mdl-3094-august-2026-count2026-09-15T04:39:41Zweekly https://semaglutides.org/news/2026/#retatrutide-expanded-access-20262026-09-15T04:39:44Zweekly https://semaglutides.org/news/2026/#canada-65-percent-semaglutide-price-trigger-20262026-09-15T05:23:54Zweekly https://semaglutides.org/news/2026/#tirzepatide-help-partial-lipodystrophy-rare-fat-storage-disorder-20262026-09-15T05:23:54Zweekly https://semaglutides.org/news/2026/#eli-lilly-holds-60-branded-obesity-market-20262026-09-15T03:42:35Zweekly https://semaglutides.org/news/2026/#structure-therapeutics-doses-patients-phase-3-accomplish-program-20262026-09-15T03:42:35Zweekly https://semaglutides.org/news/2026/#china-glp1-candidates-20262026-09-15T04:39:53Zweekly https://semaglutides.org/news/2026/#cvs-oral-glp1-formulary-20262026-09-15T04:39:53Zweekly https://semaglutides.org/news/2026/#lean-mass-glp1-20262026-09-15T04:40:11Zweekly https://semaglutides.org/news/2026/#multi-dose-wegovy-flextouch-pen-rolling-20262026-09-15T04:40:06Zweekly https://semaglutides.org/news/2026/#obesity-pipeline-broadens-20262026-09-15T04:40:08Zweekly https://semaglutides.org/news/2026/#ozempic-25mg-tablet-filing-20262026-09-15T04:39:59Zweekly https://semaglutides.org/news/2026/#pfizer-monthly-shot-20262026-09-15T04:40:18Zweekly https://semaglutides.org/news/2026/#zepbound-label-revision-updates-diabetic-retinopathy-section-20262026-09-15T04:40:09Zweekly https://semaglutides.org/news/2026/#ziltivekimab-fails-zeus-heart-trial-erasing-30-billion-20262026-09-15T03:06:43Zweekly https://semaglutides.org/news/2026/#zeus-trial-fails-20262026-09-15T03:42:37Zweekly https://semaglutides.org/news/2026/#section-232-pharmaceutical-tariffs-take-effect-17-named-20262026-09-15T03:42:51Zweekly https://semaglutides.org/news/2026/#cleveland-clinic-advises-against-microdosing-glp-1-medications-20262026-09-15T04:40:22Zweekly https://semaglutides.org/news/2026/#cms-ends-part-d-premium-stabilization-demonstration-2027-premiums-20262026-09-15T04:40:24Zweekly https://semaglutides.org/news/2026/#deadline-state-medicaid-agencies-apply-balance-model-20262026-09-15T04:40:25Zweekly https://semaglutides.org/news/2026/#503b-comment-closes-20262026-09-15T03:42:49Zweekly https://semaglutides.org/news/2026/#sun-pharma-wins-brazilian-approval-semaglutide-injections-20262026-09-15T04:40:30Zweekly https://semaglutides.org/news/2026/#lilly-resilience-750m-20262026-09-15T05:23:56Zweekly https://semaglutides.org/news/2026/#treasure-ckd-completes-without-reporting-results-20262026-09-15T05:24:11Zweekly https://semaglutides.org/news/2026/#health-canada-registry-approved-unmarketed-semaglutide-20262026-09-15T05:24:09Zweekly https://semaglutides.org/news/2026/#ftc-utah-los-angeles-county-sue-hims-hers-20262026-09-15T03:06:41Zweekly https://semaglutides.org/news/2026/#oral-semaglutide-reduces-heavy-drinking-treatment-seeking-trial-20262026-09-15T03:42:49Zweekly https://semaglutides.org/news/2026/#imak-novo-canadian-patent-extension-lapse-20262026-09-15T04:40:44Zweekly https://semaglutides.org/news/2026/#viking-confirms-oral-vk2735-phase-3-fourth-quarter-20262026-09-15T04:40:55Zweekly https://semaglutides.org/news/2026/#japanese-cohort-finds-2-5-mg-5-mg-20262026-09-15T03:43:05Zweekly https://semaglutides.org/news/2026/#altimmune-positive-phase-2-results-pemvidutide-alcohol-use-20262026-09-15T04:40:40Zweekly https://semaglutides.org/news/2026/#gubra-opens-phase-1-2a-gub-ucn2-20262026-09-15T04:40:48Zweekly https://semaglutides.org/news/2026/#cagrisema-securities-suit-survives-dismissal-20262026-09-15T04:40:58Zweekly https://semaglutides.org/news/2026/#rest-trial-protocol-published-formalizing-taper-question-20262026-09-15T03:43:05Zweekly https://semaglutides.org/news/2026/#novo-seeks-injunction-on-lilly-ads-20262026-09-15T03:43:03Zweekly https://semaglutides.org/news/2026/#two-brain-regions-found-explain-gip-paradox-20262026-09-15T03:43:25Zweekly https://semaglutides.org/news/2026/#triumph-2-3-results-20262026-09-15T03:06:54Zweekly https://semaglutides.org/news/2026/#australia-adds-naion-all-glp-1-product-information-20262026-09-15T03:43:37Zweekly https://semaglutides.org/news/2026/#fda-advisory-committee-recommends-six-peptides-503a-bulks-20262026-09-15T03:43:24Zweekly https://semaglutides.org/news/2026/#lilly-retatrutide-ready-file-targeting-obesity-sleep-apnea-20262026-09-15T03:43:34Zweekly https://semaglutides.org/news/2026/#systematic-review-finds-glp-1-drugs-raise-testosterone-20262026-09-15T04:40:50Zweekly https://semaglutides.org/news/2026/#bmj-study-finds-glp-1-drugs-raise-risk-20262026-09-15T03:43:32Zweekly https://semaglutides.org/news/2026/#novo-challenges-lilly-ads-20262026-09-15T03:07:04Zweekly https://semaglutides.org/news/2026/#president-phased-tariffs-imported-generic-drugs-20262026-09-15T03:07:07Zweekly https://semaglutides.org/news/2026/#review-maps-off-label-evidence-five-domains-finds-20262026-09-15T04:41:01Zweekly https://semaglutides.org/news/2026/#hengrui-positive-phase-3-diabetes-readout-ribupatide-china-20262026-09-15T04:41:10Zweekly https://semaglutides.org/news/2026/#rebel-wilson-becomes-nooms-chief-wellness-officer-20262026-09-15T04:41:11Zweekly https://semaglutides.org/news/2026/#lilly-agrees-acquire-ataibeckley-2-8-billion-upfront-20262026-09-15T04:41:18Zweekly https://semaglutides.org/news/2026/#boehringer-ingelheim-phase-2-trial-gubra-originated-triple-20262026-09-15T05:24:31Zweekly https://semaglutides.org/news/2026/#ec-approves-wegovy-pill-20262026-09-15T03:07:16Zweekly https://semaglutides.org/news/2026/#expert-consensus-sets-meal-pattern-targets-glp-based-20262026-09-15T04:41:16Zweekly https://semaglutides.org/news/2026/#wegovy-pill-fifth-approval-20262026-09-15T04:41:16Zweekly https://semaglutides.org/news/2026/#sams-club-bundles-weightwatchers-benefit-against-costcos-glp-20262026-09-15T04:41:18Zweekly https://semaglutides.org/news/2026/#three-case-series-describes-flat-mood-lost-motivation-20262026-09-15T04:41:25Zweekly https://semaglutides.org/news/2026/#goodrx-114-million-americans-no-commercial-coverage-zepbound-20262026-09-15T03:43:37Zweekly https://semaglutides.org/news/2026/#largest-tirzepatide-faers-study-finds-medication-errors-top-20262026-09-15T03:43:57Zweekly https://semaglutides.org/news/2026/#structure-therapeutics-accomplish-phase-3-program-aleniglipron-20262026-09-15T03:43:55Zweekly https://semaglutides.org/news/2026/#cms-bridge-guidance-20262026-09-15T04:41:29Zweekly https://semaglutides.org/news/2026/#meta-analysis-finds-no-clear-rise-birth-defects-20262026-09-15T03:44:02Zweekly https://semaglutides.org/news/2026/#military-health-system-cohort-82-one-persistence-tirzepatide-20262026-09-15T04:41:44Zweekly https://semaglutides.org/news/2026/#perceptions-survey-quantifies-workplace-side-obesity-treatment-20262026-09-15T04:41:33Zweekly https://semaglutides.org/news/2026/#bmj-network-meta-analysis-biggest-fat-loss-biggest-20262026-09-15T03:07:16Zweekly https://semaglutides.org/news/2026/#survey-finds-glp-1s-now-11-4-employer-20262026-09-15T03:44:02Zweekly https://semaglutides.org/news/2026/#fda-accepts-second-generic-tirzepatide-application-amneal-adalvo-20262026-09-15T04:41:44Zweekly https://semaglutides.org/news/2026/#novo-nordisk-publishes-full-step-body-composition-detail-20262026-09-15T04:41:34Zweekly https://semaglutides.org/news/2026/#wegovy-pill-uk-patients-20262026-09-15T04:41:46Zweekly https://semaglutides.org/news/2026/#gallup-11-adults-now-take-glp-1-weight-20262026-09-15T03:07:15Zweekly https://semaglutides.org/news/2026/#surmount-osa-post-hoc-biggest-daytime-function-gains-20262026-09-15T04:41:53Zweekly https://semaglutides.org/news/2026/#case-series-fewer-migraine-attacks-tirzepatide-large-caveat-20262026-09-15T05:34:34Zweekly https://semaglutides.org/news/2026/#masshealth-stops-covering-glp-1s-prescribed-only-weight-20262026-09-15T03:44:02Zweekly https://semaglutides.org/news/2026/#mhra-approves-wegovy-liver-disease-20262026-09-15T04:41:55Zweekly https://semaglutides.org/news/2026/#audit-finds-compounded-glp-1-market-still-operating-20262026-09-15T03:44:08Zweekly https://semaglutides.org/news/2026/#mdl-3163-authorizes-early-motion-practice-causation-preemption-20262026-09-15T04:41:58Zweekly https://semaglutides.org/news/2026/#medicare-bridge-live-20262026-09-15T03:07:29Zweekly https://semaglutides.org/news/2026/#medicare-glp-1-bridge-publishing-explicit-bmi-eligibility-20262026-09-15T03:07:37Zweekly https://semaglutides.org/news/2026/#massachusetts-gic-ends-obesity-only-glp-1-coverage-20262026-09-15T03:44:26Zweekly https://semaglutides.org/news/2026/#lilly-fda-precheck-20262026-09-15T05:24:18Zweekly https://semaglutides.org/news/2026/#apollo-care-recalls-roughly-162-000-vials-compounded-20262026-09-15T03:44:24Zweekly https://semaglutides.org/news/2026/#jama-health-forum-secret-shopper-study-finds-compounded-20262026-09-15T03:44:37Zweekly https://semaglutides.org/news/2026/#summary-judgment-briefing-completes-mdl-3094-20262026-09-15T03:44:34Zweekly https://semaglutides.org/news/2026/#nationwide-cohort-208-155-post-bariatric-patients-finds-20262026-09-15T03:44:32Zweekly https://semaglutides.org/news/2026/#amazon-foundayo-20262026-09-15T04:42:16Zweekly https://semaglutides.org/news/2026/#tga-glp1-eye-warnings-20262026-09-15T04:42:04Zweekly https://semaglutides.org/news/2026/#surpass-cn-mono-published-completing-tirzepatides-china-registration-20262026-09-15T04:42:11Zweekly https://semaglutides.org/news/2026/#foundayo-medication-guide-reissued-7-missed-dose-restart-20262026-09-15T05:24:19Zweekly https://semaglutides.org/news/2026/#foundayo-prescribing-information-revised-20262026-09-15T05:24:50Zweekly https://semaglutides.org/news/2026/#wegovy-label-consolidates-injection-tablet-one-prescribing-information-2026-22026-09-15T03:44:45Zweekly https://semaglutides.org/news/2026/#fda-scientists-publicly-flag-evidence-gaps-compounded-peptides-20262026-09-15T04:42:13Zweekly https://semaglutides.org/news/2026/#sandoz-files-revoke-novo-nordisk-semaglutide-patent-unified-20262026-09-15T04:42:29Zweekly https://semaglutides.org/news/2026/#mfn-deal-loophole-20262026-09-15T04:42:28Zweekly https://semaglutides.org/news/2026/#health-canada-approves-generic-semaglutide-weight-loss-20262026-09-15T03:07:37Zweekly https://semaglutides.org/news/2026/#astrazeneca-opens-embold-phase-3-master-protocol-elecoglipron-20262026-09-15T03:44:54Zweekly https://semaglutides.org/news/2026/#fda-accepts-sandoz-applications-generic-tirzepatide-20262026-09-15T03:44:54Zweekly https://semaglutides.org/news/2026/#uk-lilly-obesity-partnership-20262026-09-15T04:42:38Zweekly https://semaglutides.org/news/2026/#fda-503b-comment-extension-20262026-09-15T04:42:31Zweekly https://semaglutides.org/news/2026/#chmp-recommends-adding-surpass-cvot-results-eu-mounjaro-20262026-09-15T03:45:08Zweekly https://semaglutides.org/news/2026/#cms-data-shows-liraglutide-brand-spending-collapsed-generic-20262026-09-15T03:45:12Zweekly https://semaglutides.org/news/2026/#lillydirect-uk-launch-20262026-09-15T05:24:29Zweekly https://semaglutides.org/news/2026/#lilly-oura-wearable-20262026-09-15T05:24:29Zweekly https://semaglutides.org/news/2026/#lilly-completes-centessa-acquisition-20262026-09-15T05:24:47Zweekly https://semaglutides.org/news/2026/#hypothesis-paper-proposes-tirzepatide-refractory-endometriosis-no-human-20262026-09-15T05:34:43Zweekly https://semaglutides.org/news/2026/#retatrutide-compassionate-use-20262026-09-15T04:42:38Zweekly https://semaglutides.org/news/2026/#los-angeles-times-documents-how-far-microdosing-has-20262026-09-15T04:42:34Zweekly https://semaglutides.org/news/2026/#nhs-england-expands-tirzepatide-eligibility-second-cohort-20262026-09-15T04:42:51Zweekly https://semaglutides.org/news/2026/#pwc-finds-one-five-households-now-includes-glp-20262026-09-15T03:07:41Zweekly https://semaglutides.org/news/2026/#lancet-issues-expression-concern-exenatide-parkinsons-trial-20262026-09-15T04:42:56Zweekly https://semaglutides.org/news/2026/#wegovy-tablet-mash-filing-20262026-09-15T04:43:02Zweekly https://semaglutides.org/news/2026/#wegovy-label-consolidates-injection-tablet-one-prescribing-information-20262026-09-15T04:42:50Zweekly https://semaglutides.org/news/2026/#perceptions-survey-why-518-adults-tirzepatide-20262026-09-15T04:42:53Zweekly https://semaglutides.org/news/2026/#college-physicians-issues-living-guideline-obesity-pharmacotherapy-20262026-09-15T03:45:15Zweekly https://semaglutides.org/news/2026/#fda-sends-25-letters-telehealth-companies-compounded-weight-20262026-09-15T03:45:11Zweekly https://semaglutides.org/news/2026/#pooled-analysis-finds-tirzepatide-works-same-adults-65-20262026-09-15T04:43:02Zweekly https://semaglutides.org/news/2026/#fda-issues-25-warning-letters-telehealth-companies-compounded-20262026-09-15T03:45:18Zweekly https://semaglutides.org/news/2026/#fda-publishes-list-unlawful-compounded-drug-marketing-claims-20262026-09-15T03:45:17Zweekly https://semaglutides.org/news/2026/#fda-updates-guidance-page-telehealth-companies-promoting-compounded-20262026-09-15T03:45:30Zweekly https://semaglutides.org/news/2026/#polish-cohort-shows-how-widely-incretin-drugs-already-20262026-09-15T04:43:13Zweekly https://semaglutides.org/news/2026/#endo-2026-semaglutide-linked-15-percent-fewer-fractures2026-09-15T04:43:07Zweekly https://semaglutides.org/news/2026/#endo-2026-glp-1-drugs-do-not-harm2026-09-15T04:43:14Zweekly https://semaglutides.org/news/2026/#retatrutide-ada-medicare-20262026-09-15T04:43:31Zweekly https://semaglutides.org/news/2026/#bcbs-federal-employee-program-approves-zepbound-policy-requiring-20262026-09-15T03:45:42Zweekly https://semaglutides.org/news/2026/#mhra-approves-wegovy-tablet-european-20262026-09-15T03:45:37Zweekly https://semaglutides.org/news/2026/#surveys-show-employers-pulling-back-glp-1-coverage-20262026-09-15T03:45:42Zweekly https://semaglutides.org/news/2026/#mhra-wegovy-pill-approval-20262026-09-15T03:45:43Zweekly https://semaglutides.org/news/2026/#novo-it-security-incident-20262026-09-15T04:43:27Zweekly https://semaglutides.org/news/2026/#wegovy-pill-passes-3-million-prescriptions-doustdar-he-20262026-09-15T04:43:24Zweekly https://semaglutides.org/news/2026/#shaquille-oneal-he-takes-zepbound-sleep-apnea-20262026-09-15T03:45:46Zweekly https://semaglutides.org/news/2026/#pfizer-phase-3-trial-berobenatide-20262026-09-15T04:43:24Zweekly https://semaglutides.org/news/2026/#wegovy-pill-new-patients-20262026-09-15T03:45:59Zweekly https://semaglutides.org/news/2026/#goldman-sachs-raises-2030-obesity-market-forecast-114-20262026-09-15T04:43:37Zweekly https://semaglutides.org/news/2026/#achieve-3-lillys-oral-pill-beats-oral-semaglutide-20262026-09-15T03:46:03Zweekly https://semaglutides.org/news/2026/#astrazenecas-elecoglipron-moves-phase-3-11-8-weight-20262026-09-15T03:46:18Zweekly https://semaglutides.org/news/2026/#retatrutide-black-market-cbs-20262026-09-15T03:46:12Zweekly https://semaglutides.org/news/2026/#faers-comparison-puts-tirzepatides-optic-neuropathy-signal-far-20262026-09-15T03:46:14Zweekly https://semaglutides.org/news/2026/#fda-issues-warning-letters-altru-telehealth-fitish-others-20262026-09-15T03:46:14Zweekly https://semaglutides.org/news/2026/#ada-standards-of-care-20262026-09-15T04:43:33Zweekly https://semaglutides.org/news/2026/#foundayo-t2d-trials-20262026-09-15T04:44:03Zweekly https://semaglutides.org/news/2026/#wegovy-pill-3m-scripts-20262026-09-15T03:07:51Zweekly https://semaglutides.org/news/2026/#annals-oncology-glp-1-use-tied-41-percent-20262026-09-15T03:46:29Zweekly https://semaglutides.org/news/2026/#cagrisema-reimagine-ada-20262026-09-15T03:46:34Zweekly https://semaglutides.org/news/2026/#novo-nordisk-presents-cagrisema-reimagine-zenagamtide-data-ada-20262026-09-15T03:46:45Zweekly https://semaglutides.org/news/2026/#survodutide-phase-3-data-published-nejm-show-34-20262026-09-15T03:46:48Zweekly https://semaglutides.org/news/2026/#foundayo-menopause-data-20262026-09-15T04:43:38Zweekly https://semaglutides.org/news/2026/#synchronize-1-published-survodutide-dual-glp-1-glucagon-20262026-09-15T04:44:03Zweekly https://semaglutides.org/news/2026/#ten-faers-review-finds-alopecia-reporting-signals-semaglutide-20262026-09-15T04:43:53Zweekly https://semaglutides.org/news/2026/#pfizer-details-monthly-berobenatide-data-plans-10-phase-20262026-09-15T03:46:42Zweekly https://semaglutides.org/news/2026/#retatrutide-cuts-sleep-apnea-severity-60-percent-triumph-20262026-09-15T03:46:45Zweekly https://semaglutides.org/news/2026/#retatrutide-ada-full-data-20262026-09-15T03:47:00Zweekly https://semaglutides.org/news/2026/#lilly-lays-five-molecule-obesity-strategy-ada-20262026-09-15T04:44:09Zweekly https://semaglutides.org/news/2026/#novo-ada-2026-analyses2026-09-15T04:44:05Zweekly https://semaglutides.org/news/2026/#surmount-maintain-appears-print-lancet-20262026-09-15T04:44:04Zweekly https://semaglutides.org/news/2026/#ada-2026-opens2026-09-15T03:47:04Zweekly https://semaglutides.org/news/2026/#consensus-issues-practical-guidelines-glp-1-use-type-20262026-09-15T03:47:08Zweekly https://semaglutides.org/news/2026/#structure-therapeutics-publishes-aleniglipron-phase-2b-data-nature-20262026-09-15T04:44:15Zweekly https://semaglutides.org/news/2026/#prospective-cohort-18-percent-weight-loss-tirzepatide-bariatric-20262026-09-15T05:24:38Zweekly https://semaglutides.org/news/2026/#telehealth-survey-real-world-sleep-improvements-tirzepatide-20262026-09-15T05:34:39Zweekly https://semaglutides.org/news/2026/#large-cohort-quantifies-motility-risk-glp-1-drugs-20262026-09-15T03:47:14Zweekly https://semaglutides.org/news/2026/#bridge-program-limits-20262026-09-15T04:44:21Zweekly https://semaglutides.org/news/2026/#obesity-journal-asks-whether-multi-dose-tirzepatide-pens-20262026-09-15T04:44:54Zweekly https://semaglutides.org/news/2026/#rybelsus-3-7-14-mg-posted-fda-discontinuation-20262026-09-15T04:44:27Zweekly https://semaglutides.org/news/2026/#randomized-trial-tirzepatide-pcos-menstrual-pregnancy-gains-20262026-09-15T04:44:22Zweekly https://semaglutides.org/news/2026/#wegovy-new-starts-20262026-09-15T04:44:29Zweekly https://semaglutides.org/news/2026/#cigna-drops-glp-1-coverage-own-employees-20262026-09-15T03:47:12Zweekly https://semaglutides.org/news/2026/#phase-1b-trial-separates-what-gip-glp-1-20262026-09-15T03:47:20Zweekly https://semaglutides.org/news/2026/#science-held-glp-1-vision-loss-mdl-20262026-09-15T03:47:32Zweekly https://semaglutides.org/news/2026/#cvs-caremark-lifts-market-block-foundayo-20262026-09-15T03:47:34Zweekly https://semaglutides.org/news/2026/#eli-lilly-registers-pre-approval-expanded-access-program-20262026-09-15T03:47:38Zweekly https://semaglutides.org/news/2026/#survodutides-cardiovascular-outcomes-trial-reaches-primary-completion-20262026-09-15T04:44:43Zweekly https://semaglutides.org/news/2026/#ozempic-injection-label-revised-20262026-09-15T05:24:46Zweekly https://semaglutides.org/news/2026/#cagrisema-decision-date-20262026-09-15T03:47:47Zweekly https://semaglutides.org/news/2026/#surpass-early-two-results-favor-starting-tirzepatide-early-20262026-09-15T03:47:41Zweekly https://semaglutides.org/news/2026/#muscle-nutrition-glp1-20262026-09-15T04:44:49Zweekly https://semaglutides.org/news/2026/#commentary-raises-bone-reproductive-eating-disorder-questions-adolescent-20262026-09-15T04:44:39Zweekly https://semaglutides.org/news/2026/#embraze-muscle-preservation-20262026-09-15T04:45:28Zweekly https://semaglutides.org/news/2026/#orforglipron-t2d-filing-20262026-09-15T04:44:59Zweekly https://semaglutides.org/news/2026/#nature-metabolism-paper-maps-how-semaglutide-signals-hindbrain-20262026-09-15T04:45:01Zweekly https://semaglutides.org/news/2026/#wegovy-label-adds-never-share-warning-flextouch-pen-20262026-09-15T04:45:00Zweekly https://semaglutides.org/news/2026/#wegovy-label-revision-consolidates-pregnancy-lactation-pediatric-guidance-20262026-09-15T04:45:11Zweekly https://semaglutides.org/news/2026/#viking-vanquish-2-enrollment-20262026-09-15T05:24:52Zweekly https://semaglutides.org/news/2026/#fda-count-reaches-990-adverse-event-compounded-semaglutide-20262026-09-15T03:47:46Zweekly https://semaglutides.org/news/2026/#nutrients-publishes-nutrition-framework-incretin-therapy-20262026-09-15T04:45:29Zweekly https://semaglutides.org/news/2026/#stat-news-revisits-microdosing-still-popular-still-unsupported-20262026-09-15T04:45:14Zweekly https://semaglutides.org/news/2026/#stat-microdosing-glp-1s-not-thing-there-no-20262026-09-15T04:45:22Zweekly https://semaglutides.org/news/2026/#cvs-restores-zepbound-announcement-20262026-09-15T03:07:45Zweekly https://semaglutides.org/news/2026/#all-three-major-pbms-agree-cover-foundayo-20262026-09-15T03:48:03Zweekly https://semaglutides.org/news/2026/#north-carolina-treasurer-state-budget-will-not-restore-20262026-09-15T04:45:16Zweekly https://semaglutides.org/news/2026/#novo-nordisk-confirms-amycretin-has-renamed-zenagamtide-20262026-09-15T05:24:48Zweekly https://semaglutides.org/news/2026/#patients-unable-fill-generic-liraglutide-3-mg-20262026-09-15T05:24:58Zweekly https://semaglutides.org/news/2026/#anvisa-approves-brazils-generic-semaglutide-pen-20262026-09-15T03:47:59Zweekly https://semaglutides.org/news/2026/#lilly-buys-three-companies-one-build-infectious-disease-20262026-09-15T04:45:35Zweekly https://semaglutides.org/news/2026/#nurse-practitioner-commentary-frames-microdosing-access-trust-problem-20262026-09-15T04:45:33Zweekly https://semaglutides.org/news/2026/#glp-1-drugs-linked-lower-macular-degeneration-risk-20262026-09-15T05:25:09Zweekly https://semaglutides.org/news/2026/#penn-researchers-mine-400-000-reddit-posts-glp-20262026-09-15T04:45:33Zweekly https://semaglutides.org/news/2026/#bari-step-semaglutide-rescues-poor-weight-loss-bariatric-20262026-09-15T03:08:10Zweekly https://semaglutides.org/news/2026/#narb-upholds-clinically-proven-claims-must-substantiated-regardless-20262026-09-15T03:48:03Zweekly https://semaglutides.org/news/2026/#post-hoc-analysis-shows-13-weight-loss-adults-20262026-09-15T04:45:44Zweekly https://semaglutides.org/news/2026/#retatrutide-triumph-1-20262026-09-15T03:08:06Zweekly https://semaglutides.org/news/2026/#triumph-1-topline-retatrutide-reaches-28-3-weight-20262026-09-15T03:08:06Zweekly https://semaglutides.org/news/2026/#chmp-wegovy-pill-opinion-20262026-09-15T03:48:10Zweekly https://semaglutides.org/news/2026/#fda-1-700-adverse-events-tied-compounded-glp-20262026-09-15T03:48:13Zweekly https://semaglutides.org/news/2026/#hims-offering-generic-semaglutide-canada-20262026-09-15T03:48:18Zweekly https://semaglutides.org/news/2026/#narb-affirms-nad-tru-niagen-matter-20262026-09-15T03:48:37Zweekly https://semaglutides.org/news/2026/#plos-medicine-pooled-analysis-puts-naion-risk-absolute-20262026-09-15T03:48:32Zweekly https://semaglutides.org/news/2026/#compounded-to-branded-shift-20262026-09-15T04:45:47Zweekly https://semaglutides.org/news/2026/#restaurant-survey-finds-glp-1-users-eat-often-20262026-09-15T04:45:46Zweekly https://semaglutides.org/news/2026/#trumprx-prices-may-20262026-09-15T04:46:07Zweekly https://semaglutides.org/news/2026/#eli-lilly-files-roadmap-brief-seeking-summary-judgment-20262026-09-15T03:48:34Zweekly https://semaglutides.org/news/2026/#supreme-court-ends-novo-nordisks-inflation-reduction-act-20262026-09-15T04:46:06Zweekly https://semaglutides.org/news/2026/#trumprx-expands-everyday-medicines-generics-20262026-09-15T04:46:07Zweekly https://semaglutides.org/news/2026/#lilly-phase-2-obesity-trial-selective-gip-agonist-20262026-09-15T04:46:09Zweekly https://semaglutides.org/news/2026/#academy-ophthalmology-tirzepatides-naion-risk-studied-20262026-09-15T03:48:48Zweekly https://semaglutides.org/news/2026/#apotex-generic-semaglutide-injection-canada-20262026-09-15T03:48:45Zweekly https://semaglutides.org/news/2026/#teva-posts-discontinuation-notice-generic-saxenda-ndc-20262026-09-15T04:46:27Zweekly https://semaglutides.org/news/2026/#lilly-unicef-50m-20262026-09-15T05:25:11Zweekly https://semaglutides.org/news/2026/#attain-maintain-tests-switching-injection-oral-glp-1-20262026-09-15T03:08:08Zweekly https://semaglutides.org/news/2026/#eco-2026-adding-glp-1-behavioral-treatment-cuts2026-09-15T03:48:48Zweekly https://semaglutides.org/news/2026/#tirzepatide-reaches-nce-1-date-opening-door-generic-20262026-09-15T04:46:24Zweekly https://semaglutides.org/news/2026/#eco-2026-wegovy-pill-responders2026-09-15T04:46:39Zweekly https://semaglutides.org/news/2026/#surmount-maintain-lancet-20262026-09-15T03:08:20Zweekly https://semaglutides.org/news/2026/#detailed-attain-maintain-results-published-nature-medicine-20262026-09-15T03:49:16Zweekly https://semaglutides.org/news/2026/#lilly-marks-150-ceremony-indianapolis-20262026-09-15T03:49:17Zweekly https://semaglutides.org/news/2026/#lilly-foundayo-lower-dose-zepbound-maintain-weight-loss-20262026-09-15T03:49:10Zweekly https://semaglutides.org/news/2026/#eco-2026-wegovy-hd-responders2026-09-15T04:46:42Zweekly https://semaglutides.org/news/2026/#hims-hers-posts-92-million-quarter-loss-branded-20262026-09-15T04:46:25Zweekly https://semaglutides.org/news/2026/#wegovy-menopause-data-20262026-09-15T04:46:55Zweekly https://semaglutides.org/news/2026/#oral-vk2735-shows-12-2-weight-loss-13-20262026-09-15T04:46:42Zweekly https://semaglutides.org/news/2026/#fda-commissioner-marty-makary-resigns-kyle-diamantas-named-20262026-09-15T05:25:16Zweekly https://semaglutides.org/news/2026/#surpass-cvot-kidney-analysis-23-lower-rate-major-20262026-09-15T03:49:23Zweekly https://semaglutides.org/news/2026/#lilly-india-campaign-paused-20262026-09-15T05:25:07Zweekly https://semaglutides.org/news/2026/#foundayo-weekly-scripts-modest-20262026-09-15T04:46:51Zweekly https://semaglutides.org/news/2026/#omada-health-joins-lilly-employer-connect-independent-program-20262026-09-15T04:46:44Zweekly https://semaglutides.org/news/2026/#medicare-glp1-bridge-announced-20262026-09-15T03:08:17Zweekly https://semaglutides.org/news/2026/#mounjaro-passes-keytruda-worlds-best-selling-drug-20262026-09-15T03:08:31Zweekly https://semaglutides.org/news/2026/#business-group-health-finds-67-large-employers-cover-20262026-09-15T03:49:16Zweekly https://semaglutides.org/news/2026/#lilly-adds-4-5-billion-indiana-where-tirzepatide-20262026-09-15T03:49:17Zweekly https://semaglutides.org/news/2026/#q1-2026-wegovy-pill-posts-dkk-2-262026-09-15T03:49:44Zweekly https://semaglutides.org/news/2026/#doustdar-novo-nordisk-hunting-deals-ever-20262026-09-15T04:46:55Zweekly https://semaglutides.org/news/2026/#lilly-renew-ibs-d-phase-2-trial-brenipatide-20262026-09-15T05:25:30Zweekly https://semaglutides.org/news/2026/#ozempic-tablets-available-20262026-09-15T03:08:37Zweekly https://semaglutides.org/news/2026/#ozempic-pill-united-states-type-2-diabetes-20262026-09-15T03:49:47Zweekly https://semaglutides.org/news/2026/#rybelsus-relaunches-reformulated-ozempic-pill-20262026-09-15T03:49:45Zweekly https://semaglutides.org/news/2026/#french-regulator-fines-lilly-novo-20262026-09-15T05:25:22Zweekly https://semaglutides.org/news/2026/#apotex-wins-canadian-approval-apo-semaglutide-20262026-09-15T03:49:42Zweekly https://semaglutides.org/news/2026/#balance-model-delayed-20262026-09-15T03:49:54Zweekly https://semaglutides.org/news/2026/#colorado-makes-zepbound-only-weight-loss-glp-1-20262026-09-15T03:49:49Zweekly https://semaglutides.org/news/2026/#health-canada-approves-second-generic-semaglutide-apotex-20262026-09-15T03:50:07Zweekly https://semaglutides.org/news/2026/#novo-nordisk-date-ozempic-tablets-20262026-09-15T03:50:11Zweekly https://semaglutides.org/news/2026/#503b-bulks-list-proposal-publishes-federal-register-20262026-09-15T03:50:18Zweekly https://semaglutides.org/news/2026/#phase-2a-smoking-trial-misses-main-endpoint-cuts-20262026-09-15T04:47:21Zweekly https://semaglutides.org/news/2026/#fda-503b-bulk-proposal-20262026-09-15T03:08:37Zweekly https://semaglutides.org/news/2026/#iu-study-lilly-supports-47-520-indiana-jobs-20262026-09-15T03:50:23Zweekly https://semaglutides.org/news/2026/#ozempic-prescribing-information-revised-still-no-naion-warning-20262026-09-15T03:50:14Zweekly https://semaglutides.org/news/2026/#maritide-switch-study-20262026-09-15T04:47:06Zweekly https://semaglutides.org/news/2026/#fda-approves-instructions-use-single-dose-ozempic-prefilled-20262026-09-15T04:47:05Zweekly https://semaglutides.org/news/2026/#fda-approves-single-dose-prefilled-syringes-wegovy-20262026-09-15T04:47:33Zweekly https://semaglutides.org/news/2026/#novo-nordisk-amaze-12-phase-3-trial-amycretin-20262026-09-15T04:47:28Zweekly https://semaglutides.org/news/2026/#fda-proposes-exclude-semaglutide-tirzepatide-liraglutide-503b-bulks-20262026-09-15T03:08:42Zweekly https://semaglutides.org/news/2026/#lilly-60-1-incretin-market-share-20262026-09-15T03:08:47Zweekly https://semaglutides.org/news/2026/#nih-randomized-win-glp-1-drug-alcohol-use-20262026-09-15T03:08:53Zweekly https://semaglutides.org/news/2026/#eating-disorder-clinicians-warn-cultural-swing-back-thin-20262026-09-15T03:50:27Zweekly https://semaglutides.org/news/2026/#lancet-trial-semaglutide-cuts-heavy-drinking-alcohol-use-20262026-09-15T03:50:35Zweekly https://semaglutides.org/news/2026/#lilly-q1-2026-detail-20262026-09-15T03:50:41Zweekly https://semaglutides.org/news/2026/#mdl-3094-sets-expert-evidence-hearing-will-decide-20262026-09-15T03:50:50Zweekly https://semaglutides.org/news/2026/#summary-judgment-briefing-filed-mdl-3094-warnings-adequacy-20262026-09-15T03:50:51Zweekly https://semaglutides.org/news/2026/#systematic-review-quantifies-incretin-contraceptive-interaction-20262026-09-15T03:50:53Zweekly https://semaglutides.org/news/2026/#glp1-alcohol-cbt-20262026-09-15T04:47:18Zweekly https://semaglutides.org/news/2026/#empower-ruling-partial-20262026-09-15T05:25:25Zweekly https://semaglutides.org/news/2026/#court-rules-lilly-v-empower-clinic-services-compounded-20262026-09-15T03:50:51Zweekly https://semaglutides.org/news/2026/#roche-zealand-pharma-commit-petrelintide-phase-3-20262026-09-15T03:51:08Zweekly https://semaglutides.org/news/2026/#health-canada-approves-generic-semaglutide-g7-20262026-09-15T03:08:58Zweekly https://semaglutides.org/news/2026/#mdl-3094-daubert-deadline-20262026-09-15T03:51:10Zweekly https://semaglutides.org/news/2026/#meta-analysis-49-395-pregnancies-finds-no-clear-20262026-09-15T03:51:19Zweekly https://semaglutides.org/news/2026/#boehringer-ingelheims-survodutide-hits-16-6-weight-loss-20262026-09-15T03:51:21Zweekly https://semaglutides.org/news/2026/#survodutide-posts-phase-3-readout-dual-glp-1-20262026-09-15T04:47:25Zweekly https://semaglutides.org/news/2026/#hims-hers-adds-zepbound-zepbound-kwikpen-foundayo-via-20262026-09-15T03:51:26Zweekly https://semaglutides.org/news/2026/#oral-sema-pediatric-t2d-20262026-09-15T04:47:23Zweekly https://semaglutides.org/news/2026/#white-house-favored-nation-deal-regeneron-20262026-09-15T05:25:34Zweekly https://semaglutides.org/news/2026/#goodrx-npr-document-12-million-people-losing-zepbound-20262026-09-15T03:51:26Zweekly https://semaglutides.org/news/2026/#lean-prep-protocol-published-randomized-trial-lifting-weights-20262026-09-15T03:51:36Zweekly https://semaglutides.org/news/2026/#fda-approves-21-use-storage-single-dose-tirzepatide-20262026-09-15T04:47:40Zweekly https://semaglutides.org/news/2026/#multi-dose-tirzepatide-presentations-get-their-own-30-20262026-09-15T04:47:56Zweekly https://semaglutides.org/news/2026/#updated-instructions-use-approved-tirzepatide-single-dose-pen-20262026-09-15T05:25:29Zweekly https://semaglutides.org/news/2026/#cms-shelves-balance-model-medicare-part-d-extends-20262026-09-15T03:09:07Zweekly https://semaglutides.org/news/2026/#amazon-nationwide-glp-1-program-through-one-medical-20262026-09-15T03:51:44Zweekly https://semaglutides.org/news/2026/#iqvia-sizes-global-obesity-medicines-market-66-billion-20262026-09-15T03:51:49Zweekly https://semaglutides.org/news/2026/#compounded-tirzepatide-impurity-described-peer-reviewed-journal-20262026-09-15T04:47:55Zweekly https://semaglutides.org/news/2026/#trade-press-food-brands-adopting-glp-1-friendly-20262026-09-15T04:47:42Zweekly https://semaglutides.org/news/2026/#lilly-agrees-acquire-kelonia-therapeutics-deal-worth-7-20262026-09-15T03:51:47Zweekly https://semaglutides.org/news/2026/#second-court-lets-lillys-compounded-tirzepatide-advertising-claims-20262026-09-15T04:47:47Zweekly https://semaglutides.org/news/2026/#deadline-passes-medicare-part-d-plans-join-balance-20262026-09-15T04:48:08Zweekly https://semaglutides.org/news/2026/#india-fake-mounjaro-seizure-20262026-09-15T04:47:55Zweekly https://semaglutides.org/news/2026/#adjust-t1d-post-hoc-analysis-shows-early-insulin-20262026-09-15T05:25:33Zweekly https://semaglutides.org/news/2026/#indian-regulators-seize-260-counterfeit-mounjaro-pens-20262026-09-15T04:48:01Zweekly https://semaglutides.org/news/2026/#zepbound-muscle-loss-preprint-20262026-09-15T04:48:06Zweekly https://semaglutides.org/news/2026/#foundayo-first-week-scripts-20262026-09-15T04:48:14Zweekly https://semaglutides.org/news/2026/#achieve-4-results-20262026-09-15T03:09:09Zweekly https://semaglutides.org/news/2026/#lilly-q1-2026-results2026-09-15T04:48:14Zweekly https://semaglutides.org/news/2026/#wegovy-pill-price-step-20262026-09-15T05:25:37Zweekly https://semaglutides.org/news/2026/#cms-proposes-extending-electronic-prior-authorization-standards-drugs-20262026-09-15T03:52:01Zweekly https://semaglutides.org/news/2026/#fda-asks-lilly-heart-liver-data-newly-approved-20262026-09-15T03:51:57Zweekly https://semaglutides.org/news/2026/#fda-asks-more-foundayo-safety-data-20262026-09-15T03:52:07Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-life-pharma-unapproved-glp-1-20262026-09-15T04:48:14Zweekly https://semaglutides.org/news/2026/#review-maps-psoriasis-psoriatic-arthritis-research-pipeline-glp-20262026-09-15T05:26:02Zweekly https://semaglutides.org/news/2026/#apotex-wins-fda-tentative-approval-generic-semaglutide-20262026-09-15T03:52:12Zweekly https://semaglutides.org/news/2026/#india-generic-glp1-flood-20262026-09-15T04:48:19Zweekly https://semaglutides.org/news/2026/#indian-generics-reshaping-glp-1-share-worlds-price-20262026-09-15T04:48:28Zweekly https://semaglutides.org/news/2026/#foundayo-goes-sale-united-states-20262026-09-15T03:09:13Zweekly https://semaglutides.org/news/2026/#foundayo-reaches-pharmacies-20262026-09-15T03:52:20Zweekly https://semaglutides.org/news/2026/#georgetown-study-finds-glp-1-weight-loss-draws-20262026-09-15T03:52:18Zweekly https://semaglutides.org/news/2026/#lilly-foundayo-oral-glp-1-20262026-09-15T03:52:26Zweekly https://semaglutides.org/news/2026/#amazon-kiosks-foundayo-20262026-09-15T04:48:23Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-prorx-llc-sterility-quality-deficiencies-20262026-09-15T03:52:34Zweekly https://semaglutides.org/news/2026/#wegovy-hd-goes-sale-nationwide-399-self-pay-20262026-09-15T03:52:37Zweekly https://semaglutides.org/news/2026/#partnership-safe-medicines-compiles-fdas-research-chemical-warning-20262026-09-15T05:25:47Zweekly https://semaglutides.org/news/2026/#foundayo-launch-20262026-09-15T03:09:18Zweekly https://semaglutides.org/news/2026/#cms-adds-foundayo-medicare-glp-1-bridge-clarifies-20262026-09-15T03:52:39Zweekly https://semaglutides.org/news/2026/#imputed-placebo-analysis-estimates-28-mace-reduction-tirzepatide-20262026-09-15T03:52:45Zweekly https://semaglutides.org/news/2026/#multinational-study-1-8-million-older-adults-compares-20262026-09-15T04:48:31Zweekly https://semaglutides.org/news/2026/#section-232-pharmaceutical-tariff-proclamation-sets-lillys-rate-20262026-09-15T03:09:25Zweekly https://semaglutides.org/news/2026/#york-times-profiles-medvi-1-8-billion-ai-20262026-09-15T04:48:25Zweekly https://semaglutides.org/news/2026/#wegovy-pill-vs-orforglipron-itc-20262026-09-15T04:48:49Zweekly https://semaglutides.org/news/2026/#foundayo-approval-20262026-09-15T03:09:39Zweekly https://semaglutides.org/news/2026/#fda-clarifies-compounding-rules-glp-1-supply-stabilizes-20262026-09-15T03:09:32Zweekly https://semaglutides.org/news/2026/#fda-clarifies-essentially-copy-rule-four-prescription-threshold-20262026-09-15T03:09:35Zweekly https://semaglutides.org/news/2026/#fda-sets-four-prescriptions-yardstick-copy-compounding-20262026-09-15T03:09:39Zweekly https://semaglutides.org/news/2026/#fda-spells-what-counts-essentially-copy-compounded-glp-20262026-09-15T03:09:47Zweekly https://semaglutides.org/news/2026/#foundayo-orforglipron-approval-creates-biggest-comparison-opportunity-20262026-09-15T03:09:59Zweekly https://semaglutides.org/news/2026/#fda-restates-tirzepatide-neither-shortage-list-nor-503b-20262026-09-15T03:52:45Zweekly https://semaglutides.org/news/2026/#foundayo-fastest-approval-20262026-09-15T03:52:54Zweekly https://semaglutides.org/news/2026/#nhs-england-moves-tirzepatide-prescribing-gp-contract-20262026-09-15T03:53:07Zweekly https://semaglutides.org/news/2026/#novo-nordisk-pushes-back-foundayo-comparisons-same-20262026-09-15T04:48:38Zweekly https://semaglutides.org/news/2026/#foundayo-dosing-20262026-09-15T05:25:58Zweekly https://semaglutides.org/news/2026/#tos-oma-oac-give-continuing-medication-during-maintenance-20262026-09-15T03:10:02Zweekly https://semaglutides.org/news/2026/#first-wave-loe-markets-20262026-09-15T03:53:08Zweekly https://semaglutides.org/news/2026/#part-d-glp1-coverage-requirement-20262026-09-15T03:53:12Zweekly https://semaglutides.org/news/2026/#swedish-national-cohort-finds-semaglutide-linked-lower-risk-20262026-09-15T03:53:10Zweekly https://semaglutides.org/news/2026/#wegovy-hd-launch-20262026-09-15T03:53:16Zweekly https://semaglutides.org/news/2026/#wegovy-hd-united-states-20262026-09-15T04:48:47Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-gram-peptides-citing-tirzepatide-20262026-09-15T03:53:19Zweekly https://semaglutides.org/news/2026/#fda-warns-research-peptide-sellers-gram-peptides-prime-20262026-09-15T03:53:32Zweekly https://semaglutides.org/news/2026/#lilly-agrees-acquire-centessa-pharmaceuticals-6-3-billion-20262026-09-15T03:53:41Zweekly https://semaglutides.org/news/2026/#wegovy-subscription-20262026-09-15T03:53:42Zweekly https://semaglutides.org/news/2026/#opm-carrier-letter-2026-07-sets-plan-20272026-09-15T03:53:40Zweekly https://semaglutides.org/news/2026/#lilly-narcolepsy-acquisition-20262026-09-15T04:48:43Zweekly https://semaglutides.org/news/2026/#surpass-cvot-post-hoc-finds-broad-cardiorenal-benefit-20262026-09-15T03:53:50Zweekly https://semaglutides.org/news/2026/#faers-analysis-finds-tirzepatide-negatively-associated-hair-loss-20262026-09-15T04:48:58Zweekly https://semaglutides.org/news/2026/#viking-completes-enrollment-phase-3-vanquish-2-trial-20262026-09-15T04:49:16Zweekly https://semaglutides.org/news/2026/#destination-xl-blames-glp-1s-size-volatility-apparel-20262026-09-15T03:53:46Zweekly https://semaglutides.org/news/2026/#kff-puts-current-glp-1-use-12-adults-20262026-09-15T04:48:52Zweekly https://semaglutides.org/news/2026/#ubt251-reduces-hba1c-2-16-chinese-phase-2-20262026-09-15T04:49:00Zweekly https://semaglutides.org/news/2026/#meta-analysis-puts-number-what-resistance-training-changes-20262026-09-15T03:10:06Zweekly https://semaglutides.org/news/2026/#ftc-creates-internal-healthcare-task-force-20262026-09-15T04:49:01Zweekly https://semaglutides.org/news/2026/#india-price-war-20262026-09-15T03:54:08Zweekly https://semaglutides.org/news/2026/#npr-covers-what-eat-glp-1-drugs-taking-20262026-09-15T04:49:05Zweekly https://semaglutides.org/news/2026/#dozen-indian-generic-semaglutide-brands-one-20262026-09-15T03:10:06Zweekly https://semaglutides.org/news/2026/#cnbc-quantifies-glp-1-hit-restaurant-dinner-traffic-20262026-09-15T03:54:06Zweekly https://semaglutides.org/news/2026/#china-brazil-patent-expiry-20262026-09-15T03:10:21Zweekly https://semaglutides.org/news/2026/#india-patent-expiry-20262026-09-15T03:10:15Zweekly https://semaglutides.org/news/2026/#lilly-discloses-david-rickss-2025-pay-package-36-20262026-09-15T04:49:16Zweekly https://semaglutides.org/news/2026/#wegovy-hd-approval-20262026-09-15T03:10:38Zweekly https://semaglutides.org/news/2026/#imcivree-becomes-approved-treatment-acquired-hypothalamic-obesity-20262026-09-15T03:10:31Zweekly https://semaglutides.org/news/2026/#dysesthesia-enters-semaglutide-label-dose-related-side-effect-20262026-09-15T03:54:11Zweekly https://semaglutides.org/news/2026/#adpd-2026-evoke-full-data2026-09-15T03:54:15Zweekly https://semaglutides.org/news/2026/#lancet-psychiatry-semaglutide-linked-42-percent-lower-risk-20262026-09-15T03:54:11Zweekly https://semaglutides.org/news/2026/#transcend-t2d-1-results-20262026-09-15T03:54:22Zweekly https://semaglutides.org/news/2026/#wegovy-hd-approval-creates-dose-upgrade-query-cluster-20262026-09-15T03:54:46Zweekly https://semaglutides.org/news/2026/#cnpv-program-glp1-20262026-09-15T03:54:42Zweekly https://semaglutides.org/news/2026/#fda-approves-setmelanotide-acquired-hypothalamic-obesity-20262026-09-15T04:49:23Zweekly https://semaglutides.org/news/2026/#wegovy-hd-dosing-20262026-09-15T04:49:23Zweekly https://semaglutides.org/news/2026/#hsbc-downgrades-lilly-20262026-09-15T05:25:57Zweekly https://semaglutides.org/news/2026/#lilly-phase-1b-study-brenipatide-overweight-obesity-20262026-09-15T05:26:03Zweekly https://semaglutides.org/news/2026/#indiana-commits-1-billion-life-sciences-agriculture-20262026-09-15T03:54:37Zweekly https://semaglutides.org/news/2026/#zepbound-kwikpen-self-pay-pricing-reaches-pharmacies-nationwide-20262026-09-15T03:10:36Zweekly https://semaglutides.org/news/2026/#oculus-trial-stops-early-residual-stomach-contents-rise-20262026-09-15T03:54:42Zweekly https://semaglutides.org/news/2026/#roche-phase-3-enicepatide-20262026-09-15T04:49:21Zweekly https://semaglutides.org/news/2026/#structure-therapeutics-16-3-weight-loss-44-aleniglipron-20262026-09-15T04:49:24Zweekly https://semaglutides.org/news/2026/#oscars-red-carpet-reignites-hollywood-thinness-debate-20262026-09-15T04:49:40Zweekly https://semaglutides.org/news/2026/#all-15-ipay-2028-manufacturers-agree-negotiate-lilly-20262026-09-15T04:49:42Zweekly https://semaglutides.org/news/2026/#all-15-drugmakers-agree-join-third-medicare-negotiation-20262026-09-15T05:25:56Zweekly https://semaglutides.org/news/2026/#kroger-zepbound-kwikpen-20262026-09-15T05:26:07Zweekly https://semaglutides.org/news/2026/#cleveland-clinic-finds-people-who-stop-glp-1s-20262026-09-15T03:54:46Zweekly https://semaglutides.org/news/2026/#tirzepatide-b12-impurity-warning-20262026-09-15T03:54:54Zweekly https://semaglutides.org/news/2026/#novo-holdings-assets-34-2025-20262026-09-15T03:55:06Zweekly https://semaglutides.org/news/2026/#fda-retires-faers-adverse-event-monitoring-system-20262026-09-15T03:55:07Zweekly https://semaglutides.org/news/2026/#fda-approves-biocons-generic-victoza-fifth-such-application-20262026-09-15T04:49:35Zweekly https://semaglutides.org/news/2026/#lilly-china-3b-20262026-09-15T04:49:39Zweekly https://semaglutides.org/news/2026/#preprint-uncharacterized-impurity-compounded-tirzepatide-plus-b12-products-20262026-09-15T04:49:43Zweekly https://semaglutides.org/news/2026/#novo-hims-settlement-20262026-09-15T03:10:37Zweekly https://semaglutides.org/news/2026/#cms-issues-balance-implementation-details-naming-zepbound-mounjaro-20262026-09-15T03:55:10Zweekly https://semaglutides.org/news/2026/#abbvies-amylin-analog-abbv-295-posts-positive-phase-20262026-09-15T04:49:48Zweekly https://semaglutides.org/news/2026/#amazon-zepbound-kwikpen-20262026-09-15T05:40:49Zweekly https://semaglutides.org/news/2026/#hims-settlement-terms-20262026-09-15T04:50:02Zweekly https://semaglutides.org/news/2026/#lilly-balance-model-statement-20262026-09-15T04:50:02Zweekly https://semaglutides.org/news/2026/#axios-ipsos-finds-18-americans-have-weight-loss-20262026-09-15T04:49:58Zweekly https://semaglutides.org/news/2026/#china-approves-ecnoglutide-chronic-weight-management-20262026-09-15T04:50:14Zweekly https://semaglutides.org/news/2026/#who-foundation-lilly-obesity-20262026-09-15T05:26:19Zweekly https://semaglutides.org/news/2026/#eli-lilly-employer-connect-selling-zepbound-employers-449-20262026-09-15T03:10:43Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-pade-20262026-09-15T03:10:49Zweekly https://semaglutides.org/news/2026/#lilly-employer-connect-widen-workplace-obesity-coverage-20262026-09-15T04:50:09Zweekly https://semaglutides.org/news/2026/#meta-regression-maps-shape-weight-regain-stopping-glp-20262026-09-15T03:10:57Zweekly https://semaglutides.org/news/2026/#bmj-study-examines-glp-1-drugs-substance-use-20262026-09-15T04:50:09Zweekly https://semaglutides.org/news/2026/#va-analysis-600-000-people-glp-1-drugs-20262026-09-15T04:50:21Zweekly https://semaglutides.org/news/2026/#fda-30-warning-letters-20262026-09-15T03:11:06Zweekly https://semaglutides.org/news/2026/#cms-publishes-medicare-glp-1-bridge-frequently-asked-20262026-09-15T03:55:20Zweekly https://semaglutides.org/news/2026/#leadership-appointed-naion-mdl-20262026-09-15T04:50:20Zweekly https://semaglutides.org/news/2026/#novo-two-year-low-20262026-09-15T04:50:29Zweekly https://semaglutides.org/news/2026/#aaos-2026-mixed-musculoskeletal-findings-glp-1-users2026-09-15T05:26:13Zweekly https://semaglutides.org/news/2026/#march-2026-compounding-turning-point2026-09-15T03:55:19Zweekly https://semaglutides.org/news/2026/#us-label-no-naion-warning-20262026-09-15T03:55:24Zweekly https://semaglutides.org/news/2026/#prime-therapeutics-claims-data-show-real-world-one-20262026-09-15T03:55:33Zweekly https://semaglutides.org/news/2026/#two-large-claims-studies-disagree-tirzepatide-versus-semaglutide-20262026-09-15T03:55:40Zweekly https://semaglutides.org/news/2026/#pooled-surpass-5-surpass-6-analysis-supports-adding-20262026-09-15T05:26:15Zweekly https://semaglutides.org/news/2026/#hhs-secretary-restricted-peptides-will-return-category-1-20262026-09-15T04:50:40Zweekly https://semaglutides.org/news/2026/#small-real-world-study-raises-cpap-adherence-question-20262026-09-15T05:26:32Zweekly https://semaglutides.org/news/2026/#achieve-3-lancet-20262026-09-15T03:55:39Zweekly https://semaglutides.org/news/2026/#massachusetts-group-insurance-commission-votes-eliminate-glp-1-20262026-09-15T03:55:44Zweekly https://semaglutides.org/news/2026/#walgreens-adds-weight-management-virtual-healthcare-service-20262026-09-15T05:26:34Zweekly https://semaglutides.org/news/2026/#general-mills-ceo-anti-obesity-drugs-will-have-20262026-09-15T03:55:53Zweekly https://semaglutides.org/news/2026/#zepbound-label-drops-suicidality-warning-adds-intestinal-obstruction-20262026-09-15T03:55:56Zweekly https://semaglutides.org/news/2026/#novo-nordisk-partners-vivtex-deal-worth-2-1-20262026-09-15T04:50:27Zweekly https://semaglutides.org/news/2026/#uk-raids-seize-nearly-2-000-doses-labeled-20262026-09-15T04:50:30Zweekly https://semaglutides.org/news/2026/#novo-list-price-cut-20262026-09-15T03:11:07Zweekly https://semaglutides.org/news/2026/#2027-list-price-cut-guarantees-undated-cost-pages-20262026-09-15T03:56:05Zweekly https://semaglutides.org/news/2026/#falsified-mounjaro-kwikpen-15-mg-pens-found-uk-20262026-09-15T03:56:04Zweekly https://semaglutides.org/news/2026/#fda-approves-two-generic-saxenda-products-same-20262026-09-15T03:56:11Zweekly https://semaglutides.org/news/2026/#mounjaro-approved-children-10-older-type-2-diabetes-20262026-09-15T03:56:09Zweekly https://semaglutides.org/news/2026/#novo-nordisks-licensed-triple-agonist-ubt251-shows-19-20262026-09-15T03:56:20Zweekly https://semaglutides.org/news/2026/#reduced-frequency-dosing-case-series-published-obesity-20262026-09-15T03:56:32Zweekly https://semaglutides.org/news/2026/#employers-list-price-reset-20262026-09-15T04:50:45Zweekly https://semaglutides.org/news/2026/#uk-gp-bonus-mounjaro-20262026-09-15T05:26:24Zweekly https://semaglutides.org/news/2026/#drugs-com-records-zepbound-kwikpen-brands-newest-presentation-20262026-09-15T05:34:41Zweekly https://semaglutides.org/news/2026/#cagrisema-loses-tirzepatide-redefine-4-novo-nordisk-shares-20262026-09-15T03:11:05Zweekly https://semaglutides.org/news/2026/#redefine-4-miss-20262026-09-15T03:11:15Zweekly https://semaglutides.org/news/2026/#lilly-zepbound-kwikpen-same-self-pay-price-vial-20262026-09-15T03:11:19Zweekly https://semaglutides.org/news/2026/#fda-approves-four-dose-zepbound-kwikpen-putting-tirzepatide-20262026-09-15T03:56:35Zweekly https://semaglutides.org/news/2026/#lilly-calls-zepbound-prescribed-weight-management-medication-2025-20262026-09-15T03:56:34Zweekly https://semaglutides.org/news/2026/#zepbound-multi-dose-kwikpen-becomes-available-20262026-09-15T03:56:40Zweekly https://semaglutides.org/news/2026/#eli-lilly-signs-company-specific-section-232-tariff-20262026-09-15T04:50:38Zweekly https://semaglutides.org/news/2026/#cagrisema-next-trials-20262026-09-15T04:50:52Zweekly https://semaglutides.org/news/2026/#lillydirect-extends-self-pay-pricing-zepbound-kwikpens-20262026-09-15T04:50:49Zweekly https://semaglutides.org/news/2026/#fda-issues-30-warning-letters-telehealth-companies-marketing-20262026-09-15T03:11:24Zweekly https://semaglutides.org/news/2026/#fda-warns-medvi-misbranded-compounded-glp-1-products-20262026-09-15T03:56:41Zweekly https://semaglutides.org/news/2026/#circuit-upholds-health-plans-weight-loss-drug-exclusion-20262026-09-15T03:11:42Zweekly https://semaglutides.org/news/2026/#hims-hers-agrees-acquire-eucalyptus-1-15-billion-20262026-09-15T04:50:54Zweekly https://semaglutides.org/news/2026/#analysis-finds-bariatric-surgery-volume-13-glp-1-20262026-09-15T03:56:44Zweekly https://semaglutides.org/news/2026/#tirzepatide-associated-fewer-asthma-flare-ups-adults-obesity-20262026-09-15T05:26:30Zweekly https://semaglutides.org/news/2026/#european-commission-approves-wegovy-7-2-mg-20262026-09-15T03:56:56Zweekly https://semaglutides.org/news/2026/#orforglipron-1-5b-stockpile-20262026-09-15T04:50:56Zweekly https://semaglutides.org/news/2026/#largest-naion-study-date-va-cohort-finds-double-20262026-09-15T03:11:42Zweekly https://semaglutides.org/news/2026/#novo-nordisk-signals-plans-wegovy-vials-20262026-09-15T05:26:33Zweekly https://semaglutides.org/news/2026/#astrazeneca-oral-glp-1-won-both-phase-2b-20262026-09-15T04:50:56Zweekly https://semaglutides.org/news/2026/#lilly-phase-3-testing-amylin-drug-top-weekly-20262026-09-15T04:51:13Zweekly https://semaglutides.org/news/2026/#oral-ribupatide-posts-12-1-weight-loss-26-20262026-09-15T04:51:06Zweekly https://semaglutides.org/news/2026/#novo-sues-hims-20262026-09-15T03:11:38Zweekly https://semaglutides.org/news/2026/#hims-stock-drop-20262026-09-15T04:51:09Zweekly https://semaglutides.org/news/2026/#lilly-agrees-acquire-orna-therapeutics-2-4-billion-20262026-09-15T04:51:23Zweekly https://semaglutides.org/news/2026/#trinetx-cohort-links-glp-1-use-higher-hair-20262026-09-15T04:51:19Zweekly https://semaglutides.org/news/2026/#glp1-super-bowl-20262026-09-15T03:11:56Zweekly https://semaglutides.org/news/2026/#lady-gaga-ozempic-rumors-20262026-09-15T05:26:35Zweekly https://semaglutides.org/news/2026/#fda-restricts-glp1-compounding-20262026-09-15T03:11:48Zweekly https://semaglutides.org/news/2026/#fda-threatens-seizure-injunction-compounded-glp-1-marketing-20262026-09-15T03:11:52Zweekly https://semaglutides.org/news/2026/#trumprx-launches-20262026-09-15T03:12:06Zweekly https://semaglutides.org/news/2026/#bone-density-study-finds-greater-hip-bone-loss-20262026-09-15T04:51:23Zweekly https://semaglutides.org/news/2026/#hims-49-pill-launch-20262026-09-15T03:12:15Zweekly https://semaglutides.org/news/2026/#trumprx-gov-glp-1-coupons-20262026-09-15T03:12:13Zweekly https://semaglutides.org/news/2026/#lilly-q4-2025-results2026-09-15T03:57:00Zweekly https://semaglutides.org/news/2026/#wegovy-pill-economics-20262026-09-15T03:57:06Zweekly https://semaglutides.org/news/2026/#mhra-naion-dsu-20262026-09-15T03:57:10Zweekly https://semaglutides.org/news/2026/#trumprx-gov-zepbound-mounjaro-listings-20262026-09-15T03:57:14Zweekly https://semaglutides.org/news/2026/#trumprx-gov-becomes-gov-competitor-drug-pricing-queries-20262026-09-15T04:51:33Zweekly https://semaglutides.org/news/2026/#novo-exec-departures-20262026-09-15T05:26:41Zweekly https://semaglutides.org/news/2026/#lilly-2025-results-mounjaro-23-0-billion-zepbound-20262026-09-15T03:12:19Zweekly https://semaglutides.org/news/2026/#lilly-2025-revenue-65-2-billion-45-guides-20262026-09-15T03:12:25Zweekly https://semaglutides.org/news/2026/#novo-shares-plunge-feb-20262026-09-15T03:12:29Zweekly https://semaglutides.org/news/2026/#fda-approves-rybelsus-ozempic-tablets-name-change-orphaning-20262026-09-15T03:57:22Zweekly https://semaglutides.org/news/2026/#lilly-novo-nordisk-issue-sharply-diverging-2026-guidance2026-09-15T03:57:21Zweekly https://semaglutides.org/news/2026/#lilly-q4-2025-detail-20262026-09-15T03:57:26Zweekly https://semaglutides.org/news/2026/#ozempic-pill-introduced-20262026-09-15T03:57:41Zweekly https://semaglutides.org/news/2026/#novo-buybacks-20262026-09-15T04:52:02Zweekly https://semaglutides.org/news/2026/#study-links-glp-1-receptor-agonists-blunted-thirst-20262026-09-15T04:51:30Zweekly https://semaglutides.org/news/2026/#lilly-drops-three-pipeline-drugs-20262026-09-15T05:26:47Zweekly https://semaglutides.org/news/2026/#full-2025-results-sales-dkk-309-1-billion-20262026-09-15T03:12:38Zweekly https://semaglutides.org/news/2026/#novo-2026-guidance-shock2026-09-15T03:12:45Zweekly https://semaglutides.org/news/2026/#judge-dismisses-eli-lillys-case-against-willow-health-20262026-09-15T03:57:37Zweekly https://semaglutides.org/news/2026/#pfizers-monthly-glp-1-hits-phase-2b-endpoint-20262026-09-15T03:57:48Zweekly https://semaglutides.org/news/2026/#novo-2025-full-year-results2026-09-15T04:51:53Zweekly https://semaglutides.org/news/2026/#pfizer-shares-fall-phase-2b-data-berobenatide-20262026-09-15T04:51:49Zweekly https://semaglutides.org/news/2026/#analysts-trim-obesity-drug-market-forecasts-30-20262026-09-15T03:12:46Zweekly https://semaglutides.org/news/2026/#reimagine-2-results-20262026-09-15T03:57:52Zweekly https://semaglutides.org/news/2026/#claims-analysis-shows-tirzepatide-displacing-time-cpap-20262026-09-15T03:57:48Zweekly https://semaglutides.org/news/2026/#rest-trial-recruiting-randomized-test-tapering-versus-stopping-20262026-09-15T03:12:48Zweekly https://semaglutides.org/news/2026/#zepbounds-suicidal-ideation-warning-removed-severe-gastrointestinal-section-20262026-09-15T03:12:59Zweekly https://semaglutides.org/news/2026/#second-third-generic-saxenda-products-reach-pharmacies-20262026-09-15T03:58:01Zweekly https://semaglutides.org/news/2026/#suicidal-behavior-ideation-section-removed-saxenda-label-20262026-09-15T03:58:05Zweekly https://semaglutides.org/news/2026/#truveta-records-show-tirzepatide-outperforming-semaglutide-outside-trials-20262026-09-15T03:58:10Zweekly https://semaglutides.org/news/2026/#court-dismisses-lillys-complaint-against-compounded-tirzepatide-telehealth-20262026-09-15T04:51:44Zweekly https://semaglutides.org/news/2026/#fda-liposomal-rule-20262026-09-15T04:51:51Zweekly https://semaglutides.org/news/2026/#lilly-runs-never-during-milan-cortina-winter-olympics-20262026-09-15T04:51:54Zweekly https://semaglutides.org/news/2026/#surpass-switch-subgroup-analysis-finds-consistent-benefit-patient-20262026-09-15T05:26:52Zweekly https://semaglutides.org/news/2026/#us-semaglutide-market-size-20262026-09-15T05:26:56Zweekly https://semaglutides.org/news/2026/#astrazeneca-signs-obesity-deal-chinas-cspc-worth-18-20262026-09-15T03:58:16Zweekly https://semaglutides.org/news/2026/#eu-declines-separate-hfpef-indication-tirzepatide-adds-summit-20262026-09-15T03:58:15Zweekly https://semaglutides.org/news/2026/#rybelsus-becomes-ozempic-tablets-20262026-09-15T03:58:24Zweekly https://semaglutides.org/news/2026/#lilly-pennsylvania-3-5b-20262026-09-15T03:58:28Zweekly https://semaglutides.org/news/2026/#ricks-medicare-game-changer-20262026-09-15T04:52:01Zweekly https://semaglutides.org/news/2026/#mhra-strengthens-pancreatitis-warnings-entire-glp-1-class-20262026-09-15T03:13:03Zweekly https://semaglutides.org/news/2026/#chmp-refuses-eu-heart-failure-indication-accepts-summit-20262026-09-15T03:58:33Zweekly https://semaglutides.org/news/2026/#president-eli-lilly-plans-six-manufacturing-plants-20262026-09-15T04:52:06Zweekly https://semaglutides.org/news/2026/#kff-medicare-advantage-insurers-denied-4-1-million-20262026-09-15T03:58:41Zweekly https://semaglutides.org/news/2026/#reuters-novo-outspent-lilly-two-one-glp-1-20262026-09-15T03:58:40Zweekly https://semaglutides.org/news/2026/#novo-nordisks-glp-1-ad-spend-nearly-500-20262026-09-15T04:52:07Zweekly https://semaglutides.org/news/2026/#ira-round-three-selection-20262026-09-15T03:13:07Zweekly https://semaglutides.org/news/2026/#roches-enicepatide-posts-22-5-placebo-adjusted-weight-20262026-09-15T03:58:50Zweekly https://semaglutides.org/news/2026/#sun-pharma-india-generic-20262026-09-15T04:52:31Zweekly https://semaglutides.org/news/2026/#lilly-weight-stigma-film-20262026-09-15T05:27:06Zweekly https://semaglutides.org/news/2026/#eu-adds-pediatric-indication-surmount-5-data-mounjaro-20262026-09-15T04:52:56Zweekly https://semaglutides.org/news/2026/#zepbound-kwikpen-instructions-use-issued-ahead-devices-20262026-09-15T05:26:52Zweekly https://semaglutides.org/news/2026/#fda-approves-mounjaro-kwikpen-zepbound-kwikpen-20262026-09-15T03:13:16Zweekly https://semaglutides.org/news/2026/#surmount-maintain-completes-testing-step-dose-instead-stopping-20262026-09-15T03:58:51Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-genogenix-unapproved-glp-1-peptides-20262026-09-15T04:52:37Zweekly https://semaglutides.org/news/2026/#kff-counts-13-state-medicaid-programs-covering-glp-20262026-09-15T03:13:14Zweekly https://semaglutides.org/news/2026/#fda-warning-letter-boothwyn-pharmacy-compounded-glp-1-20262026-09-15T04:52:21Zweekly https://semaglutides.org/news/2026/#jefferies-estimates-glp-1s-could-save-airlines-580-20262026-09-15T03:59:00Zweekly https://semaglutides.org/news/2026/#cnpv-review-delays-reported-20262026-09-15T04:52:29Zweekly https://semaglutides.org/news/2026/#surmount-post-hoc-analysis-finds-no-increase-depression-20262026-09-15T04:52:23Zweekly https://semaglutides.org/news/2026/#surmount-osa-mediation-analysis-separates-weight-effects-sleep-20262026-09-15T04:52:39Zweekly https://semaglutides.org/news/2026/#compounder-antitrust-suit-20262026-09-15T03:59:07Zweekly https://semaglutides.org/news/2026/#fda-approves-orbiculars-generic-victoza-later-sold-cipla-20262026-09-15T04:52:50Zweekly https://semaglutides.org/news/2026/#tirzepatide-associated-lower-dementia-risk-semaglutide-sglt2-inhibitors-20262026-09-15T04:53:00Zweekly https://semaglutides.org/news/2026/#fda-asks-drugmakers-drop-suicidal-thoughts-warning-glp-20262026-09-15T03:13:20Zweekly https://semaglutides.org/news/2026/#obesity-association-publishes-2026-pharmacologic-treatment-standards-ranking2026-09-15T03:13:40Zweekly https://semaglutides.org/news/2026/#fda-asks-removal-suicidal-ideation-warning-stranding-generation-20262026-09-15T03:59:13Zweekly https://semaglutides.org/news/2026/#jpm-2026-glp1-mood2026-09-15T04:53:11Zweekly https://semaglutides.org/news/2026/#alabama-settles-clinic-unapproved-weight-loss-drugs-20262026-09-15T04:52:54Zweekly https://semaglutides.org/news/2026/#lilly-nvidia-ai-lab-20262026-09-15T05:27:10Zweekly https://semaglutides.org/news/2026/#novo-nordisks-wegovy-pill-ad-debuts-during-golden-20262026-09-15T03:59:10Zweekly https://semaglutides.org/news/2026/#year-of-the-obesity-pill-20262026-09-15T04:52:56Zweekly https://semaglutides.org/news/2026/#taltz-zepbound-psa-topline-20262026-09-15T03:59:17Zweekly https://semaglutides.org/news/2026/#bmj-meta-analysis-quantifies-weight-regain-stopping-obesity-20262026-09-15T03:59:21Zweekly https://semaglutides.org/news/2026/#fda-approves-multi-dose-tirzepatide-vials-both-brands-20262026-09-15T03:59:38Zweekly https://semaglutides.org/news/2026/#lilly-buys-ventyx-20262026-09-15T04:53:16Zweekly https://semaglutides.org/news/2026/#zepbound-multi-dose-vial-instructions-use-issued-30-20262026-09-15T05:27:05Zweekly https://semaglutides.org/news/2026/#arrowhead-tirzepatide-combo-20262026-09-15T04:53:19Zweekly https://semaglutides.org/news/2026/#lilly-nimbus-oral-obesity-20262026-09-15T05:27:09Zweekly https://semaglutides.org/news/2026/#wegovy-pill-launch-20262026-09-15T03:13:32Zweekly https://semaglutides.org/news/2026/#wegovy-pill-oral-glp-1-approved-obesity-20262026-09-15T03:13:46Zweekly https://semaglutides.org/news/2026/#faers-analysis-finds-probable-tirzepatide-optic-neuropathy-signal-20262026-09-15T04:53:13Zweekly https://semaglutides.org/news/2026/#fda-grants-breakthrough-therapy-designation-pemvidutide-mash-20262026-09-15T04:53:14Zweekly https://semaglutides.org/news/2026/#goodrx-wegovy-pill-price-20262026-09-15T04:53:15Zweekly https://semaglutides.org/news/2026/#novo-nordisks-canadian-data-exclusivity-semaglutide-expires-20262026-09-15T03:13:47Zweekly https://semaglutides.org/news/2026/#canada-patent-expiry-20262026-09-15T03:59:39Zweekly https://semaglutides.org/news/2026/#michigan-medicaid-restricts-glp-1-obesity-coverage-bmi-20262026-09-15T03:13:49Zweekly https://semaglutides.org/news/2026/#semaglutide-exclusivity-expiring-outside-united-states-20262026-09-15T03:13:56Zweekly https://semaglutides.org/news/2026/#harvard-pilgrim-excludes-all-weight-loss-drugs-bcbs-20262026-09-15T03:59:43Zweekly https://semaglutides.org/news/2026/#lilly-publishes-updated-list-prices-incretin-portfolio-20262026-09-15T03:59:40Zweekly https://semaglutides.org/news/2026/#mounjaro-joins-chinas-national-reimbursement-drug-list-20262026-09-15T03:59:46Zweekly https://semaglutides.org/news/2026/#north-dakota-becomes-state-require-aca-marketplace-small-20262026-09-15T03:59:50Zweekly https://semaglutides.org/news/2026/#cms-interoperability-prior-authorization-rule-turnaround-times-take-20262026-09-15T04:53:37Zweekly https://semaglutides.org/news/2026/#express-scripts-optum-rx-set-their-2026-tirzepatide2026-09-15T04:53:38Zweekly https://semaglutides.org/news/2026/#kansas-state-employee-health-plan-raises-glp-1-20262026-09-15T04:53:39Zweekly https://semaglutides.org/news/2026/#lilly-raises-list-prices-mounjaro-zepbound-while-cash-20262026-09-15T04:53:43Zweekly https://semaglutides.org/news/2026/#massachusetts-gic-requires-vida-health-prescribing-weight-loss-20262026-09-15T04:53:34Zweekly https://semaglutides.org/news/2026/#medicare-part-d-pocket-cap-rises-2-100-20262026-09-15T04:53:45Zweekly https://semaglutides.org/news/2026/#ira-round-one-effective-20262026-09-15T04:53:56Zweekly https://semaglutides.org/news/2026/#novo-nordisk-narrows-patient-assistance-program-ozempic-20262026-09-15T04:53:56Zweekly https://semaglutides.org/news/2026/#employer-coverage-cuts-drive-surge-insurance-denial-appeal-20262026-09-15T04:00:11Zweekly https://semaglutides.org/news/2026/#suicidal-behavior-ideation-warning-removed-wegovy-label-20262026-09-15T04:00:07Zweekly https://semaglutides.org/news/2026/#cvs-formulary-stable-20262026-09-15T04:53:56Zweekly https://semaglutides.org/news/2026/#final-vk2735-phase-2-injection-results-published-obesity-20262026-09-15T04:53:57Zweekly https://semaglutides.org/news/2026/#never-share-kwikpen-warning-added-both-tirzepatide-labels-20262026-09-15T04:54:12Zweekly https://semaglutides.org/news/2026/#jersey-becomes-26th-state-enact-anti-copay-accumulator-20262026-09-15T04:54:08Zweekly https://semaglutides.org/news/2026/#rybelsus-rename-rationale-20262026-09-15T04:54:33Zweekly https://semaglutides.org/news/2026/#tirtle1-published-randomized-trial-tirzepatide-type-1-diabetes-20262026-09-15T04:54:19Zweekly https://semaglutides.org/news/2026/#china-approves-sciwinds-ecnoglutide-type-2-diabetes-20262026-09-15T05:27:24Zweekly https://semaglutides.org/news/2026/#health-canada-rybelsus-cv-20262026-09-15T05:27:32Zweekly https://semaglutides.org/news/2026/#mounjaro-label-revision-adds-kwikpen-never-share-warning-20262026-09-15T05:27:50Zweekly https://semaglutides.org/news/2026/#vanessa-williams-ties-mounjaro-use-menopause-20262026-09-15T05:27:44Zweekly https://semaglutides.org/news/2026/#wegovy-7-2-mg-approved-united-kingdom-20262026-09-15T05:27:29Zweekly https://semaglutides.org/news/2025/#oprah-reveals-she-stopped-glp-1s-regained-20-20252026-09-15T03:14:06Zweekly https://semaglutides.org/news/2025/#novo-worst-year-20252026-09-15T04:00:19Zweekly https://semaglutides.org/news/2025/#lilly-novo-china-price-cuts-20252026-09-15T05:27:40Zweekly https://semaglutides.org/news/2025/#axios-fitness-industry-pivoting-glp-1-users-20252026-09-15T04:54:13Zweekly https://semaglutides.org/news/2025/#cms-introduces-balance-model-glp-1-coverage-medicare-20252026-09-15T03:14:15Zweekly https://semaglutides.org/news/2025/#fda-approval-wegovy-pill-opens-highest-growth-query-20252026-09-15T03:14:20Zweekly https://semaglutides.org/news/2025/#wegovy-pill-approved-20252026-09-15T03:14:25Zweekly https://semaglutides.org/news/2025/#jama-target-trial-emulation-links-incretin-drugs-lower-20252026-09-15T04:54:15Zweekly https://semaglutides.org/news/2025/#fda-expands-mounjaro-children-aged-10-older-20252026-09-15T03:14:21Zweekly https://semaglutides.org/news/2025/#altimmunes-pemvidutide-hits-key-48-endpoints-phase-2b-20252026-09-15T04:54:25Zweekly https://semaglutides.org/news/2025/#white-house-largest-set-favored-nation-pricing-deals-20252026-09-15T04:54:50Zweekly https://semaglutides.org/news/2025/#journal-marketing-research-publishes-definitive-glp-1-grocery-20252026-09-15T03:14:25Zweekly https://semaglutides.org/news/2025/#novo-nordisk-files-cagrisema-fda-20252026-09-15T03:14:41Zweekly https://semaglutides.org/news/2025/#orforglipron-holds-weight-loss-patients-switch-off-injections-20252026-09-15T03:14:57Zweekly https://semaglutides.org/news/2025/#surpass-cvot-published-tirzepatide-non-inferior-dulaglutide-20252026-09-15T03:14:51Zweekly https://semaglutides.org/news/2025/#cagrisema-nda-filed-20252026-09-15T04:00:18Zweekly https://semaglutides.org/news/2025/#kailera-opens-global-kainetic-phase-3-program-ribupatide-20252026-09-15T04:54:43Zweekly https://semaglutides.org/news/2025/#surpass-cvot-published-england-journal-medicine-2025-22026-09-15T03:14:59Zweekly https://semaglutides.org/news/2025/#lilly-canada-price-cuts-20252026-09-15T05:27:46Zweekly https://semaglutides.org/news/2025/#weightwatchers-relaunch-20252026-09-15T04:54:42Zweekly https://semaglutides.org/news/2025/#mdl-3163-created-20252026-09-15T03:15:06Zweekly https://semaglutides.org/news/2025/#jpml-creates-mdl-3163-eli-lillys-motion-declining-20252026-09-15T03:14:59Zweekly https://semaglutides.org/news/2025/#north-carolina-medicaid-restores-glp-1-coverage-obesity-20252026-09-15T04:54:51Zweekly https://semaglutides.org/news/2025/#fda-pressure-on-orforglipron-review-20252026-09-15T04:54:52Zweekly https://semaglutides.org/news/2025/#eu-backs-mounjaro-pediatric-20252026-09-15T05:27:49Zweekly https://semaglutides.org/news/2025/#mounjaro-approved-children-10-older-type-2-diabetes-20252026-09-15T03:15:12Zweekly https://semaglutides.org/news/2025/#retatrutide-delivers-71-2-pounds-average-weight-loss-20252026-09-15T03:15:15Zweekly https://semaglutides.org/news/2025/#retatrutides-phase-3-win-28-7-weight-loss-20252026-09-15T03:15:25Zweekly https://semaglutides.org/news/2025/#surpass-cvot-published-england-journal-medicine-20252026-09-15T03:15:31Zweekly https://semaglutides.org/news/2025/#destination-xl-fullbeauty-agree-merge-consolidating-plus-size-20252026-09-15T04:55:07Zweekly https://semaglutides.org/news/2025/#nejm-perspective-calls-generic-liraglutide-overlooked-option-20252026-09-15T04:00:17Zweekly https://semaglutides.org/news/2025/#lilly-alabama-6b-20252026-09-15T04:00:22Zweekly https://semaglutides.org/news/2025/#periods-opens-properly-powered-trial-tirzepatide-pcos-20252026-09-15T04:00:38Zweekly https://semaglutides.org/news/2025/#safe-drugs-act-2025-introduced-congress2026-09-15T04:00:40Zweekly https://semaglutides.org/news/2025/#large-analysis-finds-no-increase-obesity-related-cancers-20252026-09-15T04:54:58Zweekly https://semaglutides.org/news/2025/#adas-2026-standards-care-name-semaglutide-tirzepatide-preferred-20252026-09-15T03:15:35Zweekly https://semaglutides.org/news/2025/#redefine-4-completes-novo-nordisks-cagrisema-tested-directly-20252026-09-15T04:00:53Zweekly https://semaglutides.org/news/2025/#structure-therapeutics-15-3-weight-loss-oral-aleniglipron-20252026-09-15T04:00:52Zweekly https://semaglutides.org/news/2025/#mounjaro-china-reimbursement-20252026-09-15T04:55:03Zweekly https://semaglutides.org/news/2025/#nobel-laureate-carolyn-bertozzi-returns-lilly-board-20252026-09-15T05:27:55Zweekly https://semaglutides.org/news/2025/#fda-seizes-counterfeit-ozempic-labeled-authentic-lot-number-20252026-09-15T03:15:33Zweekly https://semaglutides.org/news/2025/#ftc-approves-final-order-against-telehealth-provider-nextmed-20252026-09-15T03:15:32Zweekly https://semaglutides.org/news/2025/#evoke-ctad-presentation-20252026-09-15T04:00:52Zweekly https://semaglutides.org/news/2025/#analysis-shows-aca-marketplace-glp-1-coverage-shrinking-20252026-09-15T04:00:45Zweekly https://semaglutides.org/news/2025/#faers-analysis-counts-hundreds-compounded-tirzepatide-adverse-events-20252026-09-15T04:01:12Zweekly https://semaglutides.org/news/2025/#lilly-submits-complete-responses-both-kwikpen-applications-20252026-09-15T04:55:07Zweekly https://semaglutides.org/news/2025/#eli-lilly-cuts-zepbound-single-dose-vial-prices-20252026-09-15T03:15:45Zweekly https://semaglutides.org/news/2025/#mayo-clinic-proceedings-puts-gi-side-effect-rates-20252026-09-15T04:01:07Zweekly https://semaglutides.org/news/2025/#uk-agreement-raise-uk-drug-prices-25-20252026-09-15T04:55:15Zweekly https://semaglutides.org/news/2025/#mounjaro-adds-pediatric-indication-severe-gastrointestinal-adverse-reactions-20252026-09-15T03:16:02Zweekly https://semaglutides.org/news/2025/#cornell-numerator-quantify-how-glp-1-use-changes-20252026-09-15T04:01:08Zweekly https://semaglutides.org/news/2025/#oculus-trial-randomizes-patients-hold-continue-their-glp-20252026-09-15T04:01:17Zweekly https://semaglutides.org/news/2025/#bunnie-xo-describes-suicidal-ideation-glp-1-20252026-09-15T04:55:13Zweekly https://semaglutides.org/news/2025/#customs-intercepting-thousands-glp-1-peptide-shipments-china-20252026-09-15T04:55:17Zweekly https://semaglutides.org/news/2025/#retatrutide-triumph-4-20252026-09-15T04:55:24Zweekly https://semaglutides.org/news/2025/#oprah-winfrey-describes-stopping-glp-1-twelve-restarting-20252026-09-15T05:28:03Zweekly https://semaglutides.org/news/2025/#novo-nordisk-files-fda-approval-wegovy-7-2-20252026-09-15T04:55:29Zweekly https://semaglutides.org/news/2025/#cms-negotiated-price-semaglutide-20252026-09-15T03:16:06Zweekly https://semaglutides.org/news/2025/#circana-projects-glp-1-households-will-drive-third-20252026-09-15T04:01:21Zweekly https://semaglutides.org/news/2025/#amycretin-phase-2-weight-loss-hba1c-gains-type-20252026-09-15T04:55:24Zweekly https://semaglutides.org/news/2025/#novo-nordisk-expands-amycretin-program-type-2-diabetes-20252026-09-15T04:55:30Zweekly https://semaglutides.org/news/2025/#open-label-study-80-percent-response-hidradenitis-suppurativa-20252026-09-15T05:28:06Zweekly https://semaglutides.org/news/2025/#evoke-alzheimers-failure-20252026-09-15T03:16:01Zweekly https://semaglutides.org/news/2025/#lizzo-ozempic-boom-erasing-plus-size-people-20252026-09-15T04:01:24Zweekly https://semaglutides.org/news/2025/#novo-shares-evoke-20252026-09-15T04:55:32Zweekly https://semaglutides.org/news/2025/#eli-lilly-becomes-drugmaker-worth-1-trillion-20252026-09-15T03:16:03Zweekly https://semaglutides.org/news/2025/#attain-maintain-completes-testing-switch-injections-oral-glp-20252026-09-15T04:55:45Zweekly https://semaglutides.org/news/2025/#lilly-direct-to-employer-20252026-09-15T04:55:41Zweekly https://semaglutides.org/news/2025/#mazdutide-9-mg-reaches-20-1-weight-loss-20252026-09-15T04:55:43Zweekly https://semaglutides.org/news/2025/#novo-199-intro-offer-20252026-09-15T03:16:08Zweekly https://semaglutides.org/news/2025/#brain-recordings-suggest-tirzepatides-effect-food-noise-may-20252026-09-15T04:56:51Zweekly https://semaglutides.org/news/2025/#goodrx-39-weight-loss-telehealth-subscription-lists-199-20252026-09-15T05:40:53Zweekly https://semaglutides.org/news/2025/#tirzepatide-specific-suicidality-analysis-finds-no-safety-signal-20252026-09-15T04:55:49Zweekly https://semaglutides.org/news/2025/#tirzepatide-binge-eating-signal-20252026-09-15T05:28:04Zweekly https://semaglutides.org/news/2025/#kff-finds-18-adults-have-ever-used-glp-20252026-09-15T03:16:16Zweekly https://semaglutides.org/news/2025/#novo-egm-board-takeover-20252026-09-15T03:16:30Zweekly https://semaglutides.org/news/2025/#extraordinary-general-meeting-installs-lars-rebien-sorensen-chair-20252026-09-15T04:01:41Zweekly https://semaglutides.org/news/2025/#lilly-files-supplement-would-remove-zepbounds-suicidal-ideation-20252026-09-15T04:56:18Zweekly https://semaglutides.org/news/2025/#novo-otc-wegovy-comment-20252026-09-15T04:55:58Zweekly https://semaglutides.org/news/2025/#pfizer-closes-metsera-20252026-09-15T04:01:34Zweekly https://semaglutides.org/news/2025/#sandoz-signals-unbranded-semaglutide-canada-mid-2026-20252026-09-15T04:55:59Zweekly https://semaglutides.org/news/2025/#lilly-drops-cvs-for-employees-20252026-09-15T05:28:05Zweekly https://semaglutides.org/news/2025/#pharmacy-questions-mfn-20252026-09-15T05:28:22Zweekly https://semaglutides.org/news/2025/#tan-france-zepbound-campaign-20252026-09-15T04:56:06Zweekly https://semaglutides.org/news/2025/#wegovy-mash-liver-analysis-20252026-09-15T04:56:12Zweekly https://semaglutides.org/news/2025/#rhythm-long-term-phase-2-enrollment-oral-mc4r-20252026-09-15T05:28:46Zweekly https://semaglutides.org/news/2025/#real-world-study-finds-semaglutide-tirzepatide-equally-protective-20252026-09-15T04:01:40Zweekly https://semaglutides.org/news/2025/#pfizer-wins-metsera-20252026-09-15T03:16:36Zweekly https://semaglutides.org/news/2025/#reporters-flag-gaps-tirzepatide-pricing-deal-20252026-09-15T04:56:09Zweekly https://semaglutides.org/news/2025/#lilly-agrees-trump-administration-cut-zepbound-prices-20252026-09-15T03:16:34Zweekly https://semaglutides.org/news/2025/#mfn-glp1-pricing-deal-20252026-09-15T03:16:42Zweekly https://semaglutides.org/news/2025/#lilly-government-agree-tirzepatide-pricing-including-50-medicare-20252026-09-15T03:16:40Zweekly https://semaglutides.org/news/2025/#trump-glp-1-price-deals-calls-them-fat-20252026-09-15T03:16:49Zweekly https://semaglutides.org/news/2025/#white-house-deal-sets-245-medicare-price-trumprx-20252026-09-15T03:17:03Zweekly https://semaglutides.org/news/2025/#eloralintide-phase-2-results-published-moving-lilly-beyond-20252026-09-15T04:01:47Zweekly https://semaglutides.org/news/2025/#eloralintide-phase-2-20-percent-20252026-09-15T04:01:51Zweekly https://semaglutides.org/news/2025/#lillys-amylin-analog-eloralintide-shows-20-1-weight-20252026-09-15T04:01:51Zweekly https://semaglutides.org/news/2025/#mfn-tariff-relief-vouchers-20252026-09-15T04:02:00Zweekly https://semaglutides.org/news/2025/#rfk-jr-reverses-course-backs-expanded-glp-1-20252026-09-15T04:02:08Zweekly https://semaglutides.org/news/2025/#lilly-adds-carole-ho-adrienne-brown-executive-committee-20252026-09-15T04:56:16Zweekly https://semaglutides.org/news/2025/#lilly-expects-march-2026-approval-20252026-09-15T04:56:41Zweekly https://semaglutides.org/news/2025/#mfn-other-drugs-20252026-09-15T04:56:35Zweekly https://semaglutides.org/news/2025/#lilly-authored-review-restates-tirzepatides-mechanism-discrepancy-20252026-09-15T05:28:21Zweekly https://semaglutides.org/news/2025/#tirzepatide-lowers-uric-acid-surmount-1-post-hoc-20252026-09-15T05:28:22Zweekly https://semaglutides.org/news/2025/#metsera-bidding-war-20252026-09-15T04:02:17Zweekly https://semaglutides.org/news/2025/#obesityweek-2025-oral-sema2026-09-15T05:28:33Zweekly https://semaglutides.org/news/2025/#stat-news-documents-glp-1-microdosing-boom-20252026-09-15T04:02:13Zweekly https://semaglutides.org/news/2025/#hengrui-kailera-19-2-weight-loss-chinese-phase-20252026-09-15T04:56:35Zweekly https://semaglutides.org/news/2025/#annals-internal-medicine-study-finds-tirzepatide-semaglutide-have-20252026-09-15T04:02:19Zweekly https://semaglutides.org/news/2025/#lilly-netherlands-3b-20252026-09-15T04:56:31Zweekly https://semaglutides.org/news/2025/#novo-15m-compounded-estimate-20252026-09-15T04:56:41Zweekly https://semaglutides.org/news/2025/#pfizer-sues-novo-nordisk-metsera-bidding-war-20252026-09-15T04:56:56Zweekly https://semaglutides.org/news/2025/#post-hoc-analysis-lower-albuminuria-tirzepatide-surmount-obesity-20252026-09-15T04:56:58Zweekly https://semaglutides.org/news/2025/#zepbound-overtakes-wegovy-20252026-09-15T03:17:07Zweekly https://semaglutides.org/news/2025/#federal-pricing-agreement-cuts-lillys-direct-consumer-zepbound-20252026-09-15T04:02:23Zweekly https://semaglutides.org/news/2025/#federal-pricing-agreement-sets-mounjaro-245-medicare-medicaid-20252026-09-15T04:02:30Zweekly https://semaglutides.org/news/2025/#surmount-4-post-hoc-grades-cardiometabolic-reversal-how-20252026-09-15T04:02:43Zweekly https://semaglutides.org/news/2025/#aasld-updates-mash-practice-guidance-semaglutide-20252026-09-15T04:57:01Zweekly https://semaglutides.org/news/2025/#off-scales-publishes-corporate-history-ozempic-20252026-09-15T04:57:01Zweekly https://semaglutides.org/news/2025/#novo-layoffs-complete-20252026-09-15T05:28:21Zweekly https://semaglutides.org/news/2025/#zepbound-tops-keytruda-20252026-09-15T03:17:05Zweekly https://semaglutides.org/news/2025/#cochrane-review-delivers-cautious-verdict-liraglutide-obesity-20252026-09-15T04:02:45Zweekly https://semaglutides.org/news/2025/#novo-nordisk-unsolicited-counterbid-metsera-20252026-09-15T04:02:50Zweekly https://semaglutides.org/news/2025/#lilly-q3-2025-revenue-17-6-billion-542026-09-15T04:56:57Zweekly https://semaglutides.org/news/2025/#protocol-published-randomized-semaglutide-trial-opioid-use-disorder-20252026-09-15T05:28:41Zweekly https://semaglutides.org/news/2025/#lillydirect-walmart-retail-pickup-direct-consumer-prices-20252026-09-15T04:02:44Zweekly https://semaglutides.org/news/2025/#lillydirect-walmart-pickup-20252026-09-15T04:02:50Zweekly https://semaglutides.org/news/2025/#lilly-puerto-rico-1-2b-20252026-09-15T04:57:08Zweekly https://semaglutides.org/news/2025/#lilly-nvidia-drug-discovery-supercomputer-20252026-09-15T04:57:15Zweekly https://semaglutides.org/news/2025/#fda-classifies-class-ii-recall-prorx-compounded-semaglutide-20252026-09-15T04:57:19Zweekly https://semaglutides.org/news/2025/#lilly-files-cardiovascular-outcomes-supplements-both-tirzepatide-brands-20252026-09-15T04:57:50Zweekly https://semaglutides.org/news/2025/#lilly-sues-two-texas-companies-tirzepatide-replicas-20252026-09-15T04:57:19Zweekly https://semaglutides.org/news/2025/#shaq-osa-campaign-20252026-09-15T05:28:43Zweekly https://semaglutides.org/news/2025/#mazdutide-beats-semaglutide-head-head-phase-3-glp-20252026-09-15T04:57:19Zweekly https://semaglutides.org/news/2025/#lilly-agrees-acquire-adverum-biotechnologies-20252026-09-15T05:28:48Zweekly https://semaglutides.org/news/2025/#chmp-recommends-adding-surmount-5-eu-mounjaro-label-20252026-09-15T04:57:35Zweekly https://semaglutides.org/news/2025/#cipla-india-brand-20252026-09-15T05:28:50Zweekly https://semaglutides.org/news/2025/#lancet-analysis-select-finds-cardiovascular-benefit-adiposity-levels-20252026-09-15T04:57:37Zweekly https://semaglutides.org/news/2025/#novo-board-resignations-20252026-09-15T03:17:13Zweekly https://semaglutides.org/news/2025/#terns-pharmaceuticals-abandons-oral-glp-1-weak-phase-20252026-09-15T04:57:37Zweekly https://semaglutides.org/news/2025/#obesityweek-2025-preview2026-09-15T05:29:05Zweekly https://semaglutides.org/news/2025/#rybelsus-cv-indication-20252026-09-15T03:17:12Zweekly https://semaglutides.org/news/2025/#trump-150-glp1-target-20252026-09-15T04:03:04Zweekly https://semaglutides.org/news/2025/#achieve-2-achieve-5-succeed-20252026-09-15T04:03:22Zweekly https://semaglutides.org/news/2025/#synergy-outcomes-mash-phase-3-skips-liver-biopsy-20252026-09-15T04:03:19Zweekly https://semaglutides.org/news/2025/#achieve-2-achieve-5-results-20252026-09-15T04:57:42Zweekly https://semaglutides.org/news/2025/#fda-approves-october-2025-gastrointestinal-labeling-changes-semaglutide2026-09-15T04:03:16Zweekly https://semaglutides.org/news/2025/#fda-asks-lilly-update-zepbound-label-intestinal-obstruction-20252026-09-15T04:57:42Zweekly https://semaglutides.org/news/2025/#kailera-therapeutics-raises-600-million-push-ribupatide-global-20252026-09-15T04:57:50Zweekly https://semaglutides.org/news/2025/#novo-layoffs-begin-20252026-09-15T04:57:59Zweekly https://semaglutides.org/news/2025/#novo-nordisk-agrees-buy-akero-therapeutics-5-2-20252026-09-15T04:03:23Zweekly https://semaglutides.org/news/2025/#delaware-court-issues-opinion-lilly-v-strive-pharmacy-20252026-09-15T04:03:23Zweekly https://semaglutides.org/news/2025/#north-carolina-renegotiates-cvs-caremark-right-bargain-directly-20252026-09-15T04:57:53Zweekly https://semaglutides.org/news/2025/#novo-nordisk-cutting-9-000-jobs-worldwide-20252026-09-15T04:03:32Zweekly https://semaglutides.org/news/2025/#target-trial-emulation-finds-largest-alcohol-use-disorder-20252026-09-15T04:58:03Zweekly https://semaglutides.org/news/2025/#systematic-review-finds-glp-1-drugs-improve-idiopathic-20252026-09-15T05:29:22Zweekly https://semaglutides.org/news/2025/#randomized-trial-tirzepatide-alcohol-use-disorder-enrolling-20252026-09-15T04:58:05Zweekly https://semaglutides.org/news/2025/#glp-1-scientists-pass-again-nobel-prize-20252026-09-15T05:29:06Zweekly https://semaglutides.org/news/2025/#lilly-india-manufacturing-1b-20252026-09-15T05:29:02Zweekly https://semaglutides.org/news/2025/#network-meta-analysis-56-obesity-drug-trials-published-20252026-09-15T04:03:50Zweekly https://semaglutides.org/news/2025/#study-finds-cost-not-side-effects-main-reason-20252026-09-15T04:03:46Zweekly https://semaglutides.org/news/2025/#ema-opens-tirzepatide-warfarin-interaction-signal-20252026-09-15T04:58:11Zweekly https://semaglutides.org/news/2025/#easo-first-line-glp1-20252026-09-15T04:58:12Zweekly https://semaglutides.org/news/2025/#va-study-finds-liraglutide-comparable-semaglutide-kidney-heart-20252026-09-15T04:03:48Zweekly https://semaglutides.org/news/2025/#north-carolina-medicaid-ends-coverage-glp-1s-obesity-20252026-09-15T04:58:18Zweekly https://semaglutides.org/news/2025/#all-semaglutide-labels-gain-severe-gastrointestinal-adverse-reactions-20252026-09-15T03:17:29Zweekly https://semaglutides.org/news/2025/#surpass-peds-published-tirzepatide-cuts-hba1c-2-23-20252026-09-15T04:03:52Zweekly https://semaglutides.org/news/2025/#costco-wegovy-499-20252026-09-15T04:58:35Zweekly https://semaglutides.org/news/2025/#mhra-dismantles-what-calls-worlds-largest-unlicensed-weight-20252026-09-15T04:58:27Zweekly https://semaglutides.org/news/2025/#severe-gastrointestinal-reactions-warning-added-liraglutide-labels-20252026-09-15T04:58:26Zweekly https://semaglutides.org/news/2025/#glp1-usage-surveys-20252026-09-15T04:58:51Zweekly https://semaglutides.org/news/2025/#viking-therapeutics-vk2735-maintenance-reduced-frequency-dosing-study-20252026-09-15T04:58:29Zweekly https://semaglutides.org/news/2025/#trumprx-announced-20252026-09-15T03:17:33Zweekly https://semaglutides.org/news/2025/#favored-nation-manufacturer-deal-20252026-09-15T04:58:35Zweekly https://semaglutides.org/news/2025/#step-mri-substudy-body-composition-semaglutide-7-2-20252026-09-15T04:03:55Zweekly https://semaglutides.org/news/2025/#fda-approves-inluriyo-imlunestrant-esr1-mutated-advanced-breast-20252026-09-15T04:58:44Zweekly https://semaglutides.org/news/2025/#fda-updates-tirzepatide-breastfeeding-labeling-20252026-09-15T04:58:45Zweekly https://semaglutides.org/news/2025/#lilly-halts-one-bimagrumab-plus-tirzepatide-trial-type-20252026-09-15T05:29:11Zweekly https://semaglutides.org/news/2025/#lilly-india-obesity-pill-plan-20252026-09-15T05:29:07Zweekly https://semaglutides.org/news/2025/#zepbound-labeling-supplement-031-approved-20252026-09-15T05:29:25Zweekly https://semaglutides.org/news/2025/#package-insert-medication-guide-updates-approved-both-brands-20252026-09-15T05:34:58Zweekly https://semaglutides.org/news/2025/#court-lets-eli-lillys-personalized-advertising-claim-against-20252026-09-15T04:03:56Zweekly https://semaglutides.org/news/2025/#bmj-group-retracts-apple-cider-vinegar-weight-loss-20252026-09-15T04:04:12Zweekly https://semaglutides.org/news/2025/#lilly-houston-6-5b-20252026-09-15T04:04:19Zweekly https://semaglutides.org/news/2025/#iqvia-publishes-analysis-tirzepatide-20252026-09-15T04:58:50Zweekly https://semaglutides.org/news/2025/#pfizer-agrees-buy-metsera-7-3-billion-20252026-09-15T04:04:18Zweekly https://semaglutides.org/news/2025/#fda-issues-import-alert-66-80-glp-1-20252026-09-15T04:04:23Zweekly https://semaglutides.org/news/2025/#surpass-peds-published-phase-3-tirzepatide-results-children-20252026-09-15T04:04:25Zweekly https://semaglutides.org/news/2025/#china-approves-mazdutide-type-2-diabetes-20252026-09-15T04:58:52Zweekly https://semaglutides.org/news/2025/#study-documents-racial-inequity-semaglutide-prescribing-among-people-20252026-09-15T04:58:52Zweekly https://semaglutides.org/news/2025/#oasis-4-published-oral-semaglutide-25-mg-produces-20252026-09-15T03:17:42Zweekly https://semaglutides.org/news/2025/#surpass-cvot-presented-full-easd-2025-vienna2026-09-15T03:17:41Zweekly https://semaglutides.org/news/2025/#editorial-warns-muscle-loss-glp-1-drugs-older-20252026-09-15T04:59:00Zweekly https://semaglutides.org/news/2025/#orforglipron-beats-oral-semaglutide-head-head-type-2-20252026-09-15T03:17:48Zweekly https://semaglutides.org/news/2025/#oasis-4-published-20252026-09-15T03:17:47Zweekly https://semaglutides.org/news/2025/#achieve-3-topline-20252026-09-15T04:04:27Zweekly https://semaglutides.org/news/2025/#surpass-peds-results-20252026-09-15T04:04:46Zweekly https://semaglutides.org/news/2025/#liberate-randomized-test-tirzepatide-binge-eating-disorder-20252026-09-15T04:59:02Zweekly https://semaglutides.org/news/2025/#stop-knee-oa-trial-tirzepatide-knee-replacement-continues-20252026-09-15T04:59:10Zweekly https://semaglutides.org/news/2025/#attain-1-published-lillys-oral-glp-1-pill-20252026-09-15T03:17:54Zweekly https://semaglutides.org/news/2025/#fda-hhs-compounder-letters-20252026-09-15T03:18:02Zweekly https://semaglutides.org/news/2025/#lilly-virginia-plant-20252026-09-15T04:59:16Zweekly https://semaglutides.org/news/2025/#lilly-names-goochland-county-virginia-four-plants-20252026-09-15T04:59:21Zweekly https://semaglutides.org/news/2025/#inform-survey-46-percent-drop-constant-food-thoughts-20252026-09-15T05:29:22Zweekly https://semaglutides.org/news/2025/#step-published-semaglutide-7-2-mg-pushes-weight-20252026-09-15T03:18:10Zweekly https://semaglutides.org/news/2025/#step-t2d-13-2-weight-loss-7-2-20252026-09-15T04:59:09Zweekly https://semaglutides.org/news/2025/#novo-9000-layoffs-20252026-09-15T03:18:18Zweekly https://semaglutides.org/news/2025/#fda-ad-warning-letters-20252026-09-15T03:18:22Zweekly https://semaglutides.org/news/2025/#fda-sends-hims-hers-warning-letter-compounded-semaglutide-20252026-09-15T03:18:14Zweekly https://semaglutides.org/news/2025/#dtc-advertising-eo-20252026-09-15T04:04:49Zweekly https://semaglutides.org/news/2025/#fda-warning-letters-cite-eli-lilly-minimizing-zepbound-20252026-09-15T04:04:54Zweekly https://semaglutides.org/news/2025/#fda-warns-novo-nordisk-oprah-special-video-20252026-09-15T04:04:57Zweekly https://semaglutides.org/news/2025/#fda-warning-letter-treats-compounded-retatrutide-unapproved-drug-20252026-09-15T04:59:16Zweekly https://semaglutides.org/news/2025/#lilly-tunelab-opening-ai-drug-discovery-models-outside-20252026-09-15T05:29:22Zweekly https://semaglutides.org/news/2025/#lilly-remedium-gene-therapy-20252026-09-15T05:29:22Zweekly https://semaglutides.org/news/2025/#surmount-maintain-design-paper-published-20252026-09-15T05:29:35Zweekly https://semaglutides.org/news/2025/#fda-creates-glp-1-api-green-list-import-20252026-09-15T03:18:29Zweekly https://semaglutides.org/news/2025/#nc-medicaid-will-stop-covering-glp-1s-weight-20252026-09-15T04:04:48Zweekly https://semaglutides.org/news/2025/#truveta-quantifies-switching-caused-zepbound-exclusion-20252026-09-15T04:04:51Zweekly https://semaglutides.org/news/2025/#novo-nordisk-tells-ema-will-stop-marketing-victoza-20252026-09-15T04:59:29Zweekly https://semaglutides.org/news/2025/#cvs-zepbound-class-action-filed-20252026-09-15T04:59:35Zweekly https://semaglutides.org/news/2025/#truveta-publishes-data-what-cvs-switch-did-prescribing-20252026-09-15T04:59:36Zweekly https://semaglutides.org/news/2025/#byetta-bydureon-approvals-formally-cease-exist-20252026-09-15T04:05:24Zweekly https://semaglutides.org/news/2025/#patients-file-erisa-class-action-zepbound-formulary-removal-20252026-09-15T04:05:23Zweekly https://semaglutides.org/news/2025/#academy-sleep-medicine-publishes-prescribing-guidance-tirzepatide-osa-20252026-09-15T04:59:32Zweekly https://semaglutides.org/news/2025/#naperiglipron-trials-halted-20252026-09-15T05:29:41Zweekly https://semaglutides.org/news/2025/#lilly-raises-uk-mounjaro-list-prices-170-20252026-09-15T04:05:16Zweekly https://semaglutides.org/news/2025/#gallup-obesity-rate-falling-37-0-glp-1-20252026-09-15T03:18:33Zweekly https://semaglutides.org/news/2025/#chrissy-teigen-she-used-ozempic-pregnancy-loss-20252026-09-15T04:59:41Zweekly https://semaglutides.org/news/2025/#eadv-cohort-increased-hair-loss-incidence-glp-1-20252026-09-15T04:59:48Zweekly https://semaglutides.org/news/2025/#network-meta-analysis-ranks-tirzepatide-doses-above-semaglutide-20252026-09-15T04:59:39Zweekly https://semaglutides.org/news/2025/#tricare-ends-weight-loss-drug-coverage-tricare-life-20252026-09-15T04:05:20Zweekly https://semaglutides.org/news/2025/#wegovy-vs-tirzepatide-rwe-20252026-09-15T04:59:49Zweekly https://semaglutides.org/news/2025/#retatrutide-gym-use-20252026-09-15T05:00:04Zweekly https://semaglutides.org/news/2025/#denmark-halves-2025-growth-forecast-citing-novo-nordisk2026-09-15T04:05:24Zweekly https://semaglutides.org/news/2025/#court-finds-no-proximate-cause-lillys-suit-against-20252026-09-15T05:30:37Zweekly https://semaglutides.org/news/2025/#lilly-jd-health-china-20252026-09-15T05:29:37Zweekly https://semaglutides.org/news/2025/#teva-generic-glp-1-indicated-weight-loss-20252026-09-15T03:18:37Zweekly https://semaglutides.org/news/2025/#obesity-pillars-publishes-concrete-nutrition-numbers-glp-1-20252026-09-15T04:05:28Zweekly https://semaglutides.org/news/2025/#lilly-pauses-uk-mounjaro-orders-20252026-09-15T05:29:38Zweekly https://semaglutides.org/news/2025/#attain-2-completes-orforglipron-obesity-package-20252026-09-15T03:18:40Zweekly https://semaglutides.org/news/2025/#serena-williams-goes-public-zepbound-joins-ro-20252026-09-15T03:18:53Zweekly https://semaglutides.org/news/2025/#eli-lilly-asks-jpml-centralize-glp-1-vision-20252026-09-15T04:05:51Zweekly https://semaglutides.org/news/2025/#ozempic-499-cash-20252026-09-15T04:05:48Zweekly https://semaglutides.org/news/2025/#wegovy-mash-approval-20252026-09-15T03:18:54Zweekly https://semaglutides.org/news/2025/#mdl-objective-testing-20252026-09-15T03:18:58Zweekly https://semaglutides.org/news/2025/#lilly-uk-mounjaro-price-hike-20252026-09-15T04:05:55Zweekly https://semaglutides.org/news/2025/#lilly-superluminal-ai-deal-20252026-09-15T05:29:57Zweekly https://semaglutides.org/news/2025/#novo-nordisk-expands-legal-campaign-against-compounded-semaglutide-20252026-09-15T04:05:53Zweekly https://semaglutides.org/news/2025/#ricks-buys-lilly-stock-20252026-09-15T05:30:19Zweekly https://semaglutides.org/news/2025/#texas-sues-eli-lilly-adding-state-litigation-layer-20252026-09-15T05:29:52Zweekly https://semaglutides.org/news/2025/#texas-sues-lilly-kickbacks-20252026-09-15T05:29:54Zweekly https://semaglutides.org/news/2025/#target-trial-emulation-finds-semaglutide-tirzepatide-linked-higher-20252026-09-15T04:05:55Zweekly https://semaglutides.org/news/2025/#texas-attorney-general-sues-eli-lilly-mounjaro-zepbound-20252026-09-15T04:59:56Zweekly https://semaglutides.org/news/2025/#attain-1-topline-27-3-pounds-lost-highest-20252026-09-15T03:19:10Zweekly https://semaglutides.org/news/2025/#doustdar-becomes-ceo-20252026-09-15T03:19:10Zweekly https://semaglutides.org/news/2025/#lilly-q2-2025-results-20252026-09-15T04:05:58Zweekly https://semaglutides.org/news/2025/#orforglipron-attain-20252026-09-15T04:06:24Zweekly https://semaglutides.org/news/2025/#orforglipron-delivers-27-3-pounds-average-weight-loss-20252026-09-15T04:06:16Zweekly https://semaglutides.org/news/2025/#kym-whitley-named-one-zepbounds-two-paid-brand-20252026-09-15T04:59:55Zweekly https://semaglutides.org/news/2025/#novo-guidance-cut-august-20252026-09-15T04:06:25Zweekly https://semaglutides.org/news/2025/#surmount-osa-patient-outcomes-show-sleep-quality-life-20252026-09-15T05:00:03Zweekly https://semaglutides.org/news/2025/#fda-withdraws-byetta-bydureon-approvals-20252026-09-15T04:06:27Zweekly https://semaglutides.org/news/2025/#novo-nordisk-files-suits-against-12-compounding-defendants-20252026-09-15T05:00:13Zweekly https://semaglutides.org/news/2025/#mdl-judge-rules-what-evidence-supports-gastroparesis-claim-20252026-09-15T03:19:14Zweekly https://semaglutides.org/news/2025/#wegovy-label-adds-acute-kidney-injury-warning-20252026-09-15T04:06:31Zweekly https://semaglutides.org/news/2025/#wegovys-indications-section-rewritten-without-bmi-numbers-20252026-09-15T04:06:36Zweekly https://semaglutides.org/news/2025/#cdc-26-5-adults-diagnosed-diabetes-used-glp-20252026-09-15T05:00:33Zweekly https://semaglutides.org/news/2025/#wegovy-72mg-filed-20252026-09-15T05:00:17Zweekly https://semaglutides.org/news/2025/#lilly-surpass-cvot-topline-non-inferior-heart-events-20252026-09-15T03:19:18Zweekly https://semaglutides.org/news/2025/#surpass-cvot-topline-20252026-09-15T03:19:24Zweekly https://semaglutides.org/news/2025/#white-house-sends-pricing-demand-letters-drugmakers-20252026-09-15T04:06:47Zweekly https://semaglutides.org/news/2025/#lilly-files-multi-dose-vial-supplements-both-tirzepatide-20252026-09-15T05:00:14Zweekly https://semaglutides.org/news/2025/#cnn-ozempic-face-driving-cosmetic-surgery-boom-20252026-09-15T05:00:22Zweekly https://semaglutides.org/news/2025/#profit-warning-wipes-70-billion-off-novo-nordisks-20252026-09-15T03:19:26Zweekly https://semaglutides.org/news/2025/#dr-reddys-generic-plan-20252026-09-15T04:06:50Zweekly https://semaglutides.org/news/2025/#fda-approves-lupins-generic-victoza-20252026-09-15T05:00:19Zweekly https://semaglutides.org/news/2025/#zepbound-happy-gilmore-campaign-20252026-09-15T05:29:58Zweekly https://semaglutides.org/news/2025/#ohio-pharmacy-board-publishes-glp-1-compounding-guidance-20252026-09-15T05:00:30Zweekly https://semaglutides.org/news/2025/#senate-dtc-telehealth-report-20252026-09-15T05:00:32Zweekly https://semaglutides.org/news/2025/#surmount-1-analysis-shows-slow-starters-still-succeed-20252026-09-15T05:00:40Zweekly https://semaglutides.org/news/2025/#kinsey-institute-finds-glp-1s-changing-sex-dating-20252026-09-15T05:00:37Zweekly https://semaglutides.org/news/2025/#surmount-5-confirms-tirzepatide-beats-semaglutide-weight-head-20252026-09-15T03:20:38Zweekly https://semaglutides.org/news/2025/#zepbound-kwikpen-canada-20252026-09-15T05:30:22Zweekly https://semaglutides.org/news/2025/#zepbound-kwikpen-approved-canada-20252026-09-15T05:00:39Zweekly https://semaglutides.org/news/2025/#endocrine-society-review-finds-real-world-databases-do-20252026-09-15T05:00:48Zweekly https://semaglutides.org/news/2025/#all-six-zepbound-doses-become-available-through-lillydirect-20252026-09-15T05:01:20Zweekly https://semaglutides.org/news/2025/#pilot-study-tirzepatide-raises-testosterone-improves-erectile-function-20252026-09-15T05:30:17Zweekly https://semaglutides.org/news/2025/#cvs-caremark-forces-largest-molecule-switch-class-date-20252026-09-15T03:19:46Zweekly https://semaglutides.org/news/2025/#cvs-zepbound-class-action-20252026-09-15T03:19:47Zweekly https://semaglutides.org/news/2025/#ftc-charges-telehealth-company-nextmed-deceptive-glp-1-20252026-09-15T05:00:49Zweekly https://semaglutides.org/news/2025/#weightwatchers-emerges-bankruptcy-clinical-business-intact-20252026-09-15T05:00:55Zweekly https://semaglutides.org/news/2025/#fda-lists-intestinal-obstruction-fecal-impaction-class-signal-20252026-09-15T04:06:57Zweekly https://semaglutides.org/news/2025/#who-naion-statement-20252026-09-15T04:06:49Zweekly https://semaglutides.org/news/2025/#lilly-commit-trials-pairing-tirzepatide-biologic-inflammatory-bowel-20252026-09-15T04:07:01Zweekly https://semaglutides.org/news/2025/#mhra-genomics-england-hunting-genetic-cause-glp-1-20252026-09-15T05:00:55Zweekly https://semaglutides.org/news/2025/#glp1-persistence-improves-20252026-09-15T05:00:58Zweekly https://semaglutides.org/news/2025/#weightwatchers-emerges-20252026-09-15T05:01:34Zweekly https://semaglutides.org/news/2025/#novo-ends-hims-deal-20252026-09-15T03:19:50Zweekly https://semaglutides.org/news/2025/#adjust-t1d-randomized-evidence-semaglutide-type-1-diabetes-20252026-09-15T04:07:07Zweekly https://semaglutides.org/news/2025/#maritide-ada-20252026-09-15T04:07:24Zweekly https://semaglutides.org/news/2025/#60-insurers-pledge-simplify-prior-authorization-20252026-09-15T04:07:22Zweekly https://semaglutides.org/news/2025/#believe-shows-activin-pathway-drug-can-protect-muscle-20252026-09-15T05:01:07Zweekly https://semaglutides.org/news/2025/#england-mass-nhs-rollout-tirzepatide-through-gps-20252026-09-15T05:01:28Zweekly https://semaglutides.org/news/2025/#eu-regulators-back-ozempic-label-update-peripheral-artery-20252026-09-15T05:01:12Zweekly https://semaglutides.org/news/2025/#nhs-primary-care-funding-mandate-tirzepatide-england-20252026-09-15T05:01:15Zweekly https://semaglutides.org/news/2025/#redefine-1-2-published-cagrisema-passes-20-weight-20252026-09-15T03:19:56Zweekly https://semaglutides.org/news/2025/#surmount-mmo-design-published-incretin-outcome-trial-covering-20252026-09-15T04:07:21Zweekly https://semaglutides.org/news/2025/#achieve-1-nejm-ada-20252026-09-15T04:07:26Zweekly https://semaglutides.org/news/2025/#step-up-7-2mg-data-20252026-09-15T04:07:27Zweekly https://semaglutides.org/news/2025/#lizzo-admits-she-tried-ozempic-denials-20252026-09-15T04:07:45Zweekly https://semaglutides.org/news/2025/#lilly-files-mounjaro-pediatric-supplement-20252026-09-15T05:01:31Zweekly https://semaglutides.org/news/2025/#apitegromab-zepbound-muscle-20252026-09-15T05:01:31Zweekly https://semaglutides.org/news/2025/#asmbs-head-head-study-finds-bariatric-surgery-far-20252026-09-15T04:07:43Zweekly https://semaglutides.org/news/2025/#lilly-agrees-acquire-verve-therapeutics-1-3-billion-20252026-09-15T05:01:37Zweekly https://semaglutides.org/news/2025/#lilly-offers-every-zepbound-dose-single-dose-vial-20252026-09-15T04:07:49Zweekly https://semaglutides.org/news/2025/#diabetes-runs-point-counterpoint-agonizing-versus-antagonizing-gip-20252026-09-15T05:01:48Zweekly https://semaglutides.org/news/2025/#ema-naion-conclusion-20252026-09-15T03:19:50Zweekly https://semaglutides.org/news/2025/#federal-judge-rules-fda-novo-merits-semaglutide-shortage-20252026-09-15T03:20:18Zweekly https://semaglutides.org/news/2025/#kidney-analysis-surmount-1-surmount-2-finds-no-20252026-09-15T05:01:48Zweekly https://semaglutides.org/news/2025/#eloralintide-phase-1-20252026-09-15T05:01:48Zweekly https://semaglutides.org/news/2025/#novo-nordisk-briefly-regains-title-europes-valuable-company-20252026-09-15T05:02:00Zweekly https://semaglutides.org/news/2025/#amycretin-phase-3-20252026-09-15T04:07:56Zweekly https://semaglutides.org/news/2025/#surpass-cvot-completes-four-follow-20252026-09-15T04:07:59Zweekly https://semaglutides.org/news/2025/#surmount-cn-follow-measures-regain-26-tirzepatide-stopped-20252026-09-15T05:01:56Zweekly https://semaglutides.org/news/2025/#lilly-juvena-muscle-650m-20252026-09-15T05:30:13Zweekly https://semaglutides.org/news/2025/#cleveland-clinic-study-explains-trial-versus-real-world-20252026-09-15T03:20:17Zweekly https://semaglutides.org/news/2025/#ema-adds-sudden-vision-loss-european-semaglutide-labels-20252026-09-15T03:20:12Zweekly https://semaglutides.org/news/2025/#ema-declares-naion-very-rare-side-effect-semaglutide-20252026-09-15T03:21:21Zweekly https://semaglutides.org/news/2025/#uk-regulator-issues-contraception-alert-covering-mounjaro-20252026-09-15T05:02:00Zweekly https://semaglutides.org/news/2025/#lilly-camurus-long-acting-20252026-09-15T05:30:16Zweekly https://semaglutides.org/news/2025/#china-approves-mazdutide-worlds-glp-1-glucagon-dual-20252026-09-15T04:08:02Zweekly https://semaglutides.org/news/2025/#regeneron-licenses-phase-3-ready-glp-1-gip-20252026-09-15T05:02:17Zweekly https://semaglutides.org/news/2025/#review-lays-evidence-behind-both-gip-directions-20252026-09-15T05:02:34Zweekly https://semaglutides.org/news/2025/#alopecia-added-mounjaro-label-validating-long-running-search-20252026-09-15T05:02:17Zweekly https://semaglutides.org/news/2025/#fda-adds-alopecia-mounjaro-label-drops-two-limitations-20252026-09-15T05:02:14Zweekly https://semaglutides.org/news/2025/#mounjaro-package-insert-revised-20252026-09-15T05:35:05Zweekly https://semaglutides.org/news/2025/#lilly-agrees-acquire-siteone-therapeutics-1-billion-20252026-09-15T05:30:33Zweekly https://semaglutides.org/news/2025/#503b-deadline-20252026-09-15T03:20:29Zweekly https://semaglutides.org/news/2025/#fdas-compounding-allowance-semaglutide-expires-20252026-09-15T04:08:09Zweekly https://semaglutides.org/news/2025/#connecticuts-attorney-general-warns-clinics-spas-tirzepatide-products-20252026-09-15T04:08:40Zweekly https://semaglutides.org/news/2025/#cigna-evernorth-200-cap-20252026-09-15T05:02:18Zweekly https://semaglutides.org/news/2025/#lilly-open-letter-insurance-coverage-20252026-09-15T05:02:25Zweekly https://semaglutides.org/news/2025/#novo-ceo-ousted-20252026-09-15T03:20:37Zweekly https://semaglutides.org/news/2025/#select-early-benefit-20252026-09-15T05:02:32Zweekly https://semaglutides.org/news/2025/#mfn-executive-order-20252026-09-15T03:20:48Zweekly https://semaglutides.org/news/2025/#surpass-t1d-2-adds-20-long-term-arm-20252026-09-15T04:08:18Zweekly https://semaglutides.org/news/2025/#surmount-5-tirzepatide-beats-semaglutide-head-head-obesity-20252026-09-15T03:20:54Zweekly https://semaglutides.org/news/2025/#wellness-pivot-glp1-20252026-09-15T05:02:34Zweekly https://semaglutides.org/news/2025/#lilly-executive-transitions-20252026-09-15T05:02:37Zweekly https://semaglutides.org/news/2025/#district-court-grants-summary-judgment-fda-tirzepatide-case-20252026-09-15T03:21:01Zweekly https://semaglutides.org/news/2025/#court-upholds-fda-authority-tirzepatide-shortage-list-20252026-09-15T04:08:21Zweekly https://semaglutides.org/news/2025/#generic-phentermine-topiramate-er-20252026-09-15T04:08:29Zweekly https://semaglutides.org/news/2025/#weightwatchers-bankruptcy-20252026-09-15T03:21:10Zweekly https://semaglutides.org/news/2025/#novo-nordisk-permanent-injunctions-against-compounders-20252026-09-15T04:08:33Zweekly https://semaglutides.org/news/2025/#lilly-withdraws-heart-failure-application-tirzepatide-20252026-09-15T04:08:38Zweekly https://semaglutides.org/news/2025/#cvs-caremark-will-drop-zepbound-standard-commercial-formularies-20252026-09-15T03:21:10Zweekly https://semaglutides.org/news/2025/#cvs-wegovy-preferred-20252026-09-15T03:21:16Zweekly https://semaglutides.org/news/2025/#cvs-caremark-zepbound-formulary-removal-producing-largest-forced-20252026-09-15T04:08:52Zweekly https://semaglutides.org/news/2025/#lilly-q1-2025-results-20252026-09-15T04:08:59Zweekly https://semaglutides.org/news/2025/#liraglutide-labels-drop-pregnancy-contraindication-20252026-09-15T05:02:34Zweekly https://semaglutides.org/news/2025/#meta-analysis-flags-thyroid-colorectal-cancer-signals-glp-20252026-09-15T05:02:43Zweekly https://semaglutides.org/news/2025/#essence-part-1-shows-semaglutide-reverses-liver-inflammation-20252026-09-15T03:21:24Zweekly https://semaglutides.org/news/2025/#compounded-semaglutide-aers-20252026-09-15T05:02:52Zweekly https://semaglutides.org/news/2025/#novo-telehealth-partnerships-20252026-09-15T03:21:33Zweekly https://semaglutides.org/news/2025/#charles-barkley-becomes-ros-glp-1-celebrity-ambassador-20252026-09-15T04:08:54Zweekly https://semaglutides.org/news/2025/#gip-receptor-blockade-shown-work-through-different-pathway-20252026-09-15T04:09:04Zweekly https://semaglutides.org/news/2025/#surpass-t1d-1-properly-powered-incretin-trial-type-20252026-09-15T04:09:17Zweekly https://semaglutides.org/news/2025/#legal-trade-press-tallies-scale-lillys-tirzepatide-litigation-20252026-09-15T05:30:35Zweekly https://semaglutides.org/news/2025/#federal-court-denies-injunction-sought-compounders-semaglutide-20252026-09-15T03:21:38Zweekly https://semaglutides.org/news/2025/#texas-federal-court-leaves-fda-shortage-decision-place-20252026-09-15T04:09:10Zweekly https://semaglutides.org/news/2025/#fda-warning-letter-texas-outsourcer-20252026-09-15T05:03:04Zweekly https://semaglutides.org/news/2025/#eli-lilly-sues-four-telehealth-companies-compounded-tirzepatide-20252026-09-15T03:21:38Zweekly https://semaglutides.org/news/2025/#reporting-puts-compounded-tirzepatide-low-99-20252026-09-15T05:02:52Zweekly https://semaglutides.org/news/2025/#novo-centerwell-expansion-20252026-09-15T05:30:37Zweekly https://semaglutides.org/news/2025/#503a-deadline-20252026-09-15T03:21:53Zweekly https://semaglutides.org/news/2025/#zepbound-reaches-nearly-339-000-weekly-prescriptions-20252026-09-15T04:09:20Zweekly https://semaglutides.org/news/2025/#achieve-1-topline-20252026-09-15T03:21:48Zweekly https://semaglutides.org/news/2025/#lemme-glp-1-daily-federal-class-action-voluntarily-20252026-09-15T05:02:56Zweekly https://semaglutides.org/news/2025/#anaesthesia-meta-analysis-retained-stomach-contents-no-measurable-20252026-09-15T03:21:51Zweekly https://semaglutides.org/news/2025/#counterfeit-ozempic-20252026-09-15T04:09:28Zweekly https://semaglutides.org/news/2025/#pfizer-discontinues-oral-glp-1-danuglipron-liver-injury-20252026-09-15T04:09:23Zweekly https://semaglutides.org/news/2025/#itc-issues-general-exclusion-order-infringing-tirzepatide-imports-20252026-09-15T03:22:00Zweekly https://semaglutides.org/news/2025/#fda-seizes-counterfeit-ozempic-supply-chain-20252026-09-15T04:09:30Zweekly https://semaglutides.org/news/2025/#surpass-switch-finds-switching-beats-dose-escalation-people-20252026-09-15T04:09:41Zweekly https://semaglutides.org/news/2025/#meta-analysis-quantifies-weight-regain-stopping-glp-1-20252026-09-15T04:09:46Zweekly https://semaglutides.org/news/2025/#trump-drops-medicare-obesity-proposal-20252026-09-15T04:09:48Zweekly https://semaglutides.org/news/2025/#novo-nordisk-reshuffles-executive-management-20252026-09-15T05:30:34Zweekly https://semaglutides.org/news/2025/#fda-issues-two-warning-letters-empower-pharmacy-20252026-09-15T04:09:54Zweekly https://semaglutides.org/news/2025/#meitheal-liraglutide-injection-during-victoza-shortage-20252026-09-15T05:03:31Zweekly https://semaglutides.org/news/2025/#knownwell-lillydirect-20252026-09-15T05:31:15Zweekly https://semaglutides.org/news/2025/#commerce-opens-section-232-national-security-investigation-pharmaceutical-20252026-09-15T04:09:59Zweekly https://semaglutides.org/news/2025/#lilly-sues-strive-empower-compounded-tirzepatide-20252026-09-15T04:10:05Zweekly https://semaglutides.org/news/2025/#hims-adds-zepbound-lilly-objects-20252026-09-15T05:03:10Zweekly https://semaglutides.org/news/2025/#essence-published-semaglutide-resolves-mash-treated-patients-20252026-09-15T03:22:08Zweekly https://semaglutides.org/news/2025/#2025-breakthrough-prize-life-sciences-goes-five-glp2026-09-15T04:10:09Zweekly https://semaglutides.org/news/2025/#obesity-medicine-association-acofp-publish-primary-care-roadmap-20252026-09-15T05:03:09Zweekly https://semaglutides.org/news/2025/#weightwatchers-relaunches-glp-1-offering-tailored-companion-program-20252026-09-15T05:03:07Zweekly https://semaglutides.org/news/2025/#soul-acc-nejm-20252026-09-15T03:22:08Zweekly https://semaglutides.org/news/2025/#stride-pad-results-20252026-09-15T04:10:18Zweekly https://semaglutides.org/news/2025/#summit-analysis-flags-measurement-problem-kidney-function-during-20252026-09-15T05:03:12Zweekly https://semaglutides.org/news/2025/#englands-icbs-must-funding-tirzepatide-specialist-weight-management-20252026-09-15T05:03:19Zweekly https://semaglutides.org/news/2025/#mounjaro-india-launch-20252026-09-15T05:03:26Zweekly https://semaglutides.org/news/2025/#enforcement-discretion-ends-503b-outsourcing-facilities-compounding-tirzepatide-20252026-09-15T03:22:22Zweekly https://semaglutides.org/news/2025/#washington-regulator-issues-stop-service-order-glp-1-20252026-09-15T05:03:31Zweekly https://semaglutides.org/news/2025/#ricks-pay-package-20252026-09-15T05:31:02Zweekly https://semaglutides.org/news/2025/#fda-confirms-tirzepatide-compounding-timeline-ruling-20252026-09-15T04:10:15Zweekly https://semaglutides.org/news/2025/#class-action-filed-lemme-glp-1-daily-supplement-20252026-09-15T04:10:27Zweekly https://semaglutides.org/news/2025/#cagrisema-redefine2-20252026-09-15T05:03:26Zweekly https://semaglutides.org/news/2025/#claims-study-increased-hair-loss-risk-semaglutide-women-20252026-09-15T05:03:25Zweekly https://semaglutides.org/news/2025/#trial-tirzepatide-polycystic-kidney-disease-enrolling-20252026-09-15T05:03:36Zweekly https://semaglutides.org/news/2025/#teladoc-lifemd-lillydirect-self-pay-zepbound-integrations-20252026-09-15T05:03:59Zweekly https://semaglutides.org/news/2025/#telehealth-shifts-to-branded-zepbound-20252026-09-15T05:03:39Zweekly https://semaglutides.org/news/2025/#court-denies-compounders-injunction-tirzepatide-20252026-09-15T03:22:23Zweekly https://semaglutides.org/news/2025/#novocare-pharmacy-499-20252026-09-15T03:22:26Zweekly https://semaglutides.org/news/2025/#court-refuses-block-tirzepatide-delisting-20252026-09-15T05:03:59Zweekly https://semaglutides.org/news/2025/#surmount-j-japanese-obesity-results-20252026-09-15T05:03:56Zweekly https://semaglutides.org/news/2025/#lilly-anti-knockoff-ad-campaign-20252026-09-15T05:30:50Zweekly https://semaglutides.org/news/2025/#scott-disick-confirms-mounjaro-use-kardashians-20252026-09-15T05:30:53Zweekly https://semaglutides.org/news/2025/#lilly-27-billion-us-plants-20252026-09-15T03:22:25Zweekly https://semaglutides.org/news/2025/#lilly-cuts-zepbound-cash-price-20252026-09-15T04:10:35Zweekly https://semaglutides.org/news/2025/#surmount-1-dxa-sub-study-puts-numbers-tirzepatide-20252026-09-15T04:10:38Zweekly https://semaglutides.org/news/2025/#outsourcing-facilities-association-sues-fda-semaglutide-delisting-20252026-09-15T04:10:41Zweekly https://semaglutides.org/news/2025/#fda-shortage-resolved-20252026-09-15T03:22:41Zweekly https://semaglutides.org/news/2025/#ofa-sues-over-semaglutide-20252026-09-15T05:03:48Zweekly https://semaglutides.org/news/2025/#orforglipron-stockpile-20252026-09-15T05:04:01Zweekly https://semaglutides.org/news/2025/#503a-compounding-tirzepatide-copies-loses-shortage-protection-20252026-09-15T03:22:45Zweekly https://semaglutides.org/news/2025/#enforcement-discretion-ends-503a-pharmacies-compounding-tirzepatide-20252026-09-15T03:22:50Zweekly https://semaglutides.org/news/2025/#novo-nordisk-alleges-fraud-1-3-billion-kbp-20252026-09-15T05:03:57Zweekly https://semaglutides.org/news/2025/#european-commission-adopts-mounjaro-sleep-apnea-labeling-variation-20252026-09-15T05:04:11Zweekly https://semaglutides.org/news/2025/#tirzepatide-linked-less-papilledema-vision-loss-idiopathic-intracranial-20252026-09-15T05:30:56Zweekly https://semaglutides.org/news/2025/#randomized-trial-semaglutide-alcohol-use-disorder-published-20252026-09-15T03:22:56Zweekly https://semaglutides.org/news/2025/#jama-psychiatry-trial-finds-low-dose-semaglutide-cuts-20252026-09-15T05:04:30Zweekly https://semaglutides.org/news/2025/#fda-clarifies-tirzepatide-compounding-deadlines-20252026-09-15T05:04:14Zweekly https://semaglutides.org/news/2025/#fda-tirzepatide-enforcement-discretion-20252026-09-15T05:30:55Zweekly https://semaglutides.org/news/2025/#lilly-mash-oncology-deals-20252026-09-15T05:31:11Zweekly https://semaglutides.org/news/2025/#hims-hers-runs-super-bowl-ad-glp-1-20252026-09-15T03:24:05Zweekly https://semaglutides.org/news/2025/#two-senators-ask-fda-act-hims-hers-super-20252026-09-15T04:10:45Zweekly https://semaglutides.org/news/2025/#fda-approves-four-pack-zepbound-vial-presentation-20252026-09-15T05:31:08Zweekly https://semaglutides.org/news/2025/#zepbound-package-insert-carton-labeling-revised-20252026-09-15T05:35:16Zweekly https://semaglutides.org/news/2025/#lilly-2024-revenue-45-0-billion-32-20252026-09-15T04:10:48Zweekly https://semaglutides.org/news/2025/#scale-kids-published-liraglutide-lowers-bmi-children-aged-20252026-09-15T04:11:03Zweekly https://semaglutides.org/news/2025/#lilly-q4-2024-results-20252026-09-15T05:04:28Zweekly https://semaglutides.org/news/2025/#full-2024-results-sales-dkk-290-4-billion-20252026-09-15T04:11:05Zweekly https://semaglutides.org/news/2025/#exenatide-fails-largest-glp-1-trial-parkinsons-disease-20252026-09-15T04:11:05Zweekly https://semaglutides.org/news/2025/#fda-issues-action-letters-both-tirzepatide-kwikpen-applications-20252026-09-15T04:11:12Zweekly https://semaglutides.org/news/2025/#fda-adds-kidney-indication-ozempic-based-flow-20252026-09-15T03:22:50Zweekly https://semaglutides.org/news/2025/#ozempic-ckd-approval-20252026-09-15T03:23:12Zweekly https://semaglutides.org/news/2025/#colorado-moves-limit-glp-1-coverage-state-employees-20252026-09-15T05:04:17Zweekly https://semaglutides.org/news/2025/#semaglutide-ira-selected-20252026-09-15T03:23:15Zweekly https://semaglutides.org/news/2025/#high-dose-wegovy-falls-short-20252026-09-15T05:04:18Zweekly https://semaglutides.org/news/2025/#lancet-commission-proposes-replacing-bmi-based-eligibility-clinical-20252026-09-15T04:11:17Zweekly https://semaglutides.org/news/2025/#lilly-2025-guidance-cut-20252026-09-15T05:04:31Zweekly https://semaglutides.org/news/2025/#lilly-agrees-acquire-scorpion-therapeutics-pi3k-alpha-program-20252026-09-15T05:31:14Zweekly https://semaglutides.org/news/2025/#lilly-sues-two-med-spas-20252026-09-15T05:31:12Zweekly https://semaglutides.org/news/2025/#three-surmount-1-data-show-93-relative-drop-20252026-09-15T03:23:24Zweekly https://semaglutides.org/news/2025/#analysis-defines-when-tirzepatide-weight-loss-plateaus-20252026-09-15T05:04:29Zweekly https://semaglutides.org/news/2025/#medicare-covers-zepbound-osa-20252026-09-15T03:23:19Zweekly https://semaglutides.org/news/2025/#cornell-numerator-quantify-glp-1-grocery-effect-20252026-09-15T03:23:25Zweekly https://semaglutides.org/news/2025/#lilly-joins-compounder-suit-20252026-09-15T05:04:34Zweekly https://semaglutides.org/news/2025/#eli-lilly-intervenes-tirzepatide-shortage-case-defend-fda-20252026-09-15T05:04:40Zweekly https://semaglutides.org/news/2025/#ozempic-gastroparesis-label-20252026-09-15T05:04:44Zweekly https://semaglutides.org/news/2024/#fda-lists-naion-potential-signal-glp-1-class-20242026-09-15T04:11:25Zweekly https://semaglutides.org/news/2024/#japan-approves-zepbound-obesity-disease-20242026-09-15T04:11:31Zweekly https://semaglutides.org/news/2024/#hikma-fda-approved-generic-victoza-20242026-09-15T05:04:45Zweekly https://semaglutides.org/news/2024/#elon-musk-posts-ozempic-santa-20242026-09-15T05:04:46Zweekly https://semaglutides.org/news/2024/#nice-final-mounjaro-nhs-20242026-09-15T05:04:48Zweekly https://semaglutides.org/news/2024/#fda-approves-true-generic-victoza-20242026-09-15T03:23:39Zweekly https://semaglutides.org/news/2024/#itc-ruling-knockoff-imports-20242026-09-15T05:04:49Zweekly https://semaglutides.org/news/2024/#cagrisema-redefine1-20242026-09-15T03:23:49Zweekly https://semaglutides.org/news/2024/#zepbound-osa-label-20242026-09-15T03:23:51Zweekly https://semaglutides.org/news/2024/#fda-reaffirms-tirzepatide-shortage-resolved-20242026-09-15T03:23:54Zweekly https://semaglutides.org/news/2024/#fda-issues-formal-declaratory-order-ending-tirzepatide-shortage-20242026-09-15T03:23:54Zweekly https://semaglutides.org/news/2024/#fda-reaffirms-tirzepatide-shortage-resolution-wind-clocks-20242026-09-15T03:24:10Zweekly https://semaglutides.org/news/2024/#catalent-deal-closes-20242026-09-15T04:11:38Zweekly https://semaglutides.org/news/2024/#ema-mounjaro-osa-no-new-approval-20242026-09-15T05:31:18Zweekly https://semaglutides.org/news/2024/#european-regulators-conclude-tirzepatide-causes-dysesthesia-delayed-gastric-20242026-09-15T04:11:35Zweekly https://semaglutides.org/news/2024/#rfk-jr-softens-glp-1s-saying-they-have-20242026-09-15T04:11:40Zweekly https://semaglutides.org/news/2024/#chmp-recommends-adding-sleep-apnea-trial-data-eu-20242026-09-15T05:04:58Zweekly https://semaglutides.org/news/2024/#eu-adds-kidney-outcome-data-ozempic-label-20242026-09-15T05:05:05Zweekly https://semaglutides.org/news/2024/#zepbound-ro-vials-20242026-09-15T05:05:06Zweekly https://semaglutides.org/news/2024/#fda-issues-what-consultants-describe-only-supplement-side-20242026-09-15T04:11:45Zweekly https://semaglutides.org/news/2024/#rybelsus-r2-approval-20242026-09-15T04:12:03Zweekly https://semaglutides.org/news/2024/#lilly-15-billion-buyback-seventh-straight-15-dividend-20242026-09-15T05:31:23Zweekly https://semaglutides.org/news/2024/#nhs-restricts-mounjaro-rollout-20242026-09-15T05:05:06Zweekly https://semaglutides.org/news/2024/#lilly-wisconsin-3b-20242026-09-15T05:05:04Zweekly https://semaglutides.org/news/2024/#surmount-5-topline-20242026-09-15T03:24:24Zweekly https://semaglutides.org/news/2024/#conagra-puts-glp-1-friendly-label-healthy-choice-20242026-09-15T04:12:03Zweekly https://semaglutides.org/news/2024/#endoscopy-meta-analysis-finds-four-fold-higher-odds-20242026-09-15T04:12:05Zweekly https://semaglutides.org/news/2024/#tennessee-officials-seize-300-counterfeit-glp-1-vials-20242026-09-15T04:12:10Zweekly https://semaglutides.org/news/2024/#glp-1-prescription-volume-passes-9-million-20242026-09-15T04:12:10Zweekly https://semaglutides.org/news/2024/#fda-adds-1-7-mg-adolescent-dose-severe-20242026-09-15T05:05:06Zweekly https://semaglutides.org/news/2024/#maritide-phase-2-20242026-09-15T04:12:24Zweekly https://semaglutides.org/news/2024/#cms-proposes-obesity-coverage-20242026-09-15T04:12:36Zweekly https://semaglutides.org/news/2024/#generic-exenatide-reaches-pharmacies-20242026-09-15T05:05:43Zweekly https://semaglutides.org/news/2024/#lilly-laekna-muscle-20242026-09-15T05:31:51Zweekly https://semaglutides.org/news/2024/#google-broadens-site-reputation-abuse-policy-any-third-20242026-09-15T05:05:22Zweekly https://semaglutides.org/news/2024/#procter-gambles-jon-moeller-joins-lilly-board-karen-20242026-09-15T05:31:27Zweekly https://semaglutides.org/news/2024/#circulation-analysis-finds-summit-benefits-spread-symptoms-function-20242026-09-15T05:05:23Zweekly https://semaglutides.org/news/2024/#summit-mechanistic-analysis-shows-less-circulatory-overload-less-20242026-09-15T05:05:24Zweekly https://semaglutides.org/news/2024/#summit-published-aha-20242026-09-15T03:24:25Zweekly https://semaglutides.org/news/2024/#tori-spelling-she-used-mounjaro-her-fifth-child-20242026-09-15T05:31:31Zweekly https://semaglutides.org/news/2024/#jim-gaffigan-he-lost-50-pounds-mounjaro-20242026-09-15T05:05:46Zweekly https://semaglutides.org/news/2024/#three-surmount-1-data-show-94-percent-lower-20242026-09-15T03:24:25Zweekly https://semaglutides.org/news/2024/#surmount-1-176-week-detail-20242026-09-15T04:12:33Zweekly https://semaglutides.org/news/2024/#aspiration-warning-appears-semaglutide-tirzepatide-liraglutide-labels-20242026-09-15T03:24:22Zweekly https://semaglutides.org/news/2024/#fda-finalizes-gastrointestinal-aspiration-labeling-mounjaro-20242026-09-15T04:12:39Zweekly https://semaglutides.org/news/2024/#three-mounjaro-labeling-supplements-approved-together-20242026-09-15T05:35:17Zweekly https://semaglutides.org/news/2024/#semaglutide-listed-available-20242026-09-15T04:12:35Zweekly https://semaglutides.org/news/2024/#step-9-knee-oa-20242026-09-15T04:12:40Zweekly https://semaglutides.org/news/2024/#lilly-q3-2024-miss-20242026-09-15T05:05:25Zweekly https://semaglutides.org/news/2024/#five-medical-societies-reverse-course-patients-can-keep-20242026-09-15T03:24:31Zweekly https://semaglutides.org/news/2024/#astrazeneca-discontinues-byetta-united-states-20242026-09-15T03:24:47Zweekly https://semaglutides.org/news/2024/#smart-trial-albuminuria-reduction-kidney-disease-without-diabetes-20242026-09-15T05:05:39Zweekly https://semaglutides.org/news/2024/#lilly-launches-zepbound-denmark-20242026-09-15T05:31:35Zweekly https://semaglutides.org/news/2024/#fda-remands-tirzepatide-shortage-decision-re-evaluation-20242026-09-15T04:12:59Zweekly https://semaglutides.org/news/2024/#novo-ddc-petition-20242026-09-15T04:13:06Zweekly https://semaglutides.org/news/2024/#soul-topline-20242026-09-15T03:24:49Zweekly https://semaglutides.org/news/2024/#fda-adds-surmount-3-surmount-4-data-zepbound-20242026-09-15T05:05:40Zweekly https://semaglutides.org/news/2024/#five-zepbound-labeling-supplements-approved-once-20242026-09-15T05:31:40Zweekly https://semaglutides.org/news/2024/#fda-letter-signals-enforcement-discretion-during-remand-20242026-09-15T04:13:10Zweekly https://semaglutides.org/news/2024/#lilly-uk-employment-trial-20242026-09-15T05:05:43Zweekly https://semaglutides.org/news/2024/#court-remands-tirzepatide-shortage-decision-fda-20242026-09-15T04:13:08Zweekly https://semaglutides.org/news/2024/#fda-reconsiders-tirzepatide-delisting-20242026-09-15T04:13:05Zweekly https://semaglutides.org/news/2024/#review-questions-how-completely-gastric-emptying-effect-fades-20242026-09-15T05:31:44Zweekly https://semaglutides.org/news/2024/#outsourcing-facilities-association-sues-fda-tirzepatide-shortage-delisting-20242026-09-15T04:13:21Zweekly https://semaglutides.org/news/2024/#ofa-sues-fda-20242026-09-15T03:24:56Zweekly https://semaglutides.org/news/2024/#tirzepatide-delisted-shortage-20242026-09-15T03:25:01Zweekly https://semaglutides.org/news/2024/#fda-declares-tirzepatide-shortage-resolved-october-2-20242026-09-15T03:24:56Zweekly https://semaglutides.org/news/2024/#lilly-medicine-foundry-20242026-09-15T04:13:30Zweekly https://semaglutides.org/news/2024/#kathy-bates-pushes-back-she-just-did-ozempic-20242026-09-15T05:05:52Zweekly https://semaglutides.org/news/2024/#multi-society-guidance-replaces-standalone-anesthesia-advice-glp-20242026-09-15T05:05:59Zweekly https://semaglutides.org/news/2024/#novo-generic-patent-settlements-20242026-09-15T05:06:02Zweekly https://semaglutides.org/news/2024/#novo-nordisks-ceo-grilled-bernie-sanders-glp-1-20242026-09-15T03:25:07Zweekly https://semaglutides.org/news/2024/#ceo-jorgensen-testifies-senate-help-committee-ozempic-wegovy-20242026-09-15T04:13:35Zweekly https://semaglutides.org/news/2024/#fda-warning-letters-research-chemicals-20242026-09-15T05:06:01Zweekly https://semaglutides.org/news/2024/#eu-regulators-recommend-wegovy-label-update-obesity-related-20242026-09-15T05:06:05Zweekly https://semaglutides.org/news/2024/#lilly-ireland-1-8b-20242026-09-15T05:31:42Zweekly https://semaglutides.org/news/2024/#tga-registers-mounjaro-chronic-weight-management-australia-20242026-09-15T05:32:03Zweekly https://semaglutides.org/news/2024/#lilly-new-cfo-20242026-09-15T05:31:59Zweekly https://semaglutides.org/news/2024/#fda-orders-class-wide-anesthesia-warning-glp-1-20242026-09-15T03:25:16Zweekly https://semaglutides.org/news/2024/#fda-issues-section-505-o-4-letter-pulmonary-20242026-09-15T04:13:39Zweekly https://semaglutides.org/news/2024/#lasker-award-honors-glp-1-discovery-20242026-09-15T04:13:45Zweekly https://semaglutides.org/news/2024/#scale-kids-liraglutide-results-children-aged-6-12-20242026-09-15T05:06:05Zweekly https://semaglutides.org/news/2024/#pooled-analysis-suggests-semaglutide-cuts-heart-failure-events-20242026-09-15T04:13:38Zweekly https://semaglutides.org/news/2024/#zepbound-vials-399-20242026-09-15T03:25:18Zweekly https://semaglutides.org/news/2024/#lilly-releases-zepbound-single-dose-vials-20242026-09-15T04:13:53Zweekly https://semaglutides.org/news/2024/#evidence-gip-receptor-agonism-eases-glp-1-gut-20242026-09-15T05:06:09Zweekly https://semaglutides.org/news/2024/#surmount-1-three-year-diabetes-prevention-20242026-09-15T03:25:19Zweekly https://semaglutides.org/news/2024/#ftc-finalizes-rule-consumer-reviews-testimonials-20242026-09-15T05:06:16Zweekly https://semaglutides.org/news/2024/#lilly-warns-doctors-copycats-20242026-09-15T05:06:18Zweekly https://semaglutides.org/news/2024/#novo-nordisk-withdraws-fda-heart-failure-application-wegovy-20242026-09-15T05:06:18Zweekly https://semaglutides.org/news/2024/#fda-all-tirzepatide-doses-available-20242026-09-15T04:13:58Zweekly https://semaglutides.org/news/2024/#summit-hfpef-topline-20242026-09-15T04:14:02Zweekly https://semaglutides.org/news/2024/#novo-eleven-lawsuits-20242026-09-15T05:06:23Zweekly https://semaglutides.org/news/2024/#step-10-reverses-prediabetes-81-participants-20242026-09-15T04:14:08Zweekly https://semaglutides.org/news/2024/#fda-warns-overdoses-compounded-semaglutide-dosing-errors-20242026-09-15T04:14:06Zweekly https://semaglutides.org/news/2024/#tirzepatide-china-obesity-approval-20242026-09-15T05:06:22Zweekly https://semaglutides.org/news/2024/#simone-biles-mounjaro-campaign-20242026-09-15T05:31:56Zweekly https://semaglutides.org/news/2024/#jama-internal-medicine-tirz-vs-sema-20242026-09-15T04:14:13Zweekly https://semaglutides.org/news/2024/#lilly-agrees-acquire-morphic-holding-3-2-billion-20242026-09-15T05:06:22Zweekly https://semaglutides.org/news/2024/#naion-harvard-study-20242026-09-15T03:25:34Zweekly https://semaglutides.org/news/2024/#president-biden-senator-sanders-publish-joint-op-ed-20242026-09-15T05:06:32Zweekly https://semaglutides.org/news/2024/#novo-nordisks-listed-shares-close-all-time-high-20242026-09-15T03:25:33Zweekly https://semaglutides.org/news/2024/#china-approves-wegovy-long-term-weight-management-20242026-09-15T04:14:19Zweekly https://semaglutides.org/news/2024/#fda-approves-generic-qsymia-20242026-09-15T04:14:28Zweekly https://semaglutides.org/news/2024/#teva-authorized-generic-victoza-20242026-09-15T03:25:36Zweekly https://semaglutides.org/news/2024/#novo-nordisk-4-1-billion-plant-clayton-north-20242026-09-15T04:14:28Zweekly https://semaglutides.org/news/2024/#surmount-osa-shows-tirzepatide-roughly-halves-sleep-apnea-20242026-09-15T03:25:48Zweekly https://semaglutides.org/news/2024/#fda-listing-anomaly-hybio-liraglutide-pen-recorded-marketed-20242026-09-15T05:31:59Zweekly https://semaglutides.org/news/2024/#lilly-publishes-open-letter-counterfeit-compounded-tirzepatide-20242026-09-15T03:25:49Zweekly https://semaglutides.org/news/2024/#lilly-files-further-legal-actions-against-med-spas-20242026-09-15T05:06:32Zweekly https://semaglutides.org/news/2024/#cell-metabolism-paper-maps-tirzepatides-effects-fat-cells-20242026-09-15T04:14:41Zweekly https://semaglutides.org/news/2024/#synergy-nash-shows-tirzepatide-resolves-fatty-liver-disease-20242026-09-15T04:14:32Zweekly https://semaglutides.org/news/2024/#surmount-adolescents-2-comorbidity-resolution-endpoint-20242026-09-15T05:06:45Zweekly https://semaglutides.org/news/2024/#counterfeit-online-sales-20242026-09-15T05:07:06Zweekly https://semaglutides.org/news/2024/#lilly-files-six-lawsuits-against-med-spas-selling-20242026-09-15T05:06:36Zweekly https://semaglutides.org/news/2024/#mdl-3094-reassigned-judge-karen-s-marston-20242026-09-15T05:06:58Zweekly https://semaglutides.org/news/2024/#novo-nine-lawsuits-20242026-09-15T05:06:49Zweekly https://semaglutides.org/news/2024/#surmount-cn-china-obesity-trial-results-jama-20242026-09-15T05:06:48Zweekly https://semaglutides.org/news/2024/#flow-published-20242026-09-15T03:25:50Zweekly https://semaglutides.org/news/2024/#lilly-indiana-5-3b-20242026-09-15T04:14:44Zweekly https://semaglutides.org/news/2024/#australia-bans-compounded-tirzepatide-compounded-incretins-20242026-09-15T05:06:52Zweekly https://semaglutides.org/news/2024/#tirzepatide-china-diabetes-approval-20242026-09-15T05:07:08Zweekly https://semaglutides.org/news/2024/#fda-warns-compounded-label-strength-expression-can-cause-20242026-09-15T05:07:08Zweekly https://semaglutides.org/news/2024/#novo-nordisk-trial-touching-alcohol-use-framed-liver-20242026-09-15T05:07:06Zweekly https://semaglutides.org/news/2024/#lilly-spa-settlement-20242026-09-15T05:32:02Zweekly https://semaglutides.org/news/2024/#kelly-clarkson-her-weight-loss-drug-not-ozempic-20242026-09-15T04:14:46Zweekly https://semaglutides.org/news/2024/#select-four-data-show-weight-loss-holds-208-20242026-09-15T04:14:58Zweekly https://semaglutides.org/news/2024/#google-enforcing-site-reputation-abuse-policy-reshaping-commercial-20242026-09-15T05:07:17Zweekly https://semaglutides.org/news/2024/#johann-hari-publishes-magic-pill-mass-market-glp-20242026-09-15T05:07:26Zweekly https://semaglutides.org/news/2024/#hims-hers-compounded-semaglutide-injections-20242026-09-15T04:14:53Zweekly https://semaglutides.org/news/2024/#kff-finds-12-adults-have-ever-taken-glp-20242026-09-15T04:15:00Zweekly https://semaglutides.org/news/2024/#nestl-vital-pursuit-glp-1-users-20242026-09-15T04:15:04Zweekly https://semaglutides.org/news/2024/#real-world-study-links-semaglutide-half-rate-alcohol-20242026-09-15T05:07:30Zweekly https://semaglutides.org/news/2024/#billie-jean-king-ties-her-glp-1-use-20242026-09-15T05:07:43Zweekly https://semaglutides.org/news/2024/#lilly-buys-nexus-plant-20242026-09-15T05:07:25Zweekly https://semaglutides.org/news/2024/#eu-approves-six-additional-mounjaro-strengths-multi-dose-20242026-09-15T05:07:43Zweekly https://semaglutides.org/news/2024/#step-hfpef-dm-extends-heart-failure-benefit-people-20242026-09-15T05:07:34Zweekly https://semaglutides.org/news/2024/#surmount-osa-topline-20242026-09-15T03:26:01Zweekly https://semaglutides.org/news/2024/#zepbound-mounjaro-supply-june-20242026-09-15T05:07:42Zweekly https://semaglutides.org/news/2024/#ema-suicidality-conclusion-20242026-09-15T04:15:07Zweekly https://semaglutides.org/news/2024/#lilly-loses-compounder-ruling-20242026-09-15T05:32:11Zweekly https://semaglutides.org/news/2024/#step-hfpef-dm-20242026-09-15T05:07:52Zweekly https://semaglutides.org/news/2024/#costco-adds-members-weight-loss-program-including-glp-20242026-09-15T05:07:47Zweekly https://semaglutides.org/news/2024/#fda-adds-zepbound-drug-shortage-list-20242026-09-15T04:15:13Zweekly https://semaglutides.org/news/2024/#snl-airs-ozempic-ramadan-20242026-09-15T05:07:54Zweekly https://semaglutides.org/news/2024/#fda-approves-zepbound-single-dose-vials-20242026-09-15T04:15:22Zweekly https://semaglutides.org/news/2024/#zepbound-carton-medication-guide-insert-revisions-approved-20242026-09-15T05:35:10Zweekly https://semaglutides.org/news/2024/#whoopi-goldberg-sunny-hostin-disclose-mounjaro-use-view-20242026-09-15T04:15:27Zweekly https://semaglutides.org/news/2024/#oprah-glp1-special-20242026-09-15T03:26:08Zweekly https://semaglutides.org/news/2024/#zepbound-new-scripts-pass-wegovy-20242026-09-15T04:15:31Zweekly https://semaglutides.org/news/2024/#zepbound-amazon-pharmacy-20242026-09-15T05:08:01Zweekly https://semaglutides.org/news/2024/#lilly-runs-big-night-shame-oscar-night-20242026-09-15T04:15:28Zweekly https://semaglutides.org/news/2024/#wegovy-cv-indication-20242026-09-15T03:26:24Zweekly https://semaglutides.org/news/2024/#zepbound-passes-wegovy-weekly-prescriptions-time-20242026-09-15T03:26:16Zweekly https://semaglutides.org/news/2024/#market-capitalization-passes-600-billion-amycretin-data-20242026-09-15T04:15:38Zweekly https://semaglutides.org/news/2024/#evernorth-pbm-financial-guarantee-glp-1-spend-20242026-09-15T04:15:42Zweekly https://semaglutides.org/news/2024/#lilly-impurity-warning-knockoffs-20242026-09-15T04:15:45Zweekly https://semaglutides.org/news/2024/#flow-topline-20242026-09-15T03:26:23Zweekly https://semaglutides.org/news/2024/#semaglutide-hiv-liver-20242026-09-15T05:32:18Zweekly https://semaglutides.org/news/2024/#s-lite-only-controlled-test-exercise-glp-1-20242026-09-15T04:16:00Zweekly https://semaglutides.org/news/2024/#bmj-journal-publishes-apple-cider-vinegar-weight-loss-20242026-09-15T05:08:05Zweekly https://semaglutides.org/news/2024/#west-virginia-peia-cancels-1-000-person-glp-20242026-09-15T05:08:01Zweekly https://semaglutides.org/news/2024/#oprah-winfrey-leaves-weightwatchers-board-20242026-09-15T04:16:00Zweekly https://semaglutides.org/news/2024/#guideline-evidence-review-finds-almost-no-data-weight-20242026-09-15T05:08:09Zweekly https://semaglutides.org/news/2024/#population-pharmacokinetic-model-pins-tirzepatides-half-life-5-20242026-09-15T05:08:09Zweekly https://semaglutides.org/news/2024/#cms-finalizes-prior-authorization-timelines-exclude-drugs-20242026-09-15T05:08:10Zweekly https://semaglutides.org/news/2024/#zepbound-first-quarter-sales-20242026-09-15T05:08:31Zweekly https://semaglutides.org/news/2024/#novo-catalent-deal-announced-20242026-09-15T03:26:18Zweekly https://semaglutides.org/news/2024/#tirzepatide-blood-pressure-20242026-09-15T05:08:20Zweekly https://semaglutides.org/news/2024/#step-7-12-1-weight-loss-predominantly-east-20242026-09-15T05:32:15Zweekly https://semaglutides.org/news/2024/#mdl-3094-created-20242026-09-15T03:26:34Zweekly https://semaglutides.org/news/2024/#jpml-creates-mdl-3094-eli-lilly-named-defendant-20242026-09-15T03:26:43Zweekly https://semaglutides.org/news/2024/#full-2023-results-sales-31-dkk-232-3-20242026-09-15T04:15:59Zweekly https://semaglutides.org/news/2024/#fda-finds-no-evidence-glp-1-drugs-cause-20242026-09-15T04:16:02Zweekly https://semaglutides.org/news/2024/#mounjaro-limited-availability-20242026-09-15T05:32:16Zweekly https://semaglutides.org/news/2024/#north-carolina-state-health-plan-votes-drop-glp-20242026-09-15T04:16:19Zweekly https://semaglutides.org/news/2024/#fda-suicidality-review-20242026-09-15T04:16:12Zweekly https://semaglutides.org/news/2024/#lilly-lillydirect-direct-patient-platform-major-drugmaker-20242026-09-15T03:26:46Zweekly https://semaglutides.org/news/2024/#lillydirect-launch-detail-20242026-09-15T03:26:47Zweekly https://semaglutides.org/news/2024/#lilly-open-letter-cosmetic-use-20242026-09-15T05:08:24Zweekly https://semaglutides.org/news/2024/#lillydirect-launch-20242026-09-15T04:16:30Zweekly https://semaglutides.org/news/2024/#nature-medicine-suicidality-20242026-09-15T04:16:34Zweekly https://semaglutides.org/news/2023/#fda-seizes-thousands-counterfeit-ozempic-pens-20232026-09-15T04:16:32Zweekly https://semaglutides.org/news/2023/#lilly-fauna-bio-20232026-09-15T05:32:24Zweekly https://semaglutides.org/news/2023/#zepbound-ro-body-program-20232026-09-15T05:32:20Zweekly https://semaglutides.org/news/2023/#surmount-4-jama-20232026-09-15T03:27:00Zweekly https://semaglutides.org/news/2023/#european-commission-adds-chronic-weight-management-mounjaro-20232026-09-15T04:16:34Zweekly https://semaglutides.org/news/2023/#zepbound-pharmacy-launch-20232026-09-15T04:16:39Zweekly https://semaglutides.org/news/2023/#surmount-4-confirms-rapid-regain-stopping-tirzepatide-20232026-09-15T04:16:47Zweekly https://semaglutides.org/news/2023/#oprah-winfrey-tells-people-she-uses-weight-loss-20232026-09-15T03:26:51Zweekly https://semaglutides.org/news/2023/#tirzepatide-users-drink-less-alcohol-20232026-09-15T05:08:26Zweekly https://semaglutides.org/news/2023/#itc-institutes-investigation-no-337-ta-1377-tirzepatide-20232026-09-15T05:08:33Zweekly https://semaglutides.org/news/2023/#tirzepatide-vs-semaglutide-rwe-20232026-09-15T05:08:22Zweekly https://semaglutides.org/news/2023/#novo-nordisk-commits-2-1-billion-euros-expand-20232026-09-15T05:32:43Zweekly https://semaglutides.org/news/2023/#lilly-germany-plant-20232026-09-15T05:08:36Zweekly https://semaglutides.org/news/2023/#lilly-files-zepbound-kwikpen-application-20232026-09-15T05:08:45Zweekly https://semaglutides.org/news/2023/#select-aha-nejm-20232026-09-15T03:27:06Zweekly https://semaglutides.org/news/2023/#ema-backs-mounjaro-obesity-20232026-09-15T05:32:35Zweekly https://semaglutides.org/news/2023/#chmp-recommends-eu-weight-management-indication-mounjaro-20232026-09-15T05:08:43Zweekly https://semaglutides.org/news/2023/#fda-approves-zepbound-20232026-09-15T03:27:18Zweekly https://semaglutides.org/news/2023/#zepbound-approved-weight-management-carrying-suicidal-ideation-warning-20232026-09-15T03:27:22Zweekly https://semaglutides.org/news/2023/#zepbound-approval-label-20232026-09-15T03:27:16Zweekly https://semaglutides.org/news/2023/#mhra-mounjaro-weight-loss-20232026-09-15T04:16:59Zweekly https://semaglutides.org/news/2023/#zepbound-approval-splits-tirzepatide-search-demand-two-brand-20232026-09-15T04:17:08Zweekly https://semaglutides.org/news/2023/#zepbound-1-059-87-flat-all-doses-20232026-09-15T04:17:10Zweekly https://semaglutides.org/news/2023/#ema-requests-suicidality-data-20232026-09-15T04:17:03Zweekly https://semaglutides.org/news/2023/#sharon-osbourne-warns-ozempic-dropping-below-100-pounds-20232026-09-15T04:17:10Zweekly https://semaglutides.org/news/2023/#novo-q3-2023-sales2026-09-15T05:08:42Zweekly https://semaglutides.org/news/2023/#gelesis-files-chapter-7-liquidation-putting-plenitys-availability-20232026-09-15T05:09:04Zweekly https://semaglutides.org/news/2023/#lilly-files-section-337-complaint-itc-against-11-20232026-09-15T04:17:17Zweekly https://semaglutides.org/news/2023/#lilly-itc-import-action-20232026-09-15T05:08:48Zweekly https://semaglutides.org/news/2023/#tirzepatide-birth-control-interaction-20232026-09-15T05:08:51Zweekly https://semaglutides.org/news/2023/#surmount-adolescents-tirzepatide-weight-trial-teenagers-20232026-09-15T05:09:03Zweekly https://semaglutides.org/news/2023/#surmount-3-lancet-20232026-09-15T04:17:30Zweekly https://semaglutides.org/news/2023/#jama-research-letter-links-glp-1-weight-loss-20232026-09-15T03:27:26Zweekly https://semaglutides.org/news/2023/#walmart-glp-1-users-buying-less-food-20232026-09-15T03:27:28Zweekly https://semaglutides.org/news/2023/#lilly-obesity-unit-leadership-20232026-09-15T05:32:40Zweekly https://semaglutides.org/news/2023/#goldman-sachs-sizes-anti-obesity-drug-market-100-20232026-09-15T04:17:28Zweekly https://semaglutides.org/news/2023/#eu-uk-counterfeit-ozempic-20232026-09-15T05:09:17Zweekly https://semaglutides.org/news/2023/#lilly-files-mounjaro-kwikpen-application-fda-20232026-09-15T05:09:20Zweekly https://semaglutides.org/news/2023/#ozempic-ileus-warning-20232026-09-15T03:27:36Zweekly https://semaglutides.org/news/2023/#lilly-first-compounding-suits-20232026-09-15T04:17:40Zweekly https://semaglutides.org/news/2023/#consumerlab-finds-problems-nearly-45-berberine-goldenseal-supplements-20232026-09-15T05:09:15Zweekly https://semaglutides.org/news/2023/#nice-backs-mounjaro-diabetes-20232026-09-15T05:34:58Zweekly https://semaglutides.org/news/2023/#novo-most-valuable-europe-20232026-09-15T03:27:56Zweekly https://semaglutides.org/news/2023/#lilly-sues-compounders-20232026-09-15T05:09:10Zweekly https://semaglutides.org/news/2023/#lilly-files-round-lawsuits-products-sold-tirzepatide-20232026-09-15T05:09:23Zweekly https://semaglutides.org/news/2023/#step-hfpef-published-20232026-09-15T04:17:40Zweekly https://semaglutides.org/news/2023/#peterson-kff-publishes-versus-peer-country-price-gap-20232026-09-15T05:09:20Zweekly https://semaglutides.org/news/2023/#peterson-kff-puts-tirzepatide-three-times-netherlands-price-20232026-09-15T05:09:27Zweekly https://semaglutides.org/news/2023/#tracy-morgan-tells-today-his-weight-loss-ozempic-20232026-09-15T05:09:50Zweekly https://semaglutides.org/news/2023/#wegovy-supply-warning-20232026-09-15T05:09:40Zweekly https://semaglutides.org/news/2023/#novo-nordisk-agrees-buy-inversago-pharma-1-billion-20232026-09-15T05:32:56Zweekly https://semaglutides.org/news/2023/#select-topline-20232026-09-15T03:27:50Zweekly https://semaglutides.org/news/2023/#lilly-record-high-mounjaro-20232026-09-15T05:09:38Zweekly https://semaglutides.org/news/2023/#first-gastroparesis-suits-20232026-09-15T04:17:34Zweekly https://semaglutides.org/news/2023/#fda-approves-mounjaro-single-dose-vials-never-marketed-20232026-09-15T05:09:42Zweekly https://semaglutides.org/news/2023/#mounjaro-label-revision-adds-carton-medication-guide-package-20232026-09-15T05:32:41Zweekly https://semaglutides.org/news/2023/#surmount-3-4-topline-20232026-09-15T04:17:45Zweekly https://semaglutides.org/news/2023/#liraglutide-injection-goes-fda-drug-shortage-list-20232026-09-15T04:17:59Zweekly https://semaglutides.org/news/2023/#lilly-agrees-acquire-versanis-bio-1-925-billion-20232026-09-15T05:09:40Zweekly https://semaglutides.org/news/2023/#lilly-buys-versanis-20232026-09-15T05:09:42Zweekly https://semaglutides.org/news/2023/#tirzepatide-labeling-changed-add-ileus-alongside-similar-semaglutide-20232026-09-15T04:18:08Zweekly https://semaglutides.org/news/2023/#asa-tells-anesthesiologists-hold-glp-1-drugs-elective-20232026-09-15T04:18:02Zweekly https://semaglutides.org/news/2023/#poison-control-case-series-documents-10-fold-compounded-20232026-09-15T05:09:58Zweekly https://semaglutides.org/news/2023/#retatrutide-phase-2-nejm-20232026-09-15T03:27:51Zweekly https://semaglutides.org/news/2023/#oasis-1-shows-daily-semaglutide-pill-can-match-20232026-09-15T04:18:10Zweekly https://semaglutides.org/news/2023/#surmount-2-tirzepatide-weight-loss-type-2-diabetes-20232026-09-15T04:18:07Zweekly https://semaglutides.org/news/2023/#orforglipron-phase-2-nejm-20232026-09-15T04:18:15Zweekly https://semaglutides.org/news/2023/#phase-2-obesity-results-14-7-weight-loss-20232026-09-15T04:18:36Zweekly https://semaglutides.org/news/2023/#novo-first-compounding-lawsuits-20232026-09-15T04:18:24Zweekly https://semaglutides.org/news/2023/#selective-gip-receptor-agonist-produces-weight-loss-without-20232026-09-15T05:09:56Zweekly https://semaglutides.org/news/2023/#amy-schumer-calls-celebrities-stop-lying-ozempic-20232026-09-15T04:18:47Zweekly https://semaglutides.org/news/2023/#gracie-mcgraw-pcos-mounjaro-20232026-09-15T05:32:52Zweekly https://semaglutides.org/news/2023/#cystatin-c-analysis-confirms-tirzepatide-kidney-signal-not-20232026-09-15T05:33:00Zweekly https://semaglutides.org/news/2023/#counterfeit-ozempic-us-pharmacy-20232026-09-15T05:10:03Zweekly https://semaglutides.org/news/2023/#fda-warns-compounded-semaglutide-20232026-09-15T04:18:43Zweekly https://semaglutides.org/news/2023/#charles-barkley-mounjaro-20232026-09-15T05:32:59Zweekly https://semaglutides.org/news/2023/#surpass-ap-combo-asia-pacific-results-against-insulin-20232026-09-15T05:09:59Zweekly https://semaglutides.org/news/2023/#wegovy-starter-dose-limits-20232026-09-15T04:18:47Zweekly https://semaglutides.org/news/2023/#randomized-trial-finds-exenatide-lowers-intracranial-pressure-iih-20232026-09-15T05:33:03Zweekly https://semaglutides.org/news/2023/#surmount-2-topline-20232026-09-15T04:18:40Zweekly https://semaglutides.org/news/2023/#surmount-5-trial-launched-20232026-09-15T04:18:49Zweekly https://semaglutides.org/news/2023/#lilly-breaks-ground-lebanon-adds-1-6-billion-20232026-09-15T05:10:20Zweekly https://semaglutides.org/news/2023/#novo-nordisk-suspended-uk-pharmaceutical-trade-association-20232026-09-15T05:10:12Zweekly https://semaglutides.org/news/2023/#jimmy-kimmels-oscars-monologue-turns-ozempic-punchline-20232026-09-15T03:28:03Zweekly https://semaglutides.org/news/2023/#lilly-cuts-insulin-list-prices-70-caps-patient-20232026-09-15T04:19:06Zweekly https://semaglutides.org/news/2023/#japan-approves-wegovy-narrow-obesity-indication-20232026-09-15T05:10:21Zweekly https://semaglutides.org/news/2023/#rosie-odonnell-posts-mounjaro-tiktok-20232026-09-15T05:33:17Zweekly https://semaglutides.org/news/2023/#lilly-q4-2022-mounjaro-miss-20232026-09-15T05:33:19Zweekly https://semaglutides.org/news/2023/#full-2022-results-sales-26-dkk-177-0-20232026-09-15T05:10:20Zweekly https://semaglutides.org/news/2023/#chelsea-handler-she-took-ozempic-without-knowing-20232026-09-15T05:10:36Zweekly https://semaglutides.org/news/2023/#lilly-rtp-450m-20232026-09-15T05:10:18Zweekly https://semaglutides.org/news/2023/#rybelsus-first-line-20232026-09-15T05:10:28Zweekly https://semaglutides.org/news/2023/#novo-nordisk-sues-mylan-generic-semaglutide-anda-20232026-09-15T05:10:39Zweekly https://semaglutides.org/news/2023/#academy-pediatrics-issues-childhood-obesity-clinical-practice-guideline-20232026-09-15T03:28:00Zweekly https://semaglutides.org/news/2023/#ozempic-face-term-20232026-09-15T05:10:36Zweekly https://semaglutides.org/news/2023/#remi-bader-her-binge-eating-worsened-stopping-ozempic-20232026-09-15T05:11:05Zweekly https://semaglutides.org/news/2023/#berberine-goes-viral-natures-ozempic-20232026-09-15T04:19:09Zweekly https://semaglutides.org/news/2022/#wegovy-adolescents-20222026-09-15T04:19:17Zweekly https://semaglutides.org/news/2022/#step-teens-20222026-09-15T05:10:37Zweekly https://semaglutides.org/news/2022/#tga-registers-mounjaro-australia-20222026-09-15T05:33:15Zweekly https://semaglutides.org/news/2022/#fda-lists-mounjaro-shortage-20222026-09-15T03:28:01Zweekly https://semaglutides.org/news/2022/#fda-adds-tirzepatide-injection-drug-shortage-list-20222026-09-15T03:28:26Zweekly https://semaglutides.org/news/2022/#step-teens-published-semaglutide-cuts-bmi-16-1-20222026-09-15T03:28:19Zweekly https://semaglutides.org/news/2022/#lilly-2023-launch-plans-20222026-09-15T05:33:20Zweekly https://semaglutides.org/news/2022/#fda-expands-wegovy-patients-12-older-obesity-20222026-09-15T03:28:27Zweekly https://semaglutides.org/news/2022/#health-canada-issues-notice-compliance-mounjaro-20222026-09-15T05:10:52Zweekly https://semaglutides.org/news/2022/#setmelanotide-phase-3-results-published-bardet-biedl-syndrome-20222026-09-15T05:10:52Zweekly https://semaglutides.org/news/2022/#step-teens-16-1-percent-bmi-reduction-adolescents-20222026-09-15T04:19:15Zweekly https://semaglutides.org/news/2022/#step-teens-extends-semaglutide-evidence-adolescents-20222026-09-15T04:19:17Zweekly https://semaglutides.org/news/2022/#mounjaro-first-full-quarter-20222026-09-15T05:11:00Zweekly https://semaglutides.org/news/2022/#sanofi-will-pull-adlyxin-20222026-09-15T05:11:19Zweekly https://semaglutides.org/news/2022/#step-5-shows-two-durability-semaglutide-weight-loss-20222026-09-15T04:19:16Zweekly https://semaglutides.org/news/2022/#tirzepatide-obesity-fast-track-20222026-09-15T05:10:56Zweekly https://semaglutides.org/news/2022/#elon-musk-credits-wegovy-his-weight-loss-twitter-20222026-09-15T04:19:32Zweekly https://semaglutides.org/news/2022/#surpass-4-post-hoc-analysis-shows-slower-kidney-20222026-09-15T04:19:42Zweekly https://semaglutides.org/news/2022/#ozempic-goes-viral-20222026-09-15T04:20:12Zweekly https://semaglutides.org/news/2022/#glp-1-prescriptions-pass-2-5-million-demand-20222026-09-15T05:11:09Zweekly https://semaglutides.org/news/2022/#japan-approves-mounjaro-type-2-diabetes-20222026-09-15T05:11:09Zweekly https://semaglutides.org/news/2022/#grade-puts-liraglutide-through-independent-five-test-20222026-09-15T04:19:45Zweekly https://semaglutides.org/news/2022/#surpass-4-post-hoc-analysis-slower-kidney-function-20222026-09-15T05:11:12Zweekly https://semaglutides.org/news/2022/#european-commission-authorizes-mounjaro-20222026-09-15T04:19:51Zweekly https://semaglutides.org/news/2022/#mounjaro-early-demand-20222026-09-15T05:33:27Zweekly https://semaglutides.org/news/2022/#australia-registers-wegovy-artg-20222026-09-15T05:11:30Zweekly https://semaglutides.org/news/2022/#novo-nordisk-acquires-forma-therapeutics-1-1-billion-20222026-09-15T05:33:41Zweekly https://semaglutides.org/news/2022/#surpass-j-mono-j-combo-japanese-phase-3-20222026-09-15T05:11:29Zweekly https://semaglutides.org/news/2022/#ozempic-shortage-listed-20222026-09-15T04:19:45Zweekly https://semaglutides.org/news/2022/#chmp-adopts-positive-opinion-mounjaro-20222026-09-15T05:11:33Zweekly https://semaglutides.org/news/2022/#qsymia-approved-patients-aged-12-older-20222026-09-15T05:11:29Zweekly https://semaglutides.org/news/2022/#surmount-1-sets-obesity-benchmark-20-9-weight-20222026-09-15T03:28:30Zweekly https://semaglutides.org/news/2022/#surpass-4-kidney-signal-20222026-09-15T05:11:31Zweekly https://semaglutides.org/news/2022/#surpass-3-mri-sub-study-large-drop-liver-20222026-09-15T05:11:36Zweekly https://semaglutides.org/news/2022/#lilly-indiana-two-plants-20222026-09-15T04:20:03Zweekly https://semaglutides.org/news/2022/#step-1-extension-shows-two-thirds-lost-weight-20222026-09-15T03:28:30Zweekly https://semaglutides.org/news/2022/#fda-approves-tirzepatide-dual-gip-glp-1-receptor-20222026-09-15T03:28:38Zweekly https://semaglutides.org/news/2022/#mounjaro-approved-thyroid-c-cell-boxed-warning-20222026-09-15T03:29:02Zweekly https://semaglutides.org/news/2022/#mounjaro-first-label-details-20222026-09-15T03:28:55Zweekly https://semaglutides.org/news/2022/#mounjaro-approval-creates-brand-term-means-one-thing-20222026-09-15T05:12:19Zweekly https://semaglutides.org/news/2022/#mounjaro-oral-contraceptive-warning-no-semaglutide-product-carries-20222026-09-15T04:20:15Zweekly https://semaglutides.org/news/2022/#wegovy-demand-outruns-supply-20222026-09-15T04:20:11Zweekly https://semaglutides.org/news/2022/#surmount-1-topline-20222026-09-15T03:28:52Zweekly https://semaglutides.org/news/2022/#mechanism-action-trial-compares-tirzepatide-semaglutide-using-glucose-20222026-09-15T04:20:15Zweekly https://semaglutides.org/news/2022/#step-1-extension-shows-weight-comes-back-semaglutide-20222026-09-15T03:29:02Zweekly https://semaglutides.org/news/2022/#ozempic-2mg-approval-20222026-09-15T05:11:50Zweekly https://semaglutides.org/news/2022/#pnas-paper-explains-structural-basis-tirzepatides-dual-agonism-20222026-09-15T04:20:23Zweekly https://semaglutides.org/news/2022/#wegovy-shortage-listed-20222026-09-15T03:28:59Zweekly https://semaglutides.org/news/2022/#cryo-em-structures-tirzepatide-bound-both-incretin-receptors-20222026-09-15T05:11:52Zweekly https://semaglutides.org/news/2022/#step-8-shows-semaglutide-beats-liraglutide-3-0-20222026-09-15T03:29:13Zweekly https://semaglutides.org/news/2022/#european-commission-authorizes-wegovy-20222026-09-15T04:20:28Zweekly https://semaglutides.org/news/2021/#full-2021-sales-dkk-140-8-billion-share2026-09-15T05:11:52Zweekly https://semaglutides.org/news/2021/#novo-nordisk-agrees-buy-dicerna-pharmaceuticals-3-3-20212026-09-15T05:33:49Zweekly https://semaglutides.org/news/2021/#wegovy-supply-disruption-20212026-09-15T04:20:49Zweekly https://semaglutides.org/news/2021/#lilly-files-mounjaro-drug-application-20212026-09-15T05:33:39Zweekly https://semaglutides.org/news/2021/#obesity-society-publishes-definitive-supplement-review-16-315-20212026-09-15T03:29:19Zweekly https://semaglutides.org/news/2021/#sustain-forte-supports-ozempic-2-mg-dose-20212026-09-15T05:11:50Zweekly https://semaglutides.org/news/2021/#surpass-2-shows-tirzepatide-beats-semaglutide-1-mg-20212026-09-15T03:29:26Zweekly https://semaglutides.org/news/2021/#surpass-1-shows-tirzepatide-monotherapy-cuts-hba1c-two-20212026-09-15T04:20:44Zweekly https://semaglutides.org/news/2021/#fda-approves-wegovy-20212026-09-15T03:29:34Zweekly https://semaglutides.org/news/2021/#wegovy-launch-price-20212026-09-15T04:20:49Zweekly https://semaglutides.org/news/2021/#gip-receptor-agonism-shown-sensitize-insulin-without-weight-20212026-09-15T05:11:56Zweekly https://semaglutides.org/news/2021/#s-lite-shows-exercise-plus-glp-1-beats-20212026-09-15T03:29:41Zweekly https://semaglutides.org/news/2021/#brain-gip-receptors-shown-required-dual-agonist-advantage-20212026-09-15T05:12:12Zweekly https://semaglutides.org/news/2021/#step-4-shows-what-happens-when-semaglutide-stops-20212026-09-15T03:30:26Zweekly https://semaglutides.org/news/2021/#step-4-maintenance-20212026-09-15T05:33:37Zweekly https://semaglutides.org/news/2021/#step-1-publishes-weight-loss-curve-anchors-every-20212026-09-15T03:29:43Zweekly https://semaglutides.org/news/2021/#step-2-shows-smaller-weight-loss-people-type-20212026-09-15T04:20:43Zweekly https://semaglutides.org/news/2021/#step-3-reaches-16-0-weight-loss-intensive-20212026-09-15T05:12:07Zweekly https://semaglutides.org/news/2021/#step-1-nejm-20212026-09-15T03:29:54Zweekly https://semaglutides.org/news/2021/#award-11-adds-3-mg-4-5-mg-20212026-09-15T05:12:09Zweekly https://semaglutides.org/news/2021/#study-quantifies-how-much-semaglutide-cuts-food-intake-20212026-09-15T04:20:53Zweekly https://semaglutides.org/news/2020/#emisphere-technologies-acquisition-completes-1-35-billion-20202026-09-15T04:21:04Zweekly https://semaglutides.org/news/2020/#fda-approves-saxenda-adolescents-12-older-glp-1-20202026-09-15T04:21:58Zweekly https://semaglutides.org/news/2020/#wegovy-filed-20202026-09-15T05:12:13Zweekly https://semaglutides.org/news/2020/#imcivree-setmelanotide-approved-rare-genetic-obesity-20202026-09-15T04:21:18Zweekly https://semaglutides.org/news/2020/#chugai-lilly-publish-how-orforglipron-activates-human-glp-20202026-09-15T05:12:19Zweekly https://semaglutides.org/news/2020/#setmelanotide-phase-3-results-published-pomc-lepr-deficiency-20202026-09-15T05:12:41Zweekly https://semaglutides.org/news/2020/#ada-publishes-practical-guidance-switching-between-glp-1s-20202026-09-15T05:12:25Zweekly https://semaglutides.org/news/2020/#tirzepatide-defined-imbalanced-biased-dual-agonist-20202026-09-15T04:21:22Zweekly https://semaglutides.org/news/2020/#novo-nordisk-buys-corvidia-therapeutics-acquiring-ziltivekimab-20202026-09-15T05:12:43Zweekly https://semaglutides.org/news/2020/#tirzepatides-gastric-emptying-effect-shown-fade-repeat-dosing-20202026-09-15T05:12:48Zweekly https://semaglutides.org/news/2020/#scale-teens-published-liraglutide-reduces-bmi-adolescents-obesity-20202026-09-15T04:21:24Zweekly https://semaglutides.org/news/2020/#sustain-10-quantifies-semaglutide-advantage-liraglutide-20202026-09-15T05:12:37Zweekly https://semaglutides.org/news/2020/#fda-requests-withdrawal-lorcaserin-belviq-cancer-signal-20202026-09-15T03:29:54Zweekly https://semaglutides.org/news/2020/#ozempic-cv-indication-20202026-09-15T04:21:25Zweekly https://semaglutides.org/news/2020/#lilly-manufacturing-buildout-strength-tirzepatide-phase-2-data-20202026-09-15T03:29:57Zweekly https://semaglutides.org/news/2019/#fda-approves-rybelsus-20192026-09-15T03:30:18Zweekly https://semaglutides.org/news/2019/#rybelsus-fasting-rules-20192026-09-15T05:33:54Zweekly https://semaglutides.org/news/2019/#pioneer-4-shows-glp-1-tablet-can-match-20192026-09-15T04:21:37Zweekly https://semaglutides.org/news/2019/#nature-medicine-publishes-human-akkermansia-muciniphila-trial-20192026-09-15T05:12:35Zweekly https://semaglutides.org/news/2019/#pioneer-6-20192026-09-15T04:21:43Zweekly https://semaglutides.org/news/2019/#rewind-gives-trulicity-cardiovascular-indication-20192026-09-15T03:30:13Zweekly https://semaglutides.org/news/2019/#ellipse-trial-opens-victoza-children-aged-10-older-20192026-09-15T04:21:53Zweekly https://semaglutides.org/news/2019/#pioneer-3-published-jama-oral-semaglutide-beats-sitagliptin-20192026-09-15T04:21:52Zweekly https://semaglutides.org/news/2019/#fda-clears-plenity-hydrogel-weight-management-device-20192026-09-15T05:12:51Zweekly https://semaglutides.org/news/2019/#oral-semaglutide-filed-20192026-09-15T05:12:51Zweekly https://semaglutides.org/news/2019/#lilly-agrees-buy-loxo-oncology-8-billion-20192026-09-15T05:13:15Zweekly https://semaglutides.org/news/2019/#sales-reach-dkk-122-0-billion-oral-semaglutide-20192026-09-15T05:14:26Zweekly https://semaglutides.org/news/2018/#phase-2-tirzepatide-results-published-lancet-20182026-09-15T04:21:55Zweekly https://semaglutides.org/news/2018/#lilly-publishes-tirzepatide-discovery-paper-20182026-09-15T03:30:30Zweekly https://semaglutides.org/news/2018/#harmony-outcomes-positive-drug-already-off-market-20182026-09-15T05:13:05Zweekly https://semaglutides.org/news/2018/#novo-nordisk-ozempic-jingle-remaking-1974-pop-hit-20182026-09-15T05:13:12Zweekly https://semaglutides.org/news/2018/#step-program-begins-20182026-09-15T05:13:06Zweekly https://semaglutides.org/news/2018/#japan-approves-ozempic-type-2-diabetes-20182026-09-15T05:13:10Zweekly https://semaglutides.org/news/2018/#european-commission-authorizes-ozempic-eu-wide-20182026-09-15T04:22:07Zweekly https://semaglutides.org/news/2018/#sustain-7-establishes-semaglutide-potent-glp-1-era-20182026-09-15T03:30:21Zweekly https://semaglutides.org/news/2018/#ozempic-us-launch-20182026-09-15T05:13:27Zweekly https://semaglutides.org/news/2018/#lilly-licenses-orforglipron-chugai-20182026-09-15T05:13:23Zweekly https://semaglutides.org/news/2017/#sustain-3-beats-exenatide-extended-release-20172026-09-15T05:13:22Zweekly https://semaglutides.org/news/2017/#fda-approves-ozempic-20172026-09-15T03:30:27Zweekly https://semaglutides.org/news/2017/#ozempic-boxed-warning-20172026-09-15T03:30:43Zweekly https://semaglutides.org/news/2017/#bydureon-bcise-autoinjector-approved-20172026-09-15T05:34:07Zweekly https://semaglutides.org/news/2017/#fda-advisory-committee-semaglutide-20172026-09-15T05:13:25Zweekly https://semaglutides.org/news/2017/#semaglutide-shown-delay-hour-gastric-emptying-people-obesity-20172026-09-15T05:13:32Zweekly https://semaglutides.org/news/2017/#exscel-misses-weekly-exenatide-not-superior-placebo-20172026-09-15T04:22:10Zweekly https://semaglutides.org/news/2017/#near-atomic-structure-activated-glp-1-receptor-published-20172026-09-15T05:13:40Zweekly https://semaglutides.org/news/2017/#sustain-4-shows-semaglutide-beats-insulin-glargine-a1c-20172026-09-15T05:13:41Zweekly https://semaglutides.org/news/2017/#three-scale-data-shows-liraglutide-delays-type-2-20172026-09-15T04:22:22Zweekly https://semaglutides.org/news/2017/#sustain-1-published-phase-3-semaglutide-results-20172026-09-15T05:13:45Zweekly https://semaglutides.org/news/2017/#david-ricks-becomes-chief-executive-eli-lilly-20172026-09-15T03:30:47Zweekly https://semaglutides.org/news/2017/#lars-fruergaard-jorgensen-becomes-ceo-sales-flatline-dkk-20172026-09-15T05:13:44Zweekly https://semaglutides.org/news/2016/#semaglutide-nda-filed-20162026-09-15T05:13:47Zweekly https://semaglutides.org/news/2016/#soliqua-xultophy-insulin-plus-glp-1-combinations-20162026-09-15T05:14:02Zweekly https://semaglutides.org/news/2016/#sustain-6-results-20162026-09-15T04:22:29Zweekly https://semaglutides.org/news/2016/#sustain-6-gives-semaglutide-two-randomized-safety-record-20162026-09-15T04:22:29Zweekly https://semaglutides.org/news/2016/#sustain-6-shows-semaglutide-cuts-heart-events-type-20162026-09-15T03:31:00Zweekly https://semaglutides.org/news/2016/#leader-shows-liraglutide-cuts-cardiovascular-events-type-2-20162026-09-15T03:31:03Zweekly https://semaglutides.org/news/2016/#jama-network-meta-analysis-ranks-approved-weight-drugs-20162026-09-15T05:14:11Zweekly https://semaglutides.org/news/2016/#fda-approves-adlyxin-lixisenatide-20162026-09-15T05:33:55Zweekly https://semaglutides.org/news/2016/#leader-shows-liraglutide-cuts-cardiovascular-death-20162026-09-15T03:30:58Zweekly https://semaglutides.org/news/2016/#scale-sleep-apnea-shows-liraglutide-reduces-apnea-events-20162026-09-15T05:14:13Zweekly https://semaglutides.org/news/2015/#elixa-lixisenatide-cardiovascular-neutral-20152026-09-15T05:14:01Zweekly https://semaglutides.org/news/2015/#lean-glp-1-liver-histology-signal-20152026-09-15T05:14:02Zweekly https://semaglutides.org/news/2015/#scale-diabetes-quantifies-smaller-weight-result-type-2-20152026-09-15T04:22:31Zweekly https://semaglutides.org/news/2015/#scale-obesity-prediabetes-published-nejm-20152026-09-15T04:22:43Zweekly https://semaglutides.org/news/2014/#saxenda-glp-1-approved-weight-management-20142026-09-15T03:31:02Zweekly https://semaglutides.org/news/2014/#saxenda-approved-glp-1-weight-management-20142026-09-15T03:31:20Zweekly https://semaglutides.org/news/2014/#award-6-ties-weekly-dulaglutide-daily-liraglutide-20142026-09-15T05:14:01Zweekly https://semaglutides.org/news/2014/#trulicity-dulaglutide-marketing-20142026-09-15T04:22:40Zweekly https://semaglutides.org/news/2014/#fda-approves-contrave-naltrexone-bupropion-er-boxed-warning-20142026-09-15T05:14:29Zweekly https://semaglutides.org/news/2014/#tanzeum-albiglutide-approved-withdrawn-three-later-20142026-09-15T05:33:57Zweekly https://semaglutides.org/news/2013/#scale-maintenance-shows-liraglutide-holds-off-regained-weight-20132026-09-15T05:14:18Zweekly https://semaglutides.org/news/2013/#duration-6-publishes-weekly-exenatide-loses-daily-liraglutide-20132026-09-15T05:14:20Zweekly https://semaglutides.org/news/2012/#fda-approves-qsymia-phentermine-topiramate-er-20122026-09-15T04:23:04Zweekly https://semaglutides.org/news/2012/#fda-approves-bydureon-once-weekly-glp-1-20122026-09-15T04:23:04Zweekly https://semaglutides.org/news/2011/#zyprexa-loses-patent-protection-opening-yz-patent-cliff-20112026-09-15T04:23:10Zweekly https://semaglutides.org/news/2010/#fda-requests-withdrawal-sibutramine-meridia-scout-trial-20102026-09-15T04:22:57Zweekly https://semaglutides.org/news/2010/#victoza-liraglutide-reaches-market-type-2-diabetes-20102026-09-15T03:31:18Zweekly https://semaglutides.org/news/2009/#lead-6-shows-liraglutide-beats-twice-daily-exenatide-20092026-09-15T04:23:11Zweekly https://semaglutides.org/news/2008/#berberine-matches-metformin-glucose-control-36-patient-pilot-20082026-09-15T05:14:29Zweekly https://semaglutides.org/news/2007/#fda-approves-alli-only-counter-weight-loss-drug-20072026-09-15T04:23:14Zweekly https://semaglutides.org/news/2005/#fda-approves-byetta-exenatide-glp-1-receptor-agonist-20052026-09-15T03:31:37Zweekly https://semaglutides.org/news/2005/#fda-approves-symlin-pramlintide-amylin-analog-20052026-09-15T05:34:08Zweekly https://semaglutides.org/news/2004/#xendos-publishes-orlistat-cuts-diabetes-progression-four-20042026-09-15T04:23:29Zweekly https://semaglutides.org/news/2004/#fda-bans-dietary-supplements-containing-ephedrine-alkaloids-20042026-09-15T04:23:51Zweekly https://semaglutides.org/news/2003/#medicare-modernization-act-excludes-weight-loss-drugs-part-20032026-09-15T04:23:38Zweekly https://semaglutides.org/news/2000/#federal-appeals-court-strips-prozac-patent-protection-two-20002026-09-15T04:23:36Zweekly https://semaglutides.org/news/2000/#novozymes-spun-novo-nordisk-20002026-09-15T05:34:17Zweekly https://semaglutides.org/news/1999/#fda-approves-orlistat-xenical-lipase-inhibitor-weight-drug-19992026-09-15T05:14:28Zweekly https://semaglutides.org/news/1997/#fenfluramine-dexfenfluramine-withdrawn-market-19972026-09-15T03:31:41Zweekly https://semaglutides.org/news/1997/#public-valvular-heart-disease-fen-phen-users-19972026-09-15T03:31:36Zweekly https://semaglutides.org/news/1992/#exendin-4-isolated-gila-monster-venom-19922026-09-15T04:23:45Zweekly https://semaglutides.org/news/1989/#novo-nordisk-merge-form-novo-nordisk-s-19892026-09-15T05:14:36Zweekly https://semaglutides.org/news/1988/#lilly-fluoxetine-prozac-19882026-09-15T04:23:42Zweekly https://semaglutides.org/news/1959/#fda-approves-phentermine-short-term-weight-management-19592026-09-15T05:14:49Zweekly https://semaglutides.org/news/1923/#novo-nordisks-founding-date-19232026-09-15T05:14:46Zweekly https://semaglutides.org/news/1923/#lilly-sells-iletin-commercially-available-insulin-united-states-19232026-09-15T03:31:41Zweekly https://semaglutides.org/news/1876/#colonel-eli-lilly-opens-laboratory-indianapolis-18762026-09-15T03:31:47Zweekly